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Summary 
     Acute hepatic failure secondary to acetaminophen (APAP) poisoning is 
associated with high mortality. PTP1B is a negative regulator of tyrosine 
kinase growth factor signaling. In the liver, this pathway confers protection 
against injury. However, the involvement of PTP1B in the intracellular 
networks activated by APAP is unknown. We have assessed PTP1B expression 
in APAP-induced liver failure in humans and its role in the molecular 
mechanisms that regulate the balance between cell death and survival in 
human and mouse hepatocytes as well as in a mouse model of APAP-induced 
hepatotoxicity. PTP1B expression was increased in human liver tissue 
removed during liver transplant from patients for APAP overdose. PTP1B was 
up-regulated by APAP in primary human and mouse hepatocytes together with 
activation of JNK and p38 MAPK, resulting in cell death. Conversely, Akt 
phosphorylation and the anti-apoptotic Bcl2 family members BclxL and Mcl1 
were decreased. PTP1B deficiency in mouse hepatocytes protected against 
APAP-induced cell death preventing GSH depletion, ROS generation and 
activation of JNK and p38 MAPK. APAP-treated PTP1B-/- hepatocytes showed 
enhanced anti-oxidant defense through the glycogen synthase kinase 
GSK3β/SKF axis, delaying tyrosine phosphorylation of Nrf2 and its nuclear 
exclusion, ubiquitination and degradation. IGFIR-mediated signaling 
decreased in APAP-treated wild-type hepatocytes, but was maintained in 
PTP1B-/- cells or in wild-type hepatocytes with reduced PTP1B levels by RNA 
interference. Likewise, both signaling cascades were modulated in mice 
resulting in less severe APAP hepatotoxicity in PTP1B-/- mice.  Our results 
demonstrated that PTP1B is a central player of the mechanisms triggered by 
APAP in hepatotoxicity suggesting a novel therapeutic target against APAP-
induced liver failure.In the initial experiments of APAP-mediated toxicity in 
hepatocytes we found that APAP also increased PTP1B and activated JNK at 
subtoxic doses. These data prompted us to evaluate the cross-talk between 
subtoxic doses of APAP and insulin signaling in hepatocytes. Insulin signaling 
was decreased in hepatocytes stimulated with subtoxic doses of APAP through 
decreasing IR and IRS1 tyrosine phosphorylation. However, PTP1B deficiency 
protected against these effects. In an in vivo chronic treatment with APAP, 
wild-type mice showed a trend towards a decrease in whole body glucose 
homeostasis whereas in mice lacking PTP1B no deleterious effects were 
observed.  
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Resumén 
     El fallo hepático agudo debido a una sobredosis de paracetamol está 
asociado con una elevada mortalidad. La PTP1B modula negativamente la 
señalización mediada por los receptores de factores de crecimiento de la súper 
familia tirosina quinasa. En el hígado, estas rutas confieren protección frente 
al daño. En esta Tesis Doctoral hemos investigado la expresión de PTP1B en el 
daño agudo inducido por sobredosis de paracetamol en humanos, así como su 
papel en la regulación de los mecanismos moleculares responsables del 
balance supervivencia/muerte celular en el hígado. Hemos encontrado un 
aumento en la expresión de PTP1B en el tejido hepático procedente de 
individuos que necesitaron trasplante tras una sobredosis de paracetamol. Así 
mismo, los niveles de PTP1B aumentaron en hepatocitos humanos y murinos 
tratados con paracetamol en paralelo con la activación de las quinasas de 
estrés JNK y P38 MAPK y la inducción de muerte celular. Por el contrario, la 
activación de Akt y los niveles de proteínas anti-apoptóticas de la familia Bcl2 
se encontraron disminuidos. La deficiencia en PTP1B protegía a los 
hepatocitos frente a la muerte inducida por paracetamol ya que preveía la 
depleción de GSH, la generación de ROS y la activación de las quinasas de 
estrés. Además, los hepatocitos PTP1B-/- tratados con APAP presentaron una 
mayor respuesta antioxidante modulando las quinasas GSK3β/SKF lo que 
retrasaba la fosforilación en tirosina del Nrf2 responsable de su salida del 
núcleo y posterior ubiquitinación y degradación. La inhibición de PTP1B 
también evitaba la disminución de la fosforilación del IGF-IR y Akt. Estos dos 
mecanismos se modulaban de igual manera en ratones sometidos a una 
sobredosis de paracetamol, presentando los ratones PTP1B-/- una menor 
hepatotoxicidad. Estos resultados demostraban que la PTP1B regula los 
mecanismos moleculares desencadenados por dosis tóxicas paracetamol, lo 
que sugiere que la PTP1B podría ser una  diana terapéutica frente a este daño 
hepatocelular. La expresión de PTP1B y la activación de las quinasas de estrés 
también aumentaban en hepatocitos estimulados con dosis subtóxicas de 
paracetamol, de manera similar a lo que ocurre en situaciones de resistencia a 
la insulina. Hemos encontrado que dosis subtóxicas de paracetamol 
disminuyen la señalización de la insulina en los hepatocitos y este efecto se 
atenúa en ausencia de PTP1B. Por último, presentamos evidencias de que la 
administración crónica de paracetamol podría alterar la homeostasis glucídica del 
organismo y esto se evitaría mediante la inhibición de la PTP1B. 
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1. General Characteristics Of The Liver.  
     The liver is the largest gland in the human body, weighting approximately 1.500 
grams (about 2.5% of adult’s body weight) and occupying a large region mostly on 
the right side of the body, below the diaphragm and behind ribs five through ten 
(Figure 1). The liver is closely associated with the small intestine, processing the 
nutrient-enriched venous blood that leaves the digestive tract. The liver is also 
considered the most complex and important internal organ in the human body. It 
performs over five hundred metabolic functions, resulting in the synthesis of the 
products that are released into the blood stream (e.g. glucose derived from 
gluconeogenesis, plasma proteins, clotting factors and urea), or that are excreted to 
the intestinal tract (bile). Also, several products are stored in the liver parenchyma 
(e.g. glycogen, fat and fat soluble vitamins). A total loss of liver function leads to 
death within minutes (Marieb 2001; Arias 1994; Netter 2006), demonstrating the 
physiological liver’s importance. 
1.1. Microscopic Anatomy Of The Liver. 
     The basic functional unit of the liver is the liver lobule. The primary structure of 
a lobule is shown in (Figure 2) and includes:    
 Hepatocytes form the bulk of the lobule and arranged as interconnected plates.                                   
 Portal triads at each corner of the lobule. 
 Central vein.                             
 Liver sinusoids that run from the central vein to the portal triads are the canals 
formed by the plates of hepatocytes. They are approximately 8-10 µm in diameter 
and are comparable with the diameter of normal capillaries.                             
 Hepatic macrophages (Kupffer cells).                                                                
 Bile canaliculi. They are little canals of 1µm in diameter formed among the walls 
of adjacent hepatocytes.   
 Space of Disse that is a small space between the sinusoids and the hepatocytes.         
The portal triads consist of three vessels: a hepatic portal arteriole, a hepatic portal 
venule and a bile duct. The blood from the arteriole and the venule flows in the 
same direction through the sinusoids towards the central vein which eventually 
leads to the hepatic vein and the inferior vena cava. Secreted bile flows in the 
opposite direction through the bile canaliculi away from the central vein towards the 
portal triad and exiting via the bile duct. As blood flows through the sinusoids and 
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the space of Disse towards the central vein, nutrients are processed and stored by 
the hepatocytes and blood cells and bacteria are engulfed by the Kupffer cells. 
 
 
 
 
 
 
1.2. The Liver Cell Types.  
     The liver has five cell types: hepatocytes, Kupffer cells, sinusoidal endothelial 
cells, bile duct epithelial cells and Ito cells. 
1-Hepatocytes:- represent 60% of the liver’s cells and about 80% of the liver’s total 
cell mass (Kuntz, 2008b). Most of the liver’s synthetic and metabolic capabilities 
stem from the work of hepatocytes. 
2-Kupffer cells:- are macrophages that reside in the sinusoids. The liver has a large 
number of these macrophage lineage cells which make up 80% of the total body 
macrophages (Bouwens et al., 1986; Seki et al., 2000; Doherty et al., 2000). These 
cells help to clear out the old red blood cells and bacteria. They also break down the 
heme (the iron-containing pigment in hemoglobin) into bilirubin which then 
becomes one of the chief pigments of bile.  
3-Sinusoidal endothelial cells:- are fenestrated (latin for “windows”), meaning that 
they have large pores that allow most proteins to pass freely through the sinusoidal 
endothelium into the space of Disse where they can make direct contact with 
hepatocytes. The pores are also bi-directional, meaning that proteins created by the 
liver and the other substances stored or processed by the liver can also be passed 
back into the blood. 
4-Bile duct epithelial cells:- line the interlobular bile ducts within the portal triads.  
5-Ito cells:- are found in the space of Disse. They are also known as stellate cells, 
lipocytes or perisinusoidal cells. They comprise approximately 15% of all liver cells 
(Bauer et al., 2001; Friedman 2000; Rockey 2001). These cells store Vitamin A and 
    Figure 2. Liver microscopic anatomy. Figure 1. Normal gross anatomy of the liver. 
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manufacture and secrete a number of important hepatic growth factors such as 
Hepatocyte Growth Factor (HGF) and Transforming Growth Factor β (TGFβ) and 
matrix components (collagen) and, therefore, they play a prominent role in liver 
regeneration and in the development of liver fibrosis, respectively. When stimulated 
by micro-environmental changes, these cells can transform into facultative fibroblasts 
or myofibroblasts. 
1.3. Functions Of The Liver. 
     The liver has many functions, acting as a gatekeeper between the digestive 
system and the circulatory system. The four essential liver functions are: 
-Synthesis of many proteins that circulate in the blood. This include albumin, 
coagulation factors, alpha1-antitrypsin, very low density lipoproteins etc.. 
-Storage of nutrients for later use. The liver balances the supply of nutrients with 
the demand. For example, the liver stores glucose as glycogen and converts it back 
into glucose when needed (Nordlie et al., 1999; Pilkis et al., 1992; Saltiel et al., 
2001). If the supply of glycogen is depleted, the liver can also synthesize glucose 
from amino acids, lactate, and glycerol. Additionally, the liver metabolizes fatty 
acids, cholesterol and amino acids (Xiao et al., 2010). When there is a surplus of 
glucose in the bloodstream, the liver can convert the excess glucose and amino 
acids into fatty acids for storage. The liver synthesizes cholesterol and removes it 
from circulation. Finally, the liver can synthesize non-essential amino acids when 
needed by the body. 
-Detoxification and elimination of toxic substances. Toxins are detoxified by the 
liver’s ability to metabolize lipophillic compounds. These compounds (bound to 
albumin) enter the liver sinusoids and then into the area of Disse. Enzymes in the 
hepatocytes are involved in the metabolism of the lipophillic compounds, which 
include toxins and many drugs. 
-Production of bile. Bile acts as a detergent that breaks fats down into smaller 
components, so they can be digested in the small intestine. Bile also provides the 
liver a way to remove wastes including bilirubin, cholesterol and toxins. Bile is 
formed in the biliary canaliculi and then drains into the interlobular bile ducts.  
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2. Drug-Induced Liver Injury. 
     The liver, as the major site of drug metabolism, is also the major site of drug 
injury. Drug-induced liver injury (DILI) continues to be a problem for many 
commonly used drugs and represents a major challenge in designing potential 
therapies (Kaplowitz 2005; Thames 2004). Paracetamol (APAP, an analgesic), 
valproic acid (an anti-convulsant drug) and zafirlukast (a drug used for asthma) are 
examples of the commonly used drugs that are associated with liver injury. The 
development of strategies to reduce DILI has important implications in liver injury. 
It may also increase the availability of many drugs involved in the treatment of a 
wide range of diseases. 
     Hepatocyte injury and death is the critical initiating event leading to the clinical 
manifestations of DILI. Hepatocyte injury can be triggered directly by some drugs 
(parent compound), but in most cases involves the formation of reactive metabolites 
generated during metabolism (Kaplowitz 2005; Uetrecht 2008). Since most drugs are 
lipophilic, drug clearance involves biotransformation by cytochrome P450 (CYP) or 
other phase I enzymes to reactive metabolites for conjugation with hydrophilic 
carriers (e.g. glucuronide, GSH) and excretion into urine or bile. However, as the 
name suggests, reactive metabolites are highly reactive molecules that not only 
covalently bind to hydrophilic carriers, but also covalently bind to proteins (Jollow et 
al., 1973; Kaplowitz 2005). Reactive metabolites can also directly, through redox 
cycling, or indirectly, through glutathione (GSH) depletion, increase the generation 
of reactive oxygen species (ROS) (superoxide O₂, hydrogen peroxide H₂O₂, hydroxyl 
radical HO·) in hepatocytes (Hanawa et al., 2008).  
     Covalent binding and ROS production caused by reactive metabolites can modify 
proteins and other macromolecules to cause hepatocyte stress and injury that can 
activate and/or inhibit a wide range of signaling pathways. Whether the hepatocyte 
survives or undergoes cell death following injury by reactive metabolites is 
determined, in great part, by the balance between pro-death and pro-survival 
signaling pathways. If pro-death pathways are primarily activated, these signaling 
pathways will initiate hepatocyte death following hepatocyte injury. Even in necrotic 
death, pro-death pathways such as the activation of the c-Jun N-terminal kinase 
(JNK) can trigger cell death to occur (Hanawa et al., 2008). Consequently, 
pharmacological inhibition of these pro-death pathways can often prevent cell 
death, even in the presence of extensive cell injury. On the other hand, the 
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activation of pro-survival pathways (e.g., protein kinase B/Akt, DNA repairing 
enzymes) may inhibit cell death by directly inhibiting pro-death signaling, or 
indirectly by increasing cell repair or metabolism (Saberi et al., 2008). The 
modulation of these pro-death and pro- survival signaling pathways in hepatocytes 
may decrease the extent of liver injury caused by drugs and, therefore, represent a 
potential therapeutic strategy for the treatment of DILI. 
2.1. APAP-Induced Liver Injury. 
     Studying the intrinsic signaling pathways involved in DILI, as well as other steps 
involved in DILI, has been hampered by the availability of good animal models (Dixit 
and Boelsterli 2007; Kaplowitz 2005). Very few drugs that cause liver injury in 
humans can be studied in animals and, consequently, a mechanistic understanding 
of how drugs cause liver injury is lacking. The noted exception is APAP, which 
causes liver injury in animals in a dose-dependent manner. Accordingly, most of the 
knowledge about DILI has come from work with APAP at high doses that cause liver 
injury in both humans and experimental animals (Kaplowitz 2005). In addition, 
since APAP-induced liver injury exhibits idiosyncratic features in animals, a number 
of recent metabolomic and genomic studies have focused on understanding the 
underlying mechanism(s) responsible for the idiosyncratic nature of APAP-mediated 
hepatotoxicity (Welch et al., 2005, 2006).  
     APAP, called acetaminophen in North America, is a widely used over the-counter 
analgesic and antipyretic drug (Bessems et al., 2001; James et al., 2003; Prescott et 
al., 1983). APAP was originally introduced as an analgesic by Von Mering in 1893, 
but was not widely used until the 1960s, following the recognition that the 
structural analogue phenacetin was nephrotoxic in chronic abusers (Hinson 1980). 
According to the US Food and Drug Administration, each week approximately 50 
million adults in the United States take APAP-containing products. At therapeutic 
doses, it is believed to be safe, having analgesic and antipyretic effects similar to 
those of aspirin or ibuprofen. Unlike these other drugs, APAP has only weak anti-
inflammatory properties. Because APAP is well tolerated, available without a 
prescription, and lacks the gastric side effects of aspirin (gastrointestinal bleeding 
and Rye’s syndrome), it has become in the recent years a common household drug. 
Although considered safe at therapeutic doses, at higher doses APAP produces a 
centrilobular hepatic necrosis that can be fatal. APAP poisoning has been recognized 
as a public health problem (Lee 2007; Kaplowitz 2004; Prescott 1980) because 
approximately one-half of all cases of acute liver failure in the US and Great Britain 
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today (Larson et al., 2005; Ostapowicz et al., 2002) are due to APAP toxicity. APAP, 
in these countries, is also the second leading cause of liver transplantation which 
accounts for considerable levels of morbidity and mortality (Lee 2004). Therefore, 
APAP-induced acute toxicity has become an essential model for studying drug-
induced liver and kidney failure. In the liver, APAP overdose produces a 
centrilobular hepatic necrosis that can be fatal as it progresses to fulminant liver 
failure (Ramachandran et al., 2009). However, despite of substantial progress in 
understanding APAP-induced hepatotoxicity (James et al., 2003; Jaeschke et al., 
2006; Han et al., 2010), additional injurious mechanisms responsible for the 
cellular damage induced by this drug remain unknown.  
2.2. Metabolism Of APAP-Mediated Hepatotoxicity. 
     In a series of four publications it has been shown that APAP was converted by 
drug metabolizing enzymes to a reactive metabolite that covalently bind to proteins 
(Jollow et al., 1973; Mitchell et al., 1973a, b; Potter et al., 1973). Subsequently, the 
reactive metabolite of APAP was identified to be N-acetyl-p-benzoquinone imine 
(NAPQI). It was found to be formed by cytochrome P-450 (CYP) by a direct two 
electron oxidation of APAP, a previously unrecognized mechanism of CYP (Dahlin et 
al., 1984; Gillette et al., 1981; Potter et al., 1987). The CYP isoforms important in 
APAP metabolism are CYP2E1, CYP1A2, CYP3A4 and CYP2D6 (Dong et al. 2000; 
Raucy et al., 1989; Snawder et al., 1994; Thummel et al., 1993).  
     At nontoxic doses, the metabolite was efficiently detoxified by GSH forming an 
APAP-GSH conjugate (Jollow et al., 1974) and eliminated  in urine or bile as APAP–
cysteine, APAP–N-acetylcysteine (APAP–NAC) and APAP-glutathione (APAP–GSH) 
(Ghosh et al., 2009) (Figure 3). However, at toxic doses, glucuronidation and 
sulfation routes become saturated and more extensive bioactivation of the drug 
occurs, leading to a rapid depletion of the hepatic GSH pool as much as 80–90% 
(Jollow et al., 1974; Mitchell et al., 1973a, b) and, subsequently, NAPQ1 covalently 
binds to proteins. The amount of covalent binding correlated with the relative 
hepatotoxicity (Jollow et al., 1973). Thus, detoxification of NAPQI is extremely rapid, 
and the rapid rate may explain why covalent binding to proteins was not observed in 
hepatocytes until GSH was almost completely depleted (Mitchell et al., 1973a, b). 
NAPQI binds to cysteine groups on cellular proteins forming APAP-protein adducts. 
NAPQI also binds to mitochondrial proteins, which, in turn, causes oxidative stress 
that may trigger signaling pathways through mitochondrial toxicity, ultimately 
leading to lethal cell injury. Moreover, generation of ROS and nitrogen species, lipid 
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peroxidation, mitochondrial dysfunction, disruption of calcium homeostasis and 
induction of apoptosis and necrosis are also involved in APAP-induced 
hepatotoxicity (Ghosh et al., 2009; Reid et al., 2005). Therefore, tight control of ROS 
levels by antioxidant molecules and detoxifying enzymes is important to restore the 
balance between oxidants and antioxidants in cells challenged with oxidative 
insults. In this regard, nuclear factor erythroid-2-related factor 2 (Nrf2) activates 
detoxifying enzymes by binding to antioxidant response elements (AREs) in 
promoters of several genes. Animals deficient in Nrf2 are highly susceptible to APAP-
induced liver injury (Enomoto et al., 2001). Thus, Nrf2 may serve as an endogenous 
regulator by which cells combat oxidative stress.  
     In initial work describing the importance of hepatic GSH in APAP-induced 
hepatotoxicity in mice, Mitchell et al. (1973a, b) showed that administration of 
cysteine prevented hepatotoxicity. This finding led to the development of N-
acetylcysteine as the preferred antidote for the treatment of APAP hepatotoxicity 
(Peterson et al., 1977; Piperno et al., 1976; Prescott et al., 1977). Rumack and 
coworkers analyzed the  toxicity data from a large number of APAP overdose 
patients treated with N-acetylcysteine (Rumack et al. 1981) and noticed that 
treatment of APAP-poisoned patients during the first 10 hours after the overdose 
was effective at decreasing the toxicity (Prescott et al., 1977; Rumack et al., 1981),  
but those patients who were treated with N-acetylcysteine after 10 hours were most 
susceptible to the development of hepatotoxixity. The mechanisms by which N-
acetylcysteine inhibits APAP toxicity have been postulated to be an increase in 
detoxification of NAPQI by a direct conjugation and also an increase in GSH 
synthesis (Corcoran et al., 1985). 
  
 
                                                                     
 
 
  
      Figure 3. Schematic representation depicting the role of metabolismin APAP Toxicity. 
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ROS (reactive oxigen species) have important roles in diverse physiological and 
pathological processes. Low levels of ROS play important roles in regulating 
vascular tone (Gutterman et al., 2005), cell adhesion (Chiarugi et al., 2003; Huo et 
al., 2009) immune responses (Grisham 2004) and growth factor actions (Hensley et 
al., 2000). Intermediate levels of oxidative stress induce an adaptive protective 
signal pathway (i.e. Keap1-Nrf2 signal pathway) to induce the antioxidant response. 
Likewise, higher amounts of ROS can trigger an inflammatory response through 
activation of Nuclear Factor Kappa B (NFκB) and Activating Protein 1 (AP-1 
transcription factors).  
     Cells have evolved adaptive mechanisms to endure oxidative stress. In general, 
there are three cellular antioxidant defence systems to fight against oxidative stress: 
low-molecular-weight antioxidants, enzymatic antioxidant pathways and free-ion 
sequestration. One of the major endogenous low molecular weight antioxidant is 
GSH because it serves as the most abundant cellular thiol resource and provides a 
buffer system to maintain cellular redox status. GSH can be either synthesized from 
glutamate-cysteine ligase (GCL) or from GSH synthase (Gss.) GSH reduces H₂O₂ 
through glutathione peroxidase (Gpx) and it is also oxidized to its disulfide form 
(GSSG). GSSG is returned to GSH through glutathione reductase (GR) using NADPH 
as a co-factor. Multiple studies have shown that the Gpx-GSH pathway is also a 
major intracellular antioxidant mechanism that repairs lipid peroxidation (Imai et 
al., 2003), DNA fragmentation (Higuchi 2003) and protein adduction (Filippin et al., 
2008). 
3. Signaling Pathways Involved In APAP Hepatotoxicity.  
3.1. The JNK-Mitochondrial Signaling Loop in APAP-Induced Liver Injury.    
     The first signaling pathway identified to modulate APAP-induced liver injury was 
mediated by JNKs (Gunawan et al., 2006; Henderson et al., 2007; 
Latchoumycandane et al., 2007). JNKs are a family of serine/threonine kinases 
belonging to the MAPK family that mediate the cellular responses to environmental 
stresses, growth factors, as well as to proinflammatory cytokines (Johnson et al., 
2007). JNK is activated through phosphorylation by MKK4/7 (MAPK kinase 4/7), 
which is in turn activated upstream by ASK1 (apoptosis signal-regulating kinase 1) 
and other MAP3Ks. In most cells, including hepatocytes, two JNK isoforms (JNK1 
and JNK2) are expressed (Johnson et al., 2007). JNK plays an important role in 
stress response and is activated by stressors such as ROS (Czaja 2007), UV light 
and proinflammatory cytokines such as Tumour Necrosis Factor α (TNF-α) (Czaja 
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2007; Han et al., 2009). Once activated, JNK regulates many metabolic and survival 
pathways, but also mediates cell death (Johnson et al., 2007; Weston et al., 2002). 
The ability of JNK to mediate both cell survival and cell death pathways is often 
determined by the duration of its activation (Han et al 2009; Liu et al., 2002). 
Transient JNK activation is associated with cell stress responses such as JunD 
phosphorylation that can protect cells, whereas sustained JNK activation promotes 
both apoptotic and necrotic cell death pathways (Czaja 2007; Han et al., 2009; 
Lamb et al., 2003). In this regard, sustained JNK is important in mediating 
apoptosis and necrosis caused by a wide range of agents, including ROS, TNFα, UV 
light and various drugs and toxins (Johnson et al., 2007; Weston et al., 2002). In 
the liver, prolonged JNK activation has been shown to mediate injury caused by 
APAP, ischemia and TNFα (Gunawan et al., 2006; Hanawa et al., 2008; Han et al., 
2010; Bradham et al., 1997). JNK-dependent cell death is accompanied in many 
cases by its translocation to mitochondria (Hanawa et al., 2008; Aoki et al. 2002; 
Chauhan et al., 2003) and cell death is preceded by loss of the mitochondrial 
function, suggesting that the direct interaction of JNK with mitochondria is 
important. JNK binding to isolated brain mitochondria has also been shown to shut 
down mitochondrial metabolism by leading to down-regulation of pyruvate 
dehydrogenase activity (Zhou et al., 2008). It has been reported that during APAP-
induced liver injury, NAPQI induced sustained JNK activation at least partially due 
to activation of the extra-mitochondrial MAPK cascade initiated by ASK1 activation 
(Nakagawa et al., 2008) and translocation to mitochondria (Hanawa et al., 2008; 
Shinohara et al., 2008). This, in turn, induces mitochondrial permeability pore 
transition leading to hepatocyte death. JNK translocation to mitochondria may also 
promote mitochondrial ROS generation, which is important in sustaining JNK 
activation in a self-amplifying loop, particularly when mitochondria are rendered 
susceptible by toxins such as APAP and anisomycin. Several studies have 
demonstrated that treatment of mice with a JNK inhibitor or knocking down JNK 
(using antisense or knockout mice) was able to markedly protect against APAP-
induced liver injury without affecting APAP metabolism (i.e., GSH depletion and 
covalent binding) (Gunawan et al., 2006; Hanawa et al., 2008). Thus, even in the 
presence of significant cytoplasmic and mitochondrial GSH depletion and covalent 
binding, hepatocyte death did not occur without JNK. This finding represents a 
paradigm shift from the notion that hepatocyte necrosis was a passive death due to 
mitochondrial GSH depletion and covalent binding and demonstrated that APAP-
induced hepatotoxicity requires the active participation of JNK (Kaplowitz et al., 
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2008). The mechanism by which JNK induces hepatocyte death following APAP 
involves a complex JNK-mitochondria signaling loop with several steps: (a) 
mitochondrial GSH depletion and ROS generation (b) redox changes and ASK-1 
activation of JNK (c) JNK modulation of Bcl-2 family members (d) JNK translocation 
to mitochondria and inhibition of mitochondrial bioenergetics. 
     Two isoforms of JNK, JNK1 and JNK2, are expressed in the liver (Bogoyevitch 
2006). JNK1 has been suggested to play an important role in insulin resistance and 
fatty liver disease (Schattenberg et al., 2006), while JNK2 has been shown to be 
involved in TNFα-induced apoptosis and ischemia reperfusion (Theruvath et al., 
2008; Wang et al., 2006). In the APAP model, both JNK1 and JNK2 appear to be 
involved in hepatotoxicity, although JNK2 may play a slightly more preferential role. 
Remarkably, knocking down either JNK1 or JNK2 alone in mice could not protect 
against APAP-induced liver injury. Only when both isoforms of JNK were 
simultaneously knocked down protection against APAP was observed (Hanawa et al., 
2008). 
3.2. The Nrf2-Keap1-ARE Transcription Pathway. 
     Nrf2:INrf2 (Keap1, Kelch-like ECH-associating protein1) are cellular sensors of 
oxidative and electrophilic stress. Nrf2 is a nuclear factor that controls the 
expression and coordinated induction of a battery of genes which encode detoxifying 
enzymes, drug transporters (MRPs), anti-apoptotic proteins and proteasomes. 
3.2.1. Nrf2. 
Nrf2 is a leucine zipper/CNC protein which when present in the nucleus functions 
as transcription factor that regulates coordinated activation of a battery of 
cytoprotective genes that include biotransformation enzymes, antioxidant proteins, 
drug transporters, anti-apoptotic proteins and proteasomes. It contains various 
domains; a N-terminal hydrophobic domain followed by Keap1 binding domain, 
transcriptional activation domain, CNC domain and basic and leucine zipper 
domain. Nrf2 through its leucine zipper domain heterodimerizes with small Maf or 
Jun proteins and bind to antioxidant response elements (ARE) in target genes  
(Kaspar  et al., 2009; Zhang 2006; Aleksunes et al., 2007;  Hayes  et al., 2009; Kwak  
et al., 2003). Coordinated induction of cytoprotective gene transcription through the 
ARE is essential for cellular protection against oxidative stress and related 
disorders. This induction is controlled by cap 'n' collar (CNC) family of factors. This 
regulatory region contains a tandem AP1-NFE2 motif, originally termed as the 
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DNase hypersensitive site 2, which has a strong enhancer activity (Moi et al., 1990; 
Ikuta et al., 1991). Subsequent work to clone the transcription factors that bind to 
this AP1-NFE2 site have identified several members belonging to the CNC subfamily 
of the basic leucine zipper (bZIP) transcription factors; among the first identified 
were p45-NFE2 ( Chan et al., 1993), Nrf1 (Chan et al., 1993) and Nrf2 (Moi et al., 
1994). Nrf3 (Kobayashi et al., 1999) and two distantly related proteins, i.e., Bach1 
(Oyake et al., 1996) and Bach2 (Muto et al., 1998) are other CNC family proteins 
discovered and characterized later. These proteins function as heterodimeric 
transcription factors by dimerizing with other bZIP proteins such as small Mafs 
(sMafs) (Igarashi et al., 1994).  
     The Nrf1 gene is essential for embryonic development and targeted gene 
disruption of Nrf1 in mice resulted in embryonic lethality with severe anemia and 
liver abnormalities such as non-alcoholic steatohepatitis (Chan et al., 1998; Xu et 
al., 2005). By contrast, Nrf2-disrupted mice were normal, fertile, and did not show a 
phenotype of developmental deficits (Chan et al., 1996; Itoh et al., 1997), suggesting 
that Nrf2 is not essential for murine development and survival. However, these mice 
were hypersensitive to oxidative stress (Chan et al., 1996, 2000; Kwak et al., 2001). 
Evidence from the past 10 years points to Nrf2 as a key regulator of the cellular 
responses to oxidative stress in multiple tissues and cell types. Therefore, the Nrf2 
signaling pathway could be a therapeutic target for preventing oxidative stress-
related diseases. 
3.2.2. Keap1. 
     Detailed analysis of Nrf2 activity and structure across various species has 
identified six evolutionarily conserved domains named Neh (Nrf2-ECH<chicken 
Nrf2>homologous domain) (Itoh et al., 1997). The domain in the N terminus, Neh2, 
was discovered as having a negative regulatory role for the transactivating activity of 
Nrf2 (Itoh et al., 1999). Deletion of Neh2 was found to remarkably increase Nrf2’s 
transactivation activity, which hinted that the Neh2 may contain a critical 
interaction site to which the negative regulator of Nrf2 binds. Using a yeast two-
hybridization system and Neh2 as a bait, Keap1 (Kelch-like ECH-associating 
protein1), a zinc metalloprotein, was identified to be the major protein-interacting 
with the Neh2 domain. Based on Keap1 cDNA sequences, the primary structure of 
murine Keap1 was predicted to be composed of 624 amino acids and there is ~95% 
homology between human and mouse (Itoh et al., 1999). Molecular dissecting 
analysis suggests that Keap1 consists of five domains: the N terminal region (NTR), 
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the BTB/POZ (Bric-a-brac, tramtrack, broad-complex/poxvirus zinc finger), the 
intervening region (IVR), the double glycine repeat (DGR) or Kelch domain and the 
C-terminal region (CTR) (Itoh et al., 2004A). The BTB/POZ domain is involved in 
protein homodimerization and heterodimerization making homomeric and 
heteromeric multimers of Keap1 (Yoshida et al., 1999). In addition, both BTB and 
IVR domains are involved in proteasome-dependent Nrf2 degradation (Kobayashi, et 
al., 2004). The DGR or Kelch domain binds to the Neh2 domain of Nrf2, anchoring 
Nrf2 into actin cytoskeleton (Itoh et al., 1999; Kang et al., 2004). From crystal 
structure analysis of the Kelch domain of human Keap1, it was revealed to have six 
structurally similar β-propeller blades (Li et al., 2004B). These inter- and intra-
blades, which are tied firmly by hydrogen bonds, are believed to construct the 
complex structure of Keap1-Nrf2 and its anchorage to actin. The C-terminal region 
of Keap1 was also shown to bind to the Neh2 domain of Nrf2 (Tong et al. 2006A). A 
“two-site molecular recognition model” has thus been proposed for Keap1-Nrf2 
complex whereby the two motifs, namely DLG and ETGE, in the Neh2 domain of 
Nrf2 independently associate with the Keap1-DC (DGR and CTR) (Tong et al., 
2006B). This double tethering of Nrf2 with Keap1 is thought to contribute to the 
overall stability of the Keap1-Nrf2 complex. 
3.2.3. The Nrf2 Signaling Pathway. 
     Under physiological/basal conditions, Keap1/Cul3-RBX1 complex is present in 
the cytosol constantly degrading Nrf2 (Kobayashi et al., 2004; Dhakshinamoorthy et 
al., 2004). In the absence of cellular stress, Nrf2 is tethered within the cytoplasmic 
Keap1 (Itoh et al., 1999; Dhakshinamoorthy et al., 2001), which interacts with the 
actin cytoskeleton (Kang et al. 2004). This interaction occurs between a single Nrf2 
protein and Keap1 dimer (Tong et al., 2006). Keap1 serves as a substrate linker 
protein for interactions with the Cullin 3 (Cul3)-based E3 ubiquitin ligase to 
regulate the stability of Nrf2 (Cullinan et al., 2004). Covalent conjugation of proteins 
by ubiquitin usually involves three enzymatic activities for activating (E1), 
conjugating (E2) and ligating (E3) ubiquitin to a substrate (Furukawa et al., 2005). 
In this case, Nrf2 serves as the substrate, while Cul3 serves as a scaffold protein 
that forms the E3 ligase complex Ring Box Protein 1 (Rbx1) that recruits a cognate 
E2 enzyme (Kobayashi et al., 2006).  
     Keap1, via its N-terminal BTB/POZ domain, binds to Cul3 (Geyer et al., 2003) 
and via its C-terminal Kelch domain binds to Nrf2, leading to the ubiquitination and 
proteasomal degradation of Nrf2 through the 26S proteasome (Stewart et al., 2003; 
Introduction 
 
 31 
Nguyen et al., 2003). While the Keap1-mediated ubiquitination and degradation 
occurs primarily in the cytosol, Keap1/Cul3-RBX1 complex is also present in the 
nucleus and degrades Nrf2 under basal conditions (Niture et al., 2009). Exposure to 
a number of stressors (such as APAP) and inducing agents leads to redox 
modulation of cysteines in Keap1, which lead to its dissociation of  Nrf2, thereby 
rescuing Nrf2 from proteasomal degradation(Figure 4) and allowing for the entry into 
the nucleus (Jain et al., 2005). Another mechanism for the activation of Nrf2 
involves secondary sensor proteins and the activation of kinase-mediated signaling 
pathways, resulting in phosphorylation of Nrf2 (Figure 4). Experiments revealed that 
phosphorylation of Nrf2 by protein kinase C (PKC) promotes its dissociation from 
Keap1 and that a serine to alanine mutation at amino acid 40 (S40A) in Nrf2, which 
is the target site for PKC, decreased this PKC-dependent dissociation (Bloom et al., 
2003; Huang et al., 2002). PKR-like endoplasmic reticulum kinase (PERK)-
dependent phosphorylation of Nrf2 also triggers dissociation of the Nrf2-Keap1 
complex (Cullinan et al., 2003). It also seems possible that PKC and/or PERK or 
their upstream signaling molecules may act as sensors for oxidative stress 
(Kobayashi et al., 2006). Therefore, it appears that both Keap1 modification and 
PKC/PERK phosphorylation of Nrf2 are required for its activation (Niture et al., 
2009). Upon interruption of Keap1-Nrf2 binding, Nrf2 translocates to the nucleus 
where, in association with small Maf proteins modulates transcription of the ARE-
containing genes (Itoh et al., 1997) and coordinates the transcription of genes 
involved in phase II detoxification and antioxidant defence (Kaspar  et al.,2009; 
Shelton et al 2013).  
     Chronic Nrf2 activation within the nucleus has been shown to be harmful and in 
mouse models results in postnatal death from malnutrition and hyperkeratosis and 
increased risk for tumorigenesis (Wakabayashi et al., 2003). Because of this 
potentially pathogenic role, mechanisms exist within the cell to degrade Nrf2 shortly 
following its activation. After translocation and accumulation of Nrf2, nuclear 
degradation occurs to prevent constitutive activation. The DGR region of Keap1 and 
prothymosin-α (PTMα), a chromatin remodeling nuclear protein, import Keap1 into 
the nucleus in a complex with CuI3 and Rbx1. Upon entering the nucleus, Keap1 
releases PTMα, binds to Nrf2, and triggers degradation to shut off downstream gene 
expression.  This autoregulatory loop between Nrf2 and Keap1 controls the 
abundance of each protein within the cytosol and nucleus, thus allowing for 
induction of phase II enzymes while preventing chronic constitutive expression of 
these genes  (Zhang et al ., 2005). 
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Along with Keap1/Cul3-RBX1 complex, additional negative regulators of Nrf2 
are present in the nucleus. In this regard, a delayed mechanism involving GSK3β 
and Src kinases family (SKF) that controls switching off of Nrf2 activation of gene 
expression has been recently demonstrated (Niture  et al., 2011; Rada et al., 2011 ). 
GSK3β is a multifunctional serine/threonine kinase, which plays a major role in 
various signaling pathways (Kannoji et al., 2008). SKF are frequently overexpressed 
and/or activated in human cancers and play key roles in cancer cell invasion, 
metastasis, proliferation, survival, and angiogenesis (Ingley 2008). The SKF contains 
two major subfamilies, including the Src subfamily and the Lyn subfamily (Ingley 
2008). Src subfamily has four members including Src, Yes, Fyn, and Fgr (Ingley 
2008).  
     Recently, it has been demonstrated that activation of GSK3β by its tyrosine 
phosphorylation at 216 by an unknown tyrosine kinase phosphorylates SKF at 
unknown threonine residue(s), leading to nuclear import/accumulation of these 
kinases that, in turn, phosphorylate Nrf2 at tyrosine 568. This was followed by Nrf2 
nuclear export and binding with Keap1 leading to its degradation (Figure 4).  
 
 
 
 
 
 
 
 
 
 
Figure4. Model depicting the role of GSK-3β in regulating nuclear 
export of Nrf2 via Fyn phosphorylation. 
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4. Molecular Mechanism Involved In Hepatocyte Survival Against  
Apoptotic Triggers: Role Of Protein Tyrosine Phosphatase 1B. 
4.1. Role Of PTP1B In The Balance Between Cell Death And Survival. 
     Cell survival and cell death are governed by stimulatory and inhibitory signals. 
Whereas trophic factors simultaneously stimulate mitosis and inhibit cell death, 
negative growth signals regulate the opposite of these biological effects. Deregulation 
of apoptosis represents an underlying cause or contributor to many diseases. In the 
liver, a balance between apoptotic and anti-apoptotic signals must be tightly 
controlled to prevent alterations during hepatic development and pathological 
conditions such as liver disease (Bursch et al., 2005) (Canbay et al., 2004). 
Activation of death receptors such as Fas/CD95 and TNFα, mitochondrial damage 
and oxidative stress of the ER are the major triggers of apoptosis that ultimately 
produce liver damage (Ockner 2001). On the other hand, in the liver, trophic factors 
include endogenous growth factors such as EGF, basic fibroblast growth factor 
(bFGF), TGF- and IGFs that act through receptors belonging to the tyrosine kinase 
superfamily (Schulte-Hermann et al., 1995). Consistent with this notion, inhibitors 
of tyrosine kinases and protein tyrosine phosphatases can also modulate apoptosis 
in the liver. 
     Protein tyrosine phosphatase 1B (PTP1B) was the first mammalian protein 
tyrosine phosphatase identified and purified to homogeneity (Tonks et al., 1988). 
This phosphatase is widely expressed and localizes predominantly to the ER 
through a cleavable proline-rich C-terminal segment. Cleavage of this segment 
appears to release the enzyme from the ER and increase its specific activity 
(Frangioni et al., 1993). The mechanism by which ER-bound PTP1B spatially and 
temporally interacts with plasma membrane or cytosolic substrates is not 
completely understood. In this regard, Haj et al. (Haj et al., 2002) demonstrated that 
dephosphorylation can occur at the ER membrane after endocytosis of activated 
receptors. On the other hand, time-lapse imaging analysis suggests that ER-bound 
PTP1B accesses its substrates by extending to immature focal adhesion sites or 
axonal growth cones in a microtubule-dependent manner and it is required for 
proper cellular matrix attachment and motility (Hernandez et al., 2006). Finally, 
some proteins may act as linkers to facilitate the binding of PTP1B to its substrates. 
In this model, phospholipase C gamma (PLC) binds simultaneously to PTP1B and 
its substrate JAK2 by forming a ternary complex and facilitates its inactivation 
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(Choi et al., 2006). Similarly, the binding of PTP1B to the cytoplasmic domain of N-
cadherin facilitates the dephosphorylation of β-catenin and promotes the assembly 
of the cell-cell adhesion N-cadherin-β-catenin complex (Balsamo et al., 1996). 
     In addition to its location at the ER surface, four mechanisms sometimes 
working in tandem are known to regulate PTP1B activity: oxidation, 
phosphorylation, sumoylation and proteolysis. PTP1B activity is regulated in vivo by 
reversible oxidation involving cysteine 215 at its active site, which temporarily 
abrogates its enzymatic activity. Such redox modification is an important 
mechanism in determining the extent and duration of phosphotyrosil-dependent 
signaling responses. In this regard, a transient burst of ROS with the subsequent 
inactivation of PTP1B has been reported in response to EGF (endogenous growth 
factors) or insulin stimulation (Meng et al., 2003). Very recently, it has been 
reported that expression of conformation-sensor scFvs as intracellular antibodies 
(intrabodies) stabilized oxidized inactive form of PTP1B and enhanced insulin-
induced tyrosyl phosphorylation of IR and its substrate IRS1 and increased insulin-
induced phosphorylation of protein kinase B (AKT). These data suggest that 
stabilization of this conformation of PTP1B with appropriate therapeutic molecules 
may offer a paradigm for phosphatase drug development (Haque et al., 2011). 
Regarding phosphorylation, PTP1B is regulated by both serine and tyrosine 
phosphorylation although this effect is still controversial. For instance, 
phosphorylation of PTP1B at Ser 50 by Akt can decrease its enzymatic activity 
towards the activated insulin receptor (IR), perhaps as a part of a positive feed-back 
loop to regulate insulin signaling (Ravichandran et al., 2001). By contrast, the dual-
specific kinases CDK-like linase 1 and 2 (CLK1 and CLK2) are also able to 
phosphorylate PTP1B at the same residue resulting in two-fold stimulation of its 
activity. The reason for these discrepant results is not known. Similar controversial 
results have been reported by tyrosine phosphorylation of PTP1B at tyrosines 66, 
152 and 153 in response to insulin stimulation (Bandyopadhyay et al., 1997; Dadke 
et al., 2001). Regarding sumoylation, a recent report showed that PTP1B interacts 
with small ubiquitin-related modifier (SUMO) E3 ligase on lysines 335 and 347 
resulting in reduction of its capacity to dephosphorylate the IR (Dadke et al., 2001). 
Finally, in vivo experiments have revealed that calpain-1 proteolyzes PTP1B into 
inactive fragments in platelets (Kuchay et al., 2007). 
     The fact that PTP1B has been related with the sensitivity of tumour cells to 
apoptosis induced by TNF (Perez et al., 1999) prompted several groups to 
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investigate the involvement of this phosphatase in the susceptibility of hepatocytes 
to undergo apoptosis induced by different stimuli in cellular systems and in models 
of hepatotoxicity in mice. In immortalized hepatocytes, PTP1B deficiency concurs 
with the attenuation of the cellular apoptotic machinery in response to growth factor 
withdrawal, whereas PTP1B over-expression accelerates cell death (Gonzalez-
Rodriguez et al., 2007b). Early activation of caspase-3 occurred in hepatocytes that 
overexpress PTP1B, but was nearly abolished in PTP1B-/- cells. At the molecular 
level, PTP1B overexpression/deficiency altered the balance of pro-(Bim) and anti-
(Bcl-xL) apoptotic members of the Bcl-2 family upon serum withdrawal. Likewise, 
cytosolic cytochrome C increased rapidly in hepatocytes with increased PTP1B 
expression whereas it was retained in the mitochondria of PTP1B-/- cells. Similar 
modulation was observed in the analysis of DNA laddering and hypodiploid cells.  
     TGF-β plays a dual role in hepatocytes, mediating both tumour suppressor and 
promoter effects (Fabregat et al., 2007). The suppressor effects of this cytokine can 
be negatively regulated by activation of survival signals, mostly dependent on 
tyrosine kinase activity. Using immortalized hepatocytes, Ortiz et al. (Ortiz et al., 
2012) have found that PTP1B deficiency conferred resistance against TGF-β 
mediated apoptosis and growth inhibition. At the molecular level, this effect 
correlated with lower Smad2/Smad3 phosphorylation and nuclear translocation, 
the lack of up-regulation of the inhibitory Smad7 and sustained activation of Akt 
and ERK1/2. Interestingly, in the presence of the general tyrosine kinase inhibitor 
genistein both responses were recovered. Moreover, PTP1B-/- hepatocytes stimulated 
with TGF-β showed elevated NF-κB activation. In the light of these results, 
knockdown of the NF-κB p65 subunit increased the response to TGF-β of PTP1B-/- 
hepatocytes in terms of Smad2/3 phosphorylation and apoptosis. The lack of PTP1B 
also promoted an altered NADPH oxidase (NOX) expression pattern induced by TGF-
β ,strongly increasing the NOX1/NOX4 ratio, which was reverted by genistein and 
NF-κB p65 subunit knock-down. Alternatively, NOX1 knock-down in PTP1B-/- 
hepatocytes recovered the apoptotic response to TGF-β through the inhibition of 
nuclear translocation of NF-κB p65 subunit, increase of Smad2 phosphorylation 
and decrease of levels of the inhibitory Smad7. Altogether, these results highlight 
the role of PTP1B in the signaling cascades activated by TGF-β that involve 
Smads2/3, Smad7, NF-κB and NOX1/4 family members. Further work will be 
necessary to study the potential role of this novel pathway in pathological conditions 
characterized by kinase hyperactivation, such as liver cancer.  
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     The role of PTP1B in response to liver damage has been studied in vivo in mice 
injected with a lethal dose of the Fas/CD95 agonist antibody Jo2, a model of 
fulminant hepatitis (Sangwan et al., 2006). In agreement with the in vitro studies in 
hepatocytes, PTP1B-/- mice are resistant to Fas-induced liver damage and lethality.  
This is due to reduced hepatic apoptosis and reduced levels of circulating liver 
enzymes compared to the lethal effects in the wild-type mice including tachypnea, 
shallow breathing, and prostration indicative of severe liver failure. Histological 
analysis of livers from the Jo-2-injected wild-type mice that showed distress 
revealed parenchymal necrosis, haemorrhage, and hepatocyte apoptosis assayed by 
TUNEL, whereas livers from the majority of PTP1B-/- mice showed no significant 
histologic pathological features. Consistent with the histological data, cleavage of 
caspases-8, -9, -3, and -6, normally activated following Fas receptor oligomerization, 
was detected in liver extracts from wild-type mice 6 hours post-Jo-2 treatment but 
was significantly abrogated in PTP1B-/-  mice. Because activation of caspase-8 is one 
of the first events following activation of Fas/CD95, these data demonstrate that one 
of the earliest events in Fas-induced apoptosis is abrogated in PTP1B-/- mice. 
Protection against Fas-mediated apoptosis in the liver of PTP1B-/- mice correlated 
with an elevation and/or activation of numerous anti-apoptotic signaling proteins 
including FLIPL, ERK1/2 and NF-κB. In addition, the resistance of PTPIB-/- 
hepatocytes to Fas-mediated apoptosis also required tyrosine kinase activity, 
because as occurred with TGF-β (Ortiz et al., 2012), PTP1B-/- hepatocytes were 
rendered susceptible to Fas-mediated apoptosis by pretreatment with genistein. 
Upon analysis of different PTP1B substrates, it was found that HGFR/Met showed 
sustained tyrosine phosphorylation and increased activation of its downstream 
mediator ERK1/2 in both livers and primary hepatocytes lacking PTP1B after Jo-2 
treatment. The observation that the majority of PTP1B-/- mice are protected against 
Fas-mediated liver damage suggests that pharmacological manipulation of PTP1B 
activity may constitute a viable therapeutic modality for treatment against 
hepatotoxins and liver damage. A similar inhibition of caspase induction and death 
receptor-induced liver damage was demonstrated for the compound suramin 
(Eichhorst et al., 2004). Notably, suramin is an inhibitor of PTP1B at concentrations 
shown to provide protection to death receptor-mediated liver damage. This effect is 
promising since the efficacy of PTP1B inhibitors in hepatoprotection remains 
unexplored. 
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4.2. Metabolic Functions Of  PTP1B. 
     In mammalian cells, insulin is the principal hormone controlling glucose 
homeostasis, as it suppresses hepatic gluconeogenesis and promotes glycogen 
synthesis and storage in liver and muscle, triglyceride synthesis in liver and storage 
in adipose tissue, and amino acid storage in muscle (DeFronzo 2004). Insulin 
resistance in major insulin target tissues such as liver, adipose tissues and skeletal 
muscle is a key pathogenic feature of type 2 diabetes mellitus (T2DM). Among them, 
the liver plays a major role in controlling blood glucose homeostasis through the 
balance between glucose utilization and storage (Klover et al., 2004; Radziuk et al., 
2001). The molecular mechanism underlying hepatic insulin resistance is not 
completely understood, however, it is believed to involve impairment of the IR 
signaling network. A number of epidemiologic and clinical studies have shown a 
close association between nonalcoholic fatty liver disease (NAFLD) and chronic 
hepatitis C virus (HCV) infection and insulin resistance  (Angulo 2002; Bugianesi et 
al., 2005; Larter et al., 2006; Lauer et al., 2001). Therefore, one of the challenges 
facing researchers in the field is the selection of therapeutic targets against hepatic 
insulin resistance among components of the insulin signaling cascade.  
     PTP1B locus maps to human chromosome 20 in the region q13.1-q13.2 (Brown-
Shimer et al., 1990) and its mouse orthologous to the H2-H3 region of chromosome 
2 has been identified as a quantitative trait locus (QTL) linked to diabetes and 
obesity (Lembertas et al., 1997). Consistent with a role of PTP1B in human insulin 
resistance, single nucleotide polymorphisms associate with diabetes have been 
found within the coding and 3´UTR regions. PTP1B directly interacts with and 
dephosphorylates the activated IR (Salmeen et al., 2000) (Seely et al., 1996) and also 
exhibits high specific activity for IRS1 (Goldstein et al., 2001) (Figure 5). It has been 
reported that overexpression of PTP1B in hepatic cellular models such as Fao 
hepatoma cells impairs insulin-stimulated glucose metabolism and reduction of 
PTP1B in these cells increased insulin signaling (Egawa et al., 2001) (Clampit et al., 
2003). In vivo experiments have demonstrated that reduction of PTP1B expression 
by 60% in the liver of ob/ob mice increased IRS1/2 tyrosine phosphorylation and 
Akt activation in response to insulin (Gum et al., 2003). Mice lacking PTP1B 
exhibited increased insulin sensitivity at 10–14 week of age owing to enhanced 
phosphorylation of IR in liver and skeletal muscle, resistance to weight gain on a 
high-fat diet (HFD), and an increased basal metabolic rate (Elchebly et al., 1999) 
(Klaman et al., 2000). More recent studies have demonstrated that PTP1B re-
Introduction 
 
 38 
expression in the liver of PTP1B null mice leads to a marked attenuation of their 
enhanced insulin sensitivity (Haj et al., 2005). Moreover, liver-specific deletion of 
PTP1B improves glucose tolerance (Delibegovic et al., 2009). Interestingly, elevated 
PTP1B expression in the liver is induced by a high fat diet and coincides with 
increased levels of TNF-α and CD68, two markers of hepatic inflammation 
associated to steatosis (Zabolotny et al., 2008).  Altogether, these results reinforce 
the complexity of PTP1B actions in hepatic metabolism and underline the 
importance of the clinical trials that are actually being carried out with small 
molecular inhibitors of PTP1B that can be promising drugs for the treatment of 
hepatic insulin resistance and T2DM (Kasibhatla et al., 2007).  
 
 
                   
 
 
 
 
 
 
 
 
Figure 5. Critical nodes form an important part of the signalling network that 
functions downstream of the insulin receptor (IR) (black arrows) and the 
growth factor-1 receptor (IGF1R) (blue arrows). 
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Protein Tyrosine Phosphatase 1B negatively modulates the signaling 
pathways activated by receptors of the tyrosine kinase superfamily which are 
involved in hepatocyte survival. In fact, previous studies of the laboratory have 
assessed the role of PTP1B in mediating hepatocyte survival and liver 
regeneration.  However, PTP1B functions in physiological responses such as 
hepatocellular survival during drug injury are poorly understood. Our 
hypothesis is that PTP1B might modulate signaling pathways triggered in 
response to alterations in liver homeostasis induced by APAP. On this basis, 
the objectives of this study are: 
 
1- Assess PTP1B expression in APAP-induced acute liver failure in humans 
and hepatocytes.  
2- Analyze the effect of PTP1B deficiency on the activation of stress and 
survival-mediated signaling pathways in mouse hepatocytes. 
3- Study the effect of PTP1B deficiency on APAP-induced oxidative stress. 
4- Study APAP-mediated hepatotoxicity in wild-type and PTP1B-deficient 
mice.  
5- Investigate the cross-talk between subtoxic doses of APAP and insulin 
signaling in hepatocytes with or without PTP1B.  
6-  Analyze the effect of chronic administration of APAP in whole body 
glucose homeostasis in wild-type and PTP1B-deficient mice. 
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     1. Materials 
     1.1. Reagents. 
 Fetal bovine serum (FBS), Medium 199, Dulbecco's Modified Eagle Medium 
(DMEM), 0.25% Trypsin-0.02% EDTA, and Trizol® were from Gibco Life 
Technologies, Gaithersburg, MD, USA (www.invitrogen.com). 
 Insulin, Paracetamol (APAP), MG132, penicillin, streptomycin, 
Trichloroacetic Acid, Ethylenediaminetetraacetic acid (EDTA), o-
phthalaldehyde (OPT), Tris, Sucrose, 1,4-Dithiothreitol (DTT), 
Dinitrophenyl hydrazine, Guanidine and Crystal Violet were from Sigma-
Aldrich, St Louis, MO, USA (www.sigma-aldrich.com). 
 Protein A-agarose, leupeptin, and aprotinin were from Roche Molecular 
Biochemicals, Barcelona, Spain (www.roche-applied-science.com). 
 PP2 was purchased from Tocris Bioscience, Ellsville, MO, USA (www.tocris.com).  
 Reagents for protein electrophoresis were from BioRad, Hercules, CA, USA 
(www.bio-rad.com). 
 RNA spin kit was from HealthCare (www.gehealthcare.com). 
 Caspase-3 substrate (Ac-DEVD-AMC) was from Enzo Life Sciences (Lausen, 
Switzerland). 
 Renilla was from Promega (Madison, CA). 
 siRNA oligos targeted for mouse PTP1B and GSK3were synthesized by 
Dharmacon (www.thermoscientific.com). 
  Immunofluorescence mounting medium, ABC reagent and DAB 
(peroxidase substrate kit were from Vector Laboratories (Burlingame, CA), 
(www.vectorlabs.com).  
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1.2. Antibodies. 
Antibody Provenance Reference 
Anti-Akt Cell Signaling     
Technology (MA, USA) 
#9272 
Anti-cleaved (Asp175)           
caspase-3 
Cell Signaling #9661 
Anti-phospho JNK 
(Thr183/Tyr185) 
Cell Signaling #4668 
Anti-phospho p38 MAPK 
(Thr180/Tyr182) 
Cell Signaling #9211 
Anti-p38 MAPK Cell Signaling #9212 
Anti-ubiquitin Cell Signaling #3936 
Anti-Bclx  BD Biosciences (San 
Diego, CA). 
610211 
Anti-phospho GSK3β 
(pY216) 
     BD Biosciences 612312 
Anti-cytochrome C Santa Cruz 
Biotechnology (Palo Alto, 
CA). 
556433 
Anti-GSK3β Santa Cruz 6102019 
Anti-JNK Santa Cruz sc-571 
Anti-phospho-Akt1/2/3 
(Ser473) 
Santa Cruz sc-7985-R 
Anti-phospho-Akt1/2/3       
(Thr 308) 
Anti-phospho IGF-IR 
(Tyr1165/1166) 
Santa Cruz 
       
           Santa Cruz  
Sc-16646-R 
 
sc-01704 
Anti-phospho IRβ 
(Tyr1162/1163) 
Anti-Nrf2 
Santa Cruz 
                                                         
Santa Cruz 
sc-25203 
                                                  
sc-722 
Anti-Mcl1 Santa Cruz sc-819 
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Anti-Fyn Santa Cruz sc-16 
Anti-Keap1 Santa Cruz sc-33569 
Anti-human PTP1B Santa Cruz sc-14021 
Anti-IRS-1 Upstate (Millipore) 06-248 
Anti-IRS2 Upstate (Millipore) 06-506 
Anti-  Upstate (Millipore) 06-195 
Anti-mouse PTP1B Upstate (Millipore) 07-088 
Anti-HO1 Upstate (Millipore) AB1284 
Anti-phospho Ser (clone 
4A4) 
Upstate (Millipore) 05-1000X 
Anti-phospho Tyr (clone 
4G10) 
Upstate (Millipore) 05-321 
Anti-phospho Tyr IRS1 
(1179) 
Anti-Lamin B 
Upstate (Millipore) 
Abcam, Cambridge, UK 
07-844 
aB16048 
Anti-Cyp2E1  Abcam  aB19140 
Anti-Cytochrome C 
oxidase subunit I 
Molecular Probes 
(Eugene, OR). 
A-6403 
Anti-β actin Sigma Chemical CO. (St. 
Louis, MO, USA) 
A-5441 
Anti-c-Src Calbiochem (Merck 
Biosciences) 
MAb-327 
Anti-GCLc and GCLm   gift from T Kavanagh University of 
Washington,USA 
Anti-IGF-IR a gift of S. Pons CSIC, Spain 
                                         
Table 1 Primary Antibodies. 
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2. Methods 
2.1. In Vitro Experiments:- 
2.1.1. Cell Culture:- 
2.1.1.1. Primary Human Hepatocytes:- 
Human hepatocytes were isolated from liver biopsies obtained from twelve 
patients (eight male and four female aged 58 ± 4.0 years) at Hospital Santa 
Sofía (Córdoba, Spain) submitted to a surgical resection for liver tumours after 
obtaining patients’ written consent.  
 Hepatocytes isolation was based on the two-step collagenase procedure 
(Pichard et al., 2006). Cell viability was consistently >85%, as determined 
by trypan blue exclusion. 
 Hepatocytes (8×106 cells; 150.000 cells/cm²) were seeded at confluence 
on type I collagen-coated dishes (Iwaki, Gyouda, Japan) and maintained 
in DMEM-Ham-F12:William's E (1:1) medium supplemented with 26 
mmol/L NaHCO₃, 15 mmol/L HEPES, 0.29 g/L glutamine, 50 mg/L 
vitamin C, 2 mg/L insulin, 200 μg/L glucagon, 50 mg/L transferrin and 
4 ng/L ethanolamine containing 5% heat-inactivated fetal bovine serum 
(FBS) for 12 h. 
 The medium was removed, replaced with a fresh culture serum-free 
medium and hepatocytes were stimulated with various doses of APAP 
for different time periods.  
2.1.1.2. Human Chang Liver Cells (CHL):- 
CHL cells, purchased to the American Type Culture Collection (ATCC), were a 
gift from Dr P. Martín-Sanz (CSIC, Spain). These cells were grown in DMEM 
with 10% heat-inactivated FBS and stimulated with different doses and 
different time-periods. 
2.1.1.3. Primary Mouse Hepatocytes:- 
Mouse hepatocytes were isolated from male wild-type (PTP1B+/+) and PTP1B-
deficient (PTP1B-/-) mice, maintained on the same mixed C57/BL6 x 129 sv 
genetic background, at 10-12 weeks by perfusion with collagenase and 
cultured as previously described (González-Rodríguez et al., 2010). Isolated 
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hepatocytes were cultured in DMEM supplemented with 10% FBS for 24 h. 
Then, the medium was removed and replaced with DMEM plus 1% FBS and 
hepatocytes were stimulated with APAP for different time periods and 
different doses. 
2.1.1.4. Immortalized Neonatal Hepatocytes:-  
The generation and characterization of immortalized hepatocyte cell lines 
from wild-type and PTP1B-/- mice was previously performed in the laboratory 
(González-Rodríguez et al., 2007). Cells were grown in DMEM with 10% heat-
inactivated FBS and stimulated with various doses of APAP for various time 
periods. 
2.1.1.5. Maintenance Of Cell Lines:- 
The obtained cell lines were grown at 37ºC in 5% CO2 in DMEM 
supplemented with: 
 10% heat-inactivated FBS.  
 20 mmol/L Hepes pH 7.4. 
 Antibiotics: penicillin-G (0.12 mg/mL) and streptomycin (0.1 mg/mL). 
          When the cells had reached confluence, they were trypsinized 
according to the following procedure:  
 The culture medium was aspirated. 
 The cells were washed two times with phosphate buffered saline (PBS), 
pH 7.4.  
 Trypsin (0.25%)-EDTA was added for 1 minute, then removed. 
 The culture plates were maintained in the incubator for 2-3 minutes. 
 Then, the plates were removed from the incubator and carefully 
shacked. 
 Trypsin action was stopped by adding culture medium supplemented 
with 10% FBS. 
 The cell suspension was distributed between several plates. Cell 
density was adjusted to the requirements of each experiment. 
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2.1.1.6. Freezing And Thawing The Cell Lines:- 
When cells reached 80% confluence, they were washed twice with warm PBS 
and trypsinized as indicated above. Trypsinization was stopped with medium 
containing FBS-12% dimetylsulfoxide (DMSO). The cell suspension was 
introduced into a cryopreservation vial. Then, the vials were frozen according 
with the following steps:  
1:  -20°C for 1-2 hours.  
2:  -80°C for 15-24 hours. 
3:  -170°C in liquid nitrogen containers.  
Conservation:  The cells were stored frozen in liquid nitrogen. 
When required, cells were thawed by removing the vials from the liquid 
nitrogen container and incubating them at 37°C for 5 minutes. Once thawed, 
the cell suspension was seeded in culture dishes. 
2.1.2. Evaluation Of Cellular Viability:- 
Cell viability was determined by two alternative methods: gross detection of 
cell viability by using the crystal violet assay (Granado-Serrano et al., 2007) 
and analysis of cytotoxicity by measuring lactate dehydrogenase (LDH) leakage 
into the extracellular medium (Alia et al., 2005). 
2.1.2.1. Analysis Of Cellular Viability By Crystal Violet:- 
Measurement of cellular viability by crystal violet is also based on the integrity 
of the cell plasma membrane since when it is altered the dye can enter into the 
cell. Then, the dye enters into both the living and the dead cells and only 
remains inside the living cells. Thus, the amount of dye is proportional to the 
number of living cells. 
 Cells were seeded at low density (104 cells per well) in 12-well 
multiwall plates and they were grown for 20 hours. 
 Once cells were cultured under the experimental conditions 
required, the culture medium was discarded. 
 Cells were washed once with PBS. 
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 Cells were fixed with a suitable fixer (1% glutaraldehiyde) at least 10 
minutes at room temperature or overnight at 4ºC.                                                                                                                                                                                                                                                                                                                                            
 Cells were washed three times with PBS. 
 The remaining viable adherent cells were stained with crystal violet 
(0.2% w/v in 2% ethanol) for 20 minutes at room temperature. 
 Excess of crystal violet was discarded and plates were rinsed with 
tap water three times.  
 1% sodium dodecyl sulfate (SDS) was added to solubilize membranes. 
 The absorbance of each plate was read in a spectrophotometer at 560 nm.  
 Plates without cells were processed in parallel to correct the non-
specific adhesion of crystal violet to the plastic.  
 Remaining viable cells were calculated as the percentage of 
absorbance with respect to control cells (incubated in the absence of 
APAP). 
2.1.2.2. LDH Leakage Assay:-  
Cellular damage was evaluated by LDH leakage assay. An LDH assay was 
performed by assessing LDH released into the media as a marker of necrotic 
cell death.  
 Cells (2 × 105 per well) were treated with APAP for different conditions. 
 Briefly, after the different treatments the cell culture medium was 
collected in a new tube.  
 Cells were scraped in PBS.  
 Cells were first sonicated to ensure the breakdown of the cell membrane 
to release the total amount of LDH.  
 Then, cells were centrifuged at 1.000 x g for 15 minutes at 4ºC to clear 
up the cellular debris. 
 LDH assay mixture (1.35 mol/L Tris pH 7.4, 0.4 mmol/L NADH and 
0.08 mol/L pyruvate; pH 7) was prepared fresh for each experiment and 
was added to the sample.                                                                                              
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 10 µL of each sample was placed in duplicate to a 96 well plate. In the 
same manner, 10 µL of each culture medium were also placed in a 96-
well multiwell plate for the assay.  
 200 µL of the buffer mentioned above were added to each well. 
 Absorbance was measured at time zero (t=0) and after 5 minutes 
(t=5) in the spectrophotometer at an emission wavelength of 460 nm 
and an excitation wavelength of 340 nm. 
 The LDH leakage was estimated by the ratio between the LDH 
activity in the culture medium to the total LDH activity in the 
medium plus in the cells, as previously described (Welder et al., 
1994; Alia et al., 2006).   
2.1.3. Quantification of Apoptosis:-  
2.1.3.1. Quantification Of Apoptotic Cells By Flow Cytometry:-  
This method is based on the staining of DNA with propidium iodide. Propidium 
iodide intercalates between DNA bases, emitting fluorescence which intensity 
is proportional to the amount of cellular DNA. Staining with propidium iodide 
allows analyzing the percentage of cells in different cell cycle phases and also 
the percentage of apoptotic (hypodiploid) cells (Darzynckiewicz et al., 1992). 
 After induction of apoptosis by APAP at different doses, the supernatant 
was collected.  Attached cells were washed once with PBS.  
 Cells were trypsinized as described above. 
 Adherent and non-adherent cells were collected by centrifugation at 
2.500 x g for 5 minutes at 4ºC. 
 Cells were washed once with PBS followed by centrifugation at 2.500 x g 
for 5 minutes at 4ºC.  
 Cells were fixed with cold ethanol (80% v/v) for 1 minute.  
 Cells were centrifuged at 2.500 x g for 5 minutes at 4ºC. The cell pellet 
was resuspended in 2 ml of cold PBS. 
 Cells were centrifuged at 2.500 x g for 5 minutes at 4ºC. 
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 The cells were then washed, resuspended in 500 µL of PBS and 
incubated with RNAse A (10 µg) for 30 minutes at 37ºC. 
 After addition of 0.05% (w/v) propidium iodide, cells were analyzed by 
flow cytometry. 
2.1.3.2. Analysis Of Caspase-3 Activity:- 
The enzymatic activity of caspase-3 was measured by a fluorometric method. 
We define a unit of caspase-3 activity as the amount of active enzyme 
necessary to produce an increase in 1 fluorimetric arbitrary unit after 2-hour 
incubation with the reaction mixture. Briefly,  
 After treatment, cells were scraped off and then collected by 
centrifugation at 600 x g for 5 minutes at 4ºC. 
 Cells were lysed in 5 mmol/L Tris/HCl pH 8, 20 mmol/L EDTA and 
0.5% (v/v) Triton X-100. 
 Lysates were clarified by centrifugation at 15.700 x g for 10 minutes at 
4ºC. 
 Lysates were incubated with reaction mixture for 2 hours at 37ºC in the 
dark.   
 Reaction mixture contained :  
-25 µL of cell lysate.  
  -325 µL of assay buffer (20 mmol/L HEPES pH 7.5, 10% (v/v) glycerol, 
2mmol/L DTT).  
          -20 µM (final concentration) caspase-3 substrate.  
 Enzymatic activity was measured in a luminescence spectrophotometer (Perkin  
          Elmer LS-50, Norwalk, CT) (excitation, 380 nm;  emission, 440 nm). 
 Then, protein concentration of cell lysates was determined and the 
results were expressed as caspase-3 activity/micrograms of total 
protein. 
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2.1.4. Determination Of Cellular Oxidative Stress:- 
2.1.4.1. Determination Of GSH:- 
The content of GSH was quantified by the fluorometric assay of Hissin and Hilf 
(1976). The method takes advantage of the reaction of GSH with o-
phthalaldehyde (OPT) at pH 8.0. Briefly,  
 After the different treatments, the culture medium was removed. 
 Cells were scraped off then collected by centrifugation at 2.000 x g for 5  
minutes at 4ºC in PBS. 
 Cells were then resuspended in 5% (w/v) trichloroacetic acid containing 
2 mmol/L EDTA. 
 The cells were homogenized by sonication for 10 minutes. 
 Homogenates were centrifuged at 1.000 x g for 30 minutes at 4ºC. 
 50 µL of the clear supernatant was transferred to a 96 multiwell plate 
for the assay.  
 Then, 15 µL of 1 mol/L NaOH, 175 µL of 0.1 mol/L sodium phosphate 
buffer (SPB)  pH 8 containing 5 mmol/L EDTA  and 10 µL of 74 mmol/L 
OPT were added per well. 
 A standard curve with increasing concentrations of GSH was prepared 
and similar amounts were added as before.  
 The plate was covered with aluminium paper and was kept at room 
temperature for 15-20 minutes. 
 Fluorescence was measured at an excitation wavelength of 340 nm and 
emission wavelength of 460 nm. The results of the samples were 
referred to a standard curve of GSH as described (Alia et al., 2006)  
2.1.4.2. Measurement Of Intracellular Reactive Oxygen Species (ROS):-  
For visualization and analysis of intracellular ROS by flow cytometry, the 
oxidation-sensitive DCFH-DA probe was used.                                  
Materials and Methods  
 
52 
 For the assay, cells were plated in 6 well-multiwell plate at a rate of 2 
×10  cells per well. 
 Then the APAP was added for 6 h. 
 Later, cells were detached by trypsinization. 
 The cells were incubated with 5 μmol/L DCFH-DA for 30 minutes at 
37ºC. 
 Cellular fluorescence intensity was measured by using a FACScan flow 
cytometer (BD, San José, CA). For each analysis, 10.000 events were 
recorded. 
2.1.4.3. Determination Of Glutathione peroxidase (GPx) And Glutathione 
reductase (GR) Enzymatic Activities:- 
The determination of GPx activity is based on the oxidation of GSH by GPx, 
using t-BOOH as a substrate, coupled to the disappearance of NADPH by GR. 
GR activity was determined by following the decrease in absorbance due to the 
oxidation of NADPH utilized in the reduction of oxidized glutathione (G-S-S-G) 
(Rodríguez-Ramiro et al., 2011).   
 For the assay of the GPx and GR activities, 1.5 × 106 cells per well were 
treated with APAP for 16 h. 
 Cells were collected in PBS and centrifuged at 1.000 x g for 5 minutes 
at 4ºC.  
 Cell pellets were resuspended in 20 mmol/L Tris containing 5 mmol/L 
EDTA and 0.5 mmol/L 2-mercaptoethanol.  
 Cells were sonicated for 10 minutes.  
 Homogenates were centrifuged at 3.000 x g for 15 minutes at 4ºC. 
 Enzyme activities were measured with a mixture of (50 mmol/L 
potassium phosphate buffer pH 7.5 mmol/L GSH  and Glutathione 
Reductase 50 U/mL, 9.6 mmol/L NADPH) for the blank.  
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 Enzyme activities were measured with the same mix with adding 
samples instead of the buffer. 
2.1.5. Transfection:- 
2.1.5.1. Transient Transfection With siRNA:- 
RNA silencing (siRNA) has become a major application in research to perform 
"knock-down" experiments. The limitations of the silencing approach rely on 
the toxicity of the transfection procedure for cells as well as the off-target 
effects on the expression of other genes or proteins. Immortalized hepatocytes 
were seeded in 6 well-multiwell dishes and incubated overnight at 37ºC with 
5% CO2.  
 When 40-50% confluence was reached, cells were transfected with10 
nmol/L of PTP1B or 25 nmol/L GSK3β siRNAs or with similar 
concentrations of scrambled control siRNA following DharmaFECT 
General Transfection Protocol. 
 48 hours after the transfection, cells were used for experiments and 
treated with APAP for different time periods. 
2.1.5.2. Luciferase Assays:- 
Transient transfections of HEK293T cells were performed with the expression 
vectors for pcDNA3.1mNrf2-V5/HisB (a gift from Dr. J.D. Hayes, Biomedical 
Research Institute, Ninewells Hospital and Medical School, University of 
Dundee, Dundee, Scotland, United Kingdom), Renilla, and 3xARE-Luc (a gift 
of Dr J. Alam, Department of Molecular Genetics, Ochsner Clinic Foundation, 
USA) combined with myc-PTP1B (a gift of Dr M. Tremblay, Mc Graw Hill 
University, CA) only in the indicated cases. 
 HEK293T cells were seeded on 24-well plates (105 cells per well) and 
cultured in DMEM with 10% heat-inactivated FBS for 16 hours. 
 Then, the cells were transfected using calcium phosphate protocol. 
 After transfection, cells were treated with vehicle (PBS), APAP (10 and 
20 mmol/L) or tBHQ (15 μmol/L) for 16 hours.  
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 Cells were lysed and assayed for luciferase activity with the dual 
luciferase assay system (Promega), according to the manufacturer’s 
instructions. 
 Relative light units were measured in a GloMax 96 microplate 
luminometer with dual injectors (Promega). 
2.1.6. Immunoflorescencee:- 
 Cells were grown in glass coverslips until 80% confluence was reached. Then, 
cells were treated directly in 6 well-multiwell plates with APAP as indicated in 
the Results section. Cells were washed twice with PBS, fixed in 100% (v/v) 
methanol at -20ºC for 2 minutes and then processed to immunofluorescence. 
2.1.6.1. Nrf2 Immunofluorescence:- 
 Cells were blocked in Blocking Buffer (1% BSA in PBS) for 30 
minutes at room temperature.  
 While blocking, primary antibody was prepared by diluting as 1/50 
in 1% BSA in PBS. Primary anti-Nrf2 antibody was applied for 1 
hour at 37ºC or overnight at 4ºC. 
 Cells were washed four times (5 minutes each) with PBS. 
  Then, cells were incubated for 45 minutes at 37ºC with 
fluorescence-conjugated secondary antibody (Alexa 488 goat anti-
rabbit) followed by four final washes of 5 minutes each in PBS. 
 Immunofluorescence was examined in a Nikon Eclipse 90i 
microscope (camera Nikon DS-Qi1Mc at plan Apo 20x, N.A 0, 75 or 
at plan Apo 40x, N.A 0, 95).  
 
2.1.6.2.  4′,6′-diamidino-2-phenylindole (DAPI) Staining:- 
To examine the apoptotic changes in nuclei, DAPI (4′,6′-Diamidino-2-
phenylindole) staining assay was performed. 
 Cells were grown in glass cover slips and fixed as described above. 
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 After 80–90% confluence was reached, the cells were treated with 
different concentrations of APAP. 
 Cells were fixed with methanol for 3 minutes at -20°C in the dark. 
 Fixed cells were washed twice with PBS. 
 Then, cells were stained with 1 µmol/L DAPI for 15 minutes in the 
dark.  
 Then, cells were washed four times (5 minutes each time) with PBS to 
remove the excess of DAPI. 
 Cover slips were placed in a glass slide with immunofluorescence 
mounting medium (Vector, Burlingame, CA). 
 Nuclear morphology was analyzed by fluorescence microscopy in a 
Nikon Eclipse 90i microscope. 
 Then, the incidence of condensed and/or fragmented nuclei was 
calculated. 
2.1.7. Analysis Of Protein Expression:-     
2.1.7.1. Protein Extracts:- 
A- Preparation of total cell lysates. 
 Detached cells were collected by centrifugation at 600 x g for 5 minutes 
at 4ºC. 
 Attached cells were scraped off in ice-cold PBS and pelleted by 
centrifugation at 600 x g for 5 minutes at 4ºC. 
 Then, cells were resuspended in lysis buffer (25 mmol/L HEPES pH 7.4, 
2.5 nmol/L EDTA, 0.1% (v/v) Triton X-100, 1 mmol/L 
phenylmethylsulfonyl fluoride (PMSF), 5 μg/ml leupeptin and 2.5μg/ml 
aprotinin). 
 Cellular lysates were clarified by centrifugation at 15.700 x g for 10 
minutes at 4ºC. 
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 The supernatants were transferred to fresh tubes for immediate use or 
frozen at -80°C. 
 B- Extraction Of Nuclear And Cytosolic Proteins.  
We followed the methods of Andrews-Faller (1991) and Schreiber-Schaffner 
(1989). Briefly,  
 Cells were resuspended at 4ºC in Buffer A (10 mmol/L HEPES-KOH, pH 
7.9, 1.5 mmol/L MgCl2, 10 mmol/L KCl, 0.5 mmol/L DTT, 0.2 mmol/L 
PMSF, 0.75 µg/mL leupeptin, 0.75 µg/mL aprotinin).  
 Cells were allowed to swell on ice for 10 minutes.  
 Then, cells were vortexed for 10 seconds.  
 Samples were centrifuged at 400 x g for 2 minutes or at 15.700 x g for 
10 seconds at 4ºC. 
 The supernatant containing the cytosolic fraction was stored at -80ºC.  
 The pellet was resuspended in cold buffer C (20 mmol/L HEPES-KOH, 
pH 7.9, 25% glycerol, 420 mmol/L NaCl, 1.5 mmol/L MgCl2, 0.2 
mmol/L EDTA, 0.5 mmol/L DTT, 0.2 mmol/L PMSF, 0.75 µg/mL 
leupeptin, 0.75 µg/mL aprotinin) and incubated on ice for 20 minutes 
for high salt extraction.  
 Cellular debris was removed by centrifugation at 15.700 x g for 2 
minutes at 4ºC and the supernatant nuclear fraction was stored at –
80ºC.  
C- Preparation Of Mitochondrial And Cytosolic Extracts. 
For the preparation of mitochondrial and cytosolic extracts we followed the 
following protocol: 
 Cells were scrapped off in the culture media and then centrifuged at 
600 x g for 5 minutes at 4ºC.  
 The precipitates were resuspended in 3 ml of isotonic isolation buffer 
and collected by centrifugation at 600 x g for 5 minutes at 4ºC. 
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 Then, the isotonic isolation buffer was removed and the cells pellets 
were resuspended in 750 µl of hypotonic isolation buffer and incubated 
at 37ºC for 5 minutes. 
  Samples were homogenized using a teflon pestle Potter (Wheaton 
Instruments, Milville, cat. 903,475). 
 250 µl of hypertonic isolation buffer was added to balance the buffer´s 
osmolarity.  
 Samples were centrifuged at 400 x g for 5 minutes at 4ºC, the 
supernatants contained the cytosolic protein fraction and the pellets 
containing the mitochondrial fraction were resuspended in lysis buffer 
and kept on ice for 30 minutes.  
 Samples were centrifuged at 15.700 x g for 5 minutes at 4ºC. 
 The supernatants contained the mitochondrial protein fraction were 
kept at -80ºC until being used. 
 
 
                                Table 2. Mitochondrial isolation buffer 
2.1.7.2. Protein Determination:- 
Protein determination was performed by the Bradford dye method in 
duplicate, using the Bio-Rad reagent and BSA to prepare the standard curve.  
2.1.7.3. Immounoprecipitations:- 
Immunoprecipitations were performed to separate a specific protein from a 
total protein extract. 
 Protein A/G beads were prepared by washing the beads in Lysis Buffer 
3 times. Then, they were resuspended in Lysis Buffer at 1/1 proportion. 
Isotonic Buffer Hypotonic Buffer Hypertonic Buffer 
10 mmol/L Hepes pH 7.6 10 mmol/L Hepes pH 7.6 10 mmol/L Hepes pH 7.6 
1 mmol/L EDTA 1 mmol/L EDTA 1 mmol/L EDTA 
250 mmol/L sucrose 50 mmol/L sucrose 450 mmol/L sucrose 
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 Then 20 µL of Protein A/G beads were added to the total protein lysate.  
 Tubes were rotated for at least 2 hours at 4ºC. Then, beads were collected 
 by centrifugation at 15.700 x g for 5 seconds at 4ºC. Beads were washed  
4 times with 500 µL of cold Lysis Buffer.  
 40 µL of sample buffer were added to the beads. Samples were 
incubated 5 minutes at 95ºC and loaded into a gel as it will be 
described in the next section. 
2.1.7.4. Western Blot:- 
The western blot is a widely accepted analytical technique used to detect 
specific proteins in a sample of protein homogenate or extract. It uses gel 
electrophoresis to separate native or denatured proteins by their molecular 
weight. The proteins are then transferred to a membrane and further stained 
with antibodies specific to the target protein.  
Polyacrilamyde Gel Electrophoresis (SDS-PAGE):- 
 Sample Preparation: the protein extracts containing equals amount of 
protein (20-100 µg) were mixed with 4x loading buffer (for a final 
concentration of 1x) and heated at 95ºC for 5 minutes. A molecular 
weight marker was loaded in one lane (Bio-Rad). 
 Samples were stored at -20°C until they were used. 
 The preparation of gels and buffers for SDS-PAGE was performed as 
described in Antibodies: A Laboratory Manual (Ed Harlow, David P Lane). 
Loading Buffer Electrophoresis Buffer 
100 mmol/L Tris pH 7.6 25 mmol/L Tris pH 8.3 
10% Glycerol   (v/v) 250 mmol/L Glycine 
4% SDS (p/v) 0.1% SDS (p/v) 
0.2% Bromophenol blue (p/v)  
2 mmol/L β-mercaptoethanol  
                    
Table 3. Composition of the loading and electrophoresis buffer 
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B. Protein Transfer:- 
After the proteins were separated by SDS-PAGE, they were transferred to a 
nylon membrane (Immobilon P, Millipore). Membranes were activated for 1 
minute in methanol and then washed twice with distilled water. Membranes 
were maintained wet in transfer buffer. Two types of transfer were used:    
1-Semi-dry Transfer: We used the Trans-blot SD Semi-Dry (Bio-Rad). The 
conditions used were: voltage 15V and time 30-45 minutes depending on the 
size of the gel, the percentage of acrylamide and the size of the protein to 
study. 
 
 
 
 
 
 
 
 
Table 4. Composition of Transfer buffer. 
2-Wet Transfer: Wet transfer equipment Trans-Blot (Bio-Rad). The conditions 
used were: voltage: 70V and time 2 hours.  
C. Antibody staining:- 
 The membranes were blocked for 1 hour at room temperature or 
overnight at 4°C using blocking solution (5% non-fat dried milk or 3% 
bovine serum albumin(BSA)).  
 The membranes were washed with TBS supplemented with 0.05% (v/v) 
Tween 20 (TTBS) for four times (10 minutes each). 
 Then, the membranes were incubated with appropriate dilutions of 
primary antibody in TTBS overnight at 4°C or for 2 hours at room 
temperature. 
 The membranes were washed four times with TTBS (10 minutes each). 
SEMI-DRY  Transfer buffer      WET Transfer buffer 
48 mmol/L Tris pH 8.3 66 mmol/L Tris pH 8.5 
40 mmol/L Glycine 383 mmol/L Glycine 
20% (v/v) Methanol 20% (v/v) Methanol 
 0.1% (p/v) SDS 
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 Then, the membranes were incubated with the recommended dilution of 
labelled secondary antibody in TTBS at room temperature for 1 hour. 
 The membranes were washed three times with TTBS (10 minutes each) 
and we performed a final wash with TBS without Tween for another 10 
minutes. 
 For signal development immunoreactive bands were visualized using the 
ECL western blotting protocol (Millipore) and Agfa radiographic films. 
2.2. In Vivo Experiments:- 
2.2.1. Animal Models:- 
2.2.1.1 Acute APAP Treatment:- 
3 month-old wild type (PTP1B+/+) mice and PTP1B-deficient (PTP1B-/-) mice 
were used throughout the study. Mice were obtained from Abbot Laboratories 
as previously described (González-Rodríguez et al., 2010) and maintained on 
the same mixed genetic background (C57Bl/6J x 129 Sv/J). All Animal 
experimentation was conducted accordingly to the accepted guidelines for 
animal care of the Comunidad de Madrid (Spain). Mice were fed a standard 
chow diet ad libitum and had free access to drinking water. Overnight fasted 
mice were intraperitoneally (i.p.) injected with 300 mg/kg APAP dissolved in 
physiological saline. Control mice received an equivalent volume of saIine. 
Mice were sacrificed at 1, 3, 6 and 24 h and livers were collected and kept at -
80ºC. 
2.2.1.2. Chronic APAP Treatment:- 
3 month-old wild type (PTP1B+/+) mice and PTP1B-/- mice were used 
throughout the study. Mice were fed a standard chow diet ad libitum. Mice 
were treated with APAP in the drinking water for 6 months. APAP dose was 90 
mg/kg/day during the first 3 months of the treatment. Then, the APAP dose 
was increased to 120 mg/kg/day during the last 3 months of the treatment. 
Control mice had free access to drinking normal water. Mice were sacrificed 
after 6 months.  
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2.2.2. Analysis Of Alanine Amino Transaminase (ALT) Activity:- 
Blood was collected in tubes containing heparin and diluted 1/30 with saline 
(0.9% NaCl). ALT activity was determined by direct measurement with the 
Reflotron test (Ref. 10745120, Roche Diagnostics). 
2.2.3. Glucose, Pyruvate And Insulin Tolerance Tests:- 
Briefly, after chronic APAP treatment mice were fasted overnight and given an 
i.p. injection of 2 g D-glucose/kg for glucose tolerance tests (GTT) or sodium 
pyruvate (1.5 g/kg) for the pyruvate tolerance test (PTT) both dissolved in 
sterile saline. 
For measuring fasted glucose levels, blood was obtained from the tail vein and 
glucose concentrations were measured with an Accu-Check Aviva glucometer 
(Roche). Blood glucose was measured at time zero (t=0) before starting the 
experiment. Then, glucose or pyruvate were injected and glucose 
measurements were taken at 30, 60 and 90 minutes after injection. The area 
under the curve (AUC) was calculated as AUCGround (AUCG mmol/Lol/L * 
minutes) and represented in graph (Pruessner et al., 2003).   
Intraperitoneal insulin tolerance tests (ITT) were performed on 4 h fasted mice 
injected with 0.75 U/kg human regular insulin. Blood glucose was measured 
at time zero, 30 and 60 minutes after injection. 
2.2.4 Measurment of the Insulin Levels:-  
 
The blood was collected from mice that had been fasted for 24 h and the 
serum insulin was determined by RIA (Fernández-Millán et al., 2013). 
2.2.5. Liver histology:- 
Liver histology was performed according to the following steps: 
1-Chemical fixation of the tissue: after sacrifice, liver samples were fixed in 
4% paraformaldehyde for 48 hours. Subsequently, fixation was continued 
for a further 24 hours in 70% ethanol. 
2- Liver specimens were embedded in paraffin. Then, liver specimens were cut 
in 10 µm thickness slices and placed on glass slides (this step was 
performed at the histology service at IIB). 
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3- Hematoxilin and Eosin (H&E) staining was performed for the analysis of 
liver structures. 
4- Histological changes were analyzed and histological grading of hepatic 
necrosis was performed by two blinded observers as indicated. 
Necrosis in 30% of the total area (1 point). 
Necrosis in 30–60% of the total area (2 points). 
Necrosis in 60% of the total area (3 points). 
2.2.6. PTP1B immunohistochemistry:- 
We analysed PTP1B by immunohistochemistry in human liver samples. We 
obtained samples from 8 patients, some individuals intoxicated with APAP (five 
patients) and some healthy subjects (3persones). These samples were kindly 
donated from Dr Kenneth J. Simpson in the division of Clinical and Surgical 
Sciences, University of Edinburgh, Edinburgh EH164TJ, United Kingdom. 
Informed written consent was obtained from each patient. We also analysed 
mouse liver samples that were fixed as described above (section 2.2.5).  
2.2.6.1- Deparafinize/hydrate sections:-  
Tissue sections were embedded in paraffin and deparaffinised and dehydrated 
accordingly the following steps.  
 Sections were incubated twice in xylene for 5 minutes each. 
 Sections were incubated once in100% ethanol for 3minutes each. 
 Sections were incubated twice in 90% ethanol for 3 minutes each. 
 Sections were incubated once in 70% ethanol for 3 minutes each. 
 Sections were washed twice in distilled H2O for 5 minutes each. 
2.2.6.2 -Antigen Unmasking:- 
Antigen retrieval was performed by boiling the slides in 10 mmol/L sodium 
citrate buffer pH 6.0 for 2 minutes.  
2.2.6.3-Staining:- 
 Sections were washed in PBS three times for 5 minutes each. 
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 Then, sections were incubated in hydrogen peroxide 3% in PBS for 10 
minutes to block the endogenous peroxidase. 
 Sections were blocked with 6% BSA in PBS for 45 minutes at room 
temperature.  
 Blocking solution was removed and then slides were incubated with the 
primary antibody anti-PTP1B (1/250 dilutions in 1% BSA in PBS) 
overnight at 4ºC.  
 Antibody solution was removed and sections were washed three times 
in PBS for 5 minutes each. 
 Samples were incubated with a secondary antibody for 1 h at room 
temperature (biotinylated goat anti-rabbit antiserum 1/500 dilutions in 
1% BSA in PBS).    
 Secondary antibody solution was removed and sections were washed for 
four times with PBS for 5 minutes each. 
 Then, the slides were incubated with streptavidin/peroxidase for 30 
minutes at room temperature.  
 75-100 µl of DAB reagent (Vector Laboratories) was added to each 
section. 
 As soon as the sections develop stain, slides were washed in PBS for 5 
minutes followed by two washes with distilled H2O for 5 minutes each. 
 Sections were counterstained in Hematoxylin. 
 Sections were washed in distilled H2O two times for 5 minutes each to 
remove the excess of the dye. 
 Sections were dehydrated and mounted:  
o Sections were incubated in 70% ethanol twice for 10 seconds 
each. 
o Sections were incubated in 90% ethanol twice for 10 seconds 
each. 
o Sections were incubated in 100% ethanol twice for 10 seconds 
each. 
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o Sections were incubated in xylene twice for 10 seconds each. 
o The sections were mounted using DePeX (SERVA electrophoresis) 
as a mounting medium 
 Sections were examined in a Nikon Eclipse 90i microscope and light-
microphotographs were taken with an associated Leitz digital camera 
(Leitz DFC300 FXC).  
2.2.7. Analysis  of Oxidative Stress:- 
2.2.7.1. Determination of GSH:- 
For the analysis in liver samples, 50 mg of tissue were homogenized as 
described in section (2.1.4.1) Fluorescence was measured at an excitation 
wavelength of 340 nm and an emission wavelength of 460 nm. The results of 
the samples were referred to a standard curve of GSH.  
2.2.7.2. Determination Of Protein Carbonyl Content:- 
 Liver tissue (100-200 mg) was homogenized (1:5 w/v) in 0.25 mol/L Tris, 0.2 
mol/L sucrose and 5 mmol/L 1,4-dithiothreitol cold buffer, pH 7.4. 
 Then, samples were centrifuged at 10.000 x g for 30 minutes at 4ºC. 
 Liver homogenates were incubated with 4 volumes of 10 mmol/L DNPH 
for 1 hour in dark at room temperature. The samples were vortexed 
every 15 minutes. 
 In parallel, the corresponding blank was prepared for each sample in 
the same order but the liver homogenates were incubated with 4 
volumes of 2 mol/L HCL. 
 Both samples and blanks were precipitated with the same volume of 
20% TCA (final TCA concentration 10%).  
 Samples were incubated 10 minutes on ice  
 Samples were centrifuged at 10.500 x g for 1 minute at 4ºC. 
 The pellets were washed three times in 1 mL of a mix of ethyl acetate 
and 96% ethanol (1:1). 
 Pellets were resuspended in 500 μL of 6 M guanidine, pH 2.5. 
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 Protein oxidation of liver homogenates was measured as carbonyl 
groups content according to the method of Richert (Richert etal., 2002).  
 Absorbance was measured at 360 nm and carbonyl content was 
expressed as nmol/mg protein using the extinction coefficient 22.000 
nmol/L/cm. Protein content in liver homogenates was measured with 
the Bradford reagent. 
 2.2.8. Determination Of APAP-Protein Adducts:- 
Analysis of APAP covalently bound to proteins in liver was measured by initial 
protease treatment of liver homogenates. 
 100 mg of liver tissue were placed into 1 mL of ice cold PBS containing 
8.0 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na₂PO₄ and 0.24 g/L KH₂PO₄ and 
adjusted to pH 7.2.  
 Samples were homogenized and the homogenates were centrifuged at 
10.000 x g for 30 minutes at 4ºC.  
 The supernatants were removed and stored at -80°C. 
Samples were sent to Drs Lynda Letzig and Laura P. James in the Section of 
Clinical Pharmacology and Toxicology, Arkansas Children´s Hospital, Little 
Rock, USA for analysis of APAP-cysteine adducts by high performance liquid 
chromatography-electrochemical (HPLC-EC) as described in Kenneth et al., 
2002.  
 
2.2.9. Analysis of Protein Expression:-  
2.2.9.1. Preparation of Protein extracts:- 
 Frozen livers were homogenized in 16 volumes (w/v) of ice-cold lysis 
buffer containing 50 mmol/L Tris-HCl, 1% Triton X-100, 2 mmol/L 
EGTA, 10 mmol/L EDTA acid, 100 mmol/L NaF, 1 mmol/L Na4P2O7, 2 
mmol/L Na3VO4, 100 µg/ml PMSF, 1 µg/ml aprotinin, 1 µg/ml 
pepstatin A and 1 µg/ml leupeptin.  
 Liver was homogenized in the same lysis buffer using the Brinkman PT 
10/35 Polytron.  
 Extracts were kept ice-cold at all times.  
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 Liver extracts were cleared by microcentrifugation at 40.000 x g for 20 
minutes at 4ºC. The supernatant was aliquoted and stored at -80ºC. 
2.2.9.2 - Extraction of nuclear and cytosolic proteins:- 
 Livers were resuspended at 4ºC in 10 mmol/L HEPES-KOH, pH 7.9, 1.5 
mmol/L MgCl2, 10 mmol/L KCl, 0.5 mmol/L DTT, 0.2 mmol/L PMSF, 
0.75 µg/ml leupeptin and 0.75 µg/ml aprotinin (Buffer A).  
 Then, samples were allowed to swell on ice for 10 minutes. 
 Samples were vortexed for 10 seconds at maximum speed.  
 Samples were centrifuged at 1.500 x g for 3 minutes at 4ºC.  
 The supernatant containing the cytosolic fraction was stored at -80ºC.  
 Pellet was re-suspended in cold buffer B (20 mmol/L HEPES-KOH, pH 
7.9, 25% glycerol, 420 mmol/L NaCl, 1.5 mmol/L MgCl2, 0.2 mmol/L 
EDTA, 0.5 mmol/L DTT, 0.2 mmol/L PMSF, 0.75 µg/ml leupeptin and 
0.75 µg/ml aprotinin) and rotate at 4ºC in the cold room for 20 
minutes. 
 Cellular debris was removed by centrifugation at 15.700 x g for 10 
minutes at 4ºC and the nuclear supernatant fraction was stored at –
80ºC.  
The analysis of protein expression was performed by western blot as described 
in 2.2.7.4 section. 
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2.2.10. Analysis of gene expression by Quantitative Real-time PCR. 
Total RNA extraction from liver samples was performed with Trizol. Total RNA 
was reverse transcribed using the SuperScriptTM III First-Strand Synthesis 
System for qPCR following manufacturer¨s indications (Invitrogen). qPCR was 
performed with an ABI 7900 sequence detector using the SyBr Green method 
and d(N)6 random hexamer with the primers indicated in Table 2. Primer-
predesigned TaqMan gene expression assays (Applied Biosystems).  
Table 5. Primers used in qPCR reactions. 
2.2.11. Data Analysis. 
Data are expressed as mean ± SEM. Comparisons between groups were made 
using one-way ANOVA. For qRT-PCR a two way ANOVA test followed by a 
Bonferroni’s post-test has been used. Differences were considered to be 
statistically significant at P<0.05. The data were analyzed by the SPSS for 
Windows statistical package, version 9.0.1. 
Gene Product Forward Primer Reverse Primer 
NQO1 5’-GGTAGCGGCTCCATGTACTC-3’ 5’-CATCCTTCCAGGATCTGCAT-3’ 
GPx 5’-GGACTACACCGAGATGAACG-3’ 5’-GATGTACTTGGGGTCGGTCA-3’ 
HO-1 5’-CACAGATGGCGTCACTTCGTC-3’ 5’-GTGAGGACCCACTGGAGGAG-3’ 
GCLM 5’-TTACCGAGGCTACGTGTCAGAC-3’ 5’-TATCGATGGTCAGGTCGATGTC-3’ 
GCLC 5’-AATCAGCCCCGATTTAGTCAGG-3’ 5’-CCAGCTGTGCAACTCCAAGGAC-3’ 
Β-actin 5’-TCCTTCCTGGGCATGGAG-3’   5’-AGGAGGAGCAATGATCTTGATCTT-3’ 
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1. ROLE OF PTP1B IN APAP-INDUCED ACUTE LIVER FAILURE:- 
1.1 Induction of cell death paralleled PTP1B expression during APAP-
induced liver injury in human liver and APAP-treated human hepatocytes.  
First, we investigated if PTP1B protein levels were modulated during APAP-
induced human liver injury. For this goal, we analyzed PTP1B expression by 
immunohistochemistry in liver sections of individuals intoxicated with APAP. 
These samples were obtained from Dr Kenneth J. Simpson in the division of 
Clinical and Surgical Sciences, University of Edinburgh, Edinburgh EH164TJ, 
United Kingdom. 
Characteristics of five patients transplanted following APAP overdose are shown 
in Table 1. Figure 6A shows elevated PTP1B expression in surviving 
hepatocytes, mainly in the areas surrounding the central veins (middle panel), 
during APAP intoxication as compared to a normal liver (left panel). In a more 
severe intoxication (right panel), where is difficult to detect surviving 
hepatocytes, strong staining was observed in precipitated proteins released from 
dead cells and not yet cleared (Characteristics of five patients transplanted 
following APAP overdose are shown in table 6).  
In agreement with this, PTP1B protein content was up-regulated in human 
primary hepatocytes and in the human liver cell line CHL treated with APAP in a 
dose and time-dependent manner (Figures 6B, 6C, Figure 7). Elevated PTP1B 
expression was detected at 8 h after APAP addition whereas cells with death 
morphology were visualized at 16 h.  
 
Table 6. Demographic and biochemical characteristics of patients with APAP hepatotoxicity. A= 
not available; Normal range alanine aminotransferase 10-50IU/L, creatinine 60 120 umol/L, 
prothrombin time 10.2-12.7 secons. 
 
Moreover, in APAP-treated human hepatocytes in a dose-dependent manner for 
24h, activation of c-Jun N-terminal kinases 1/2 (JNK) and p38 mitogen-
activated protein kinase (p38 MAPK) and inhibition of Akt phosphorylation 
correlated with decreased levels of the anti-apoptotic Bcl2 family members BclxL  
 
Patient 
Number 
 
Age (years) 
 
 
Sex 
 
Acetamino
phen dose 
 
Staggered 
overdose 
Admission 
Alanine 
aminotran
sferase 
(IU/L) 
 
Admission 
Creatinine    
(umol/L) 
 
Prothromb
in time 
(seconds) 
Overdose 
to 
Transplant 
(hours) 
1 42 Female 32g No 12755 218 77 212 
2 43 Female NA* NA 7106 192 182 NA 
3 48 Male 16g Yes 20800 124 96 NA 
4 45 Female 10g No 1097 142 69 176 
5 36 Male 50g No 9847 152 87 70 
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and Mcl1  (myeloid cell leukemia sequence 1) and with detection of the active 
caspase-3 fragment (Figure 6D). 
 
Figure 6. PTP1B expression is increased during APAP-induced liver injury and in 
human primary hepatocytes treated with APAP. A. Representative anti-PTP1B 
immunostaining of liver biopsy sections from patients with histologically normal liver 
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(NL) or with an APAP overdose (APAP) (n=7). Bar scale 50 µm. B. Human primary 
hepatocytes were treated with various doses of APAP (5-20 mM) for 24 h. Total cell 
lysates were analyzed by Western blot with the corresponding antibodies against 
PTP1B and b actin as a loading control. Autoradiograms corresponding were 
quantitated by scanning densitometry. Results are means ± SEM. *P<0.05 and 
***P<0.001 APAP-treated versus non-treated cells. Representative phase-contrast 
microscopy images after APAP treatment. Bar scale 100 µm. C. Human primary 
hepatocytes were treated with 20 mM APAP for various time-periods (4, 8 and 24 h). 
Total cell lysates were analyzed by Western blot with the corresponding antibodies 
against PTP1B and b actin as a loading control. Autoradiograms corresponding were 
quantitated by scanning densitometry. Results are means ± SEM. *P<0.05 APAP-
treated versus non-treated cells. Representative phase-contrast microscopy images 
after APAP treatment. Bar scale 100 µm. D. Human primary hepatocytes were treated 
with various doses of APAP for 24 h and total cell lysates were analyzed by Western 
blot with the antibodies against phospho-JNK1/2, JNK1/2, phospho-p38, p38, active 
caspase-3, phospho-Akt, Akt, BclxL, Mcl1 and p85-PI3K as a loading control. *P<0.05 
and ***P<0.001 APAP-treated versus non-treated cells (n=3 independent experiments). 
 
 
Figure7. PTP1B expression is increased in CHL liver cells treated with APAP. A. CHL 
human liver cells were treated with various doses of APAP for 24 h or with 20 mM APAP for 
various time-periods. B. (upper panels) Total cell lysates were analyzed by western blot with 
the corresponding antibodies against PTP1B and b actin as a loading control. (lower panels) 
Representative phase-contrast microscopy images after APAP treatment. Bar scale 100 µm. 
  
 
1.2 PTP1B-deficient mouse hepatocytes are protected against APAP-
induced cell death.  
As occurred in human primary hepatocytes (Figure 6C), PTP1B was up-
regulated in primary hepatocytes from wild-type (PTP1B+/+) mice treated with 
APAP (10 mM) at 8 h whereas maximal cell death was observed at 16 h (Figure 
8A). 
Next, we explored the role of PTP1B in APAP-induced hepatotoxicity in mouse 
primary hepatocytes. Wild-type and PTP1B-/- primary hepatocytes were treated 
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with 5 and 10 mM APAP for 16 h and cell death was analyzed. Phase-contrast 
microscopy revealed many APAP-treated wild-type primary hepatocytes with 
death cell morphology.  
By contrast, most of PTP1B-/- primary hepatocytes remained attached to the 
plate and only few cells displayed a death phenotype (Figure 8B).  
Quantification analysis of crystal violet staining and released LDH activity 
showed that primary PTP1B-/- hepatocytes were more protected against APAP 
cytotoxicity. Analysis of nuclear morphology in cells treated with APAP for 16 h 
confirmed an increased incidence of condensed and/or fragmented nuclei in 
wild-type primary hepatocytes compared to PTP1B-/- cells (Figure 8C). Also, the 
percentage of hypodiploid (sub G0/G1) population increased in wild-type, but 
not in PTP1B-/- primary hepatocytes, as compared to their respective untreated 
cells. 
Apoptosis in APAP-treated wild-type primary hepatocytes correlated with 
release of cytochrome C from mitochondria as revealed by the decrease in its 
content in the mitochondrial compartment and with the subsequent activation 
of caspase-3 (Figure 8D). These effects were significantly ameliorated in 
PTP1B-/- primary hepatocytes. 
 
 
Results  
 
73 
 
 
Figure 8 PTP1B-deficient hepatocytes are protected against APAP-induced cell 
death. A. (left panel) Wild-type (PTP1B+/+) mouse primary hepatocytes were treated 
with 10 mM APAP for various time-periods. The expression of PTP1B was analyzed by 
Western blot. *P<0.05 APAP-treated versus non-treated cells (n=3 independent 
experiments). (right panel)  Representative phase-contrast microscopy images and 
analysis of the percentage of sub G0/G1 cell population by flow cytometry. B. 
PTP1B+/+ and PTP1B-/- primary hepatocytes were treated with APAP (5 and 10 mM) for 
16 h. (left panel) Representative phase-contrast microscopy images. Bar scale 100 µm. 
(right panel) Cellular viability and released LDH activity. C. PTP1B+/+ and PTP1B-/- 
primary hepatocytes were treated with APAP (5 and 10 mM) for 16 h. (left panel) 
Representative nuclear morphology images after DAPI staining and analysis by 
fluorescence microscopy. (right panel) Quantification of apoptotic nuclei. Percentage of 
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sub G0/G1 cell population analyzed by flow cytometry. D. (left panel) PTP1B+/+ and 
PTP1B-/- primary hepatocytes were treated with APAP (5 and 10 mM) for 16 h.  
Western blot with anti-cytochrome C and anti-cytochrome C oxidase antibodies in 
mitochondrial extracts. (right panel) PTP1B+/+ and PTP1B-/- primary hepatocytes were 
treated with APAP (10 mM) for various time-periods. Analysis of caspase-3 enzymatic 
activity. *P<0.05, **P<0.01 and ***P<0.001 PTP1B-/- versus PTP1B+/+ (n=4 independent 
experiments. 
 
 
 
 
 
1.3 PTP1B-deficient mouse immortalized hepatocytes are protected 
against APAP-induced cell death.  
 
Immortalized PTP1B+/+ hepatocytes were treated with APAP (1 mM) for 
different time periodes. PTP1B was up-regulated in PTP1B+/+ immortalized 
hepatocytes treated with APAP (1 mM) at 8 h (maximal cell death was observed   
later at 16 h).  
Phase-contrast microscopy revealed many APAP-treated wild-type hepatocytes 
with death cell morphology. But, most of PTP1B-/- immortalized hepatocytes 
remained attached to the plate and only few cells displayed a death phenotype 
(Figure 9A). Quantification analysis of crystal violet staining and released LDH 
activity showed that PTP1B-/- hepatocytes were more protected against APAP 
cytotoxicity. Analysis of nuclear morphology in cells treated with 1 mM APAP 
for 16 h confirmed an increased incidence of condensed and/or fragmented 
nuclei in wild-type hepatocytes compared to PTP1B-/- cells (Figure 4B). Also, 
the percentage of hypodiploid (sub G0/G1) population increased in wild-type, 
but not in PTP1B-/- hepatocytes, as compared to their respective untreated 
cells. In agreement with previous reports ( Wiger et al., 1997), APAP arrested 
both kinds of hepatocytes in S phase, but this effect was significantly reduced 
in PTP1B-deficient cells (Figure 10). Apoptosis in APAP-treated wild-type 
hepatocytes correlated with release of cytochrome C from mitochondria (Figure 
4C) and subsequent activation of caspase-3 at 8 (Figure 11) and 16 h (Figure 
2C), this effect being ameliorated in PTP1B-/- hepatocytes.  (Figure 9). 
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Figure 9. Immortalized PTP1B-deficient hepatocytes are protected against 
APAP-induced cell death. A. (left panel) Wild-type (PTP1B+/+) immortalized 
hepatocytes were treated with 1 mM APAP for various time-periods. The 
expression of PTP1B was analyzed by western blot. *P<0.05 APAP-treated vs. non-
treated cells (n=3 independent experiments). (right panel) Representative phase-
contrast microscopy images. Percentage of Sub G0/G1 cell population analyzed 
by flow cytometry. B. PTP1B+/+ and PTP1B-/- hepatocytes were treated with 
various doses of APAP for 16 h. (left panel) Representative phase-contrast 
microscopy images. (right panel) Cellular viability and released LDH activity. C. 
PTP1B+/+ and PTP1B-/- hepatocytes were treated with various doses of APAP for 
16 h. (left panel) Representative nuclear morphology images after DAPI stainning 
and analysis by fluorescence microscopy. (right panel) Quantification of 
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fragmented nuclei and percentage of Sub G0/G1 cell population by flow 
cytometry. D. PTP1B+/+ and PTP1B-/- hepatocytes were treated with various 
doses of APAP for 16 h. (left panel) Western blot of cleavage caspase-3 in total 
lysates and cytochrome C in mitochondrial extracts. (right panel) Analysis of 
caspase-3 enzymatic activity. *P<0.05, **P<0.01 and ***P<0.005 PTP1B-/- vs. 
PTP1B+/+ (n=4 independent experiments). Bar scale 50 µm. 
Figure 10. PTP1B-deficient hepatocytes are protected against 
APAP-induced S phase arrest. PTP1B+/+ and PTP1B-/- hepatocytes 
were treated with various doses of APAP for 16 h. A. S phase cell 
population percentage measured by flow cytometer. *P<0.05, **P<0.01 
and ***P<0.005 PTP1B-/- vs. PTP1B+/+ (n=4 independent experiments). 
Figure 11. PTP1B-deficient hepatocytes are protected against 
APAP-induced caspase-3 activation. PTP1B+/+ and PTP1B-/- 
hepatocytes were treated with various doses of APAP for 8 h. A. (upper 
panel) Analysis of total cell lysates by western blot. (lower panel) 
Caspase-3 enzymatic activity. *P<0.05 and ***P<0.005 PTP1B-/- vs. 
PTP1B+/+ (n=4 independent experiments). 
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1.4 Effect of PTP1B deficiency on the activation of stress and survival-
mediated signalling pathways in mouse primary and immortalized 
hepatocytes.  
Next, we analyzed stress-mediated and survival signalling in primary 
hepatocytes from wild-type and PTP1B-/- mice. JNK and p38 MAPK 
phosphorylation was detected at 8 h in primary hepatocytes treated with 10 mM 
APAP, this response being ameliorated in PTP1B-/- cells (Figure 12A). Survival 
signalling monitored by IGFIR phosphorylation, levels of insulin receptor 
substrates 1 (IRS1) and 2 (IRS2) and Akt phosphorylation, was reduced in 
APAP-treated wild-type primary hepatocytes, but it was preserved in PTP1B-/- 
cells.  
Consistently, anti-apoptotic markers BclxL and Mcl1 were decreased in wild-
type primary hepatocytes treated with APAP, but again, this effect was reduced 
in PTP1B-/- hepatocytes.  
 As observed in human and primary hepatocytes, APAP increased PTP1B 
expression in immortalized mouse hepatocytes. With regard to stress-mediated 
signaling, both JNK and p38 MAPK phosphorylation increased in APAP-treated 
wild-type hepatocytes in a dose dependent-manner, these effects being 
ameliorated in PTP1B-/- cells. Survival signaling monitored by IGFIR 
phosphorylation, levels of insulin receptor substrates 1 (IRS1) and 2 (IRS2) and 
Akt phosphorylation, was significantly reduced in APAP-treated wild-type 
hepatocytes, but it was preserved in PTP1B-/- cells treated with APAP. 
Consistently, anti-apoptotic markers BclxL and Mcl1 were decreased in wild-
type hepatocytes treated with APAP, but again, this effect was reduced in 
PTP1B-/- hepatocytes.  
In order to exclude the possibility that the protection elicited by PTP1B 
deficiency against APAP-induced cell death could be secondary to compensatory 
adaptations in immortalized cell lines, we established siRNA assays. As similar 
responses have been found in APAP-treated wild-type and PTP1B-/- primary and 
immortalized hepatocytes (Figure 12A, 12B), we used immortalized cell lines to 
conduct siRNA assays. Reduction of PTP1B expression in wild-type immortalized 
hepatocytes decreased APAP-induced JNK phosphorylation and the levels of the 
active caspase-3 fragment (Figure 12C). Silencing of PTP1B also maintained 
IGFIR tyrosine phosphorylation, IRS1 and IRS2 expression, Akt phosphorylation 
and abolished down-regulation of BclxL upon APAP treatment. 
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Figure 12. Effect of PTP1B deficiency in stress and survival signaling in 
hepatocytes. A. (left panel) PTP1B+/+ and PTP1B-/- mouse primary hepatocytes 
were treated with APAP (10 mM) for various time periods. Total cell lysates were 
analyzed by Western blot with the antibodies against phospho-JNK1/2, 
JNK1/2, phospho-p38 MAPK and p38 MAPK. Representative autoradiograms 
corresponding to three independent experiments are shown. (right panel) 
PTP1B+/+ and PTP1B-/- mouse primary hepatocytes were treated with APAP (5 
and 10 mM) for 16 h. Total cell lysates were analyzed by Western blot with the 
antibodies against phospho-IGFIR, IGFIR, IRS1, IRS2, phospho-Akt, Akt, BclxL, 
Mcl1 and b actin as a loading control. Representative autoradiograms 
corresponding to three independent experiments are shown. B. PTP1B+/+ and 
PTP1B-/- immortalized hepatocytes were treated with various doses of APAP for 
16 h. Total cell lysates were analyzed by Western blot with the indicated 
antibodies. Representative autoradiograms corresponding to three independent 
experiments are shown. C. Immortalized PTP1B+/+ hepatocytes transfected with 
10 nM of control or PTP1B siRNA for 48 h were further treated with various 
doses of APAP for 16 h. Total cell lysates were analyzed by Western blot with the 
indicated antibodies. Representative autoradiograms corresponding to three 
independent experiments are shown. 
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1.5 PTP1B deficiency protects mouse hepatocytes against GSH depletion 
and elevation of ROS: prolonged Nrf2 nuclear accumulation 
In the liver, Cyp2e1 converts APAP to NAPQI that rapidly depletes GSH, and 
therefore the degree of GSH consumption is a biomarker for APAP bioactivation 
(Kon et al., 2004). Since the expression of Cyp2e1 did not change in primary 
and immortalized hepatocytes from both genotypes of mice (Figure 13), we used 
immortalized cells for further experiments. 
 
Figure 13. Basal expression of Cyp2e1, GCL-C and GCL-M in mouse 
primary and immortalized hepatocytes. Whole cell lysates from 
PTP1B
+/+
 and PTP1B
-/- 
mouse
 
primary (left panel) and immortalized 
(right panel) hepatocytes  were analyzed by western blot with the 
indicated antibodies. Representative autoradiograms are shown.  
 
APAP-induced depletion of GSH was observed in wild-type immortalized 
hepatocytes after 4h treatment albeit this effect was absent in PTP1B-/- cells  
(Figure 14A). Likewise, a significant elevation of ROS (DCFH) was detected in 
APAP-treated wild type hepatocytes for 6 h, but not in PTP1B-/- cells. 
Next, we measured the enzymatic activity of detoxifying enzymes glutathione 
peroxidase (GPx) and glutathione reductase (GR). As depicted (in Figure 14A), 
GPx activity increased in APAP-treated wild-type hepatocytes as compared to 
untreated controls as expected for an anti-oxidant defense. Conversely, GR was 
not increased by APAP suggesting impairment in replenish of GSH stores.  
However, PTP1B-/- hepatocytes did not activate the GPx/GR system in response 
to APAP probably due to an insufficient threshold to trigger activation of 
detoxifying enzymes under these experimental conditions.  
To inspect at molecular level the reasons for protection of PTP1B deficiency 
against APAP-induced oxidative stress, we analyzed the dynamics of Nrf2 
nuclear accumulation. Since we did not observe differences in Nrf2 serine 
phosphorylation that leads to the dissociation of Nrf2 from its inhibitor Keap1 at 
early time-periods upon APAP treatment (Figure 15A), we studied nuclear 
accumulation of Nrf2 at later time-periods.  
Both western blot and immunofluorescence analysis revealed that Nrf2 was 
maximally accumulated in the nucleus at 8h after APAP treatment in both 
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kinds of immortalized hepatocytes, but it was retained for up to 16 h 
exclusively in PTP1B-/- cells (Figure 14B). Tyrosine phosphorylation of Nrf2 
results in its nuclear export, ubiquitination and degradation in the cytosol 
(Niture et al., 2011). As depicted in Figure 14C, in wild-type hepatocytes 
maximal Nrf2 tyrosine phosphorylation was observed at 8 h after APAP 
stimulation and total Nrf2 protein content decreased at 16h. In PTP1B-/- cells, 
maximal Nrf2 tyrosine phosphorylation was observed at 16 h, time at which 
total Nrf2 levels were maintained as in non-treated cells. Nuclear Nrf2 
accumulation was accompanied by decreases in cytosolic expression (Figure 
15B). These data correlated with a higher increase in the expression of the 
Nrf2downstream target heme oxygenase-1 (HO-1) in hepatocytes lacking 
PTP1B. As occurred in immortalized hepatocytes, Nrf2 levels were maintained 
and the induction of HO-1 was higher in APAP-treated mouse primary PTP1B-
/- hepatocytes for 16 h as compared to the wild-type cells. 
Next, ubiquitination analysis of Nrf2 was performed in immortalized 
hepatocytes treated with APAP for 8-24 h either in absence or presence of 
proteasome inhibitor MG132 (Figure 14D). 
In APAP-treated wild-type cells, ubiquitinated Nrf2 was detected at earlier 
time-period (8 h) compared with PTP1B-/- cells that displayed this response at 
16 h, this effect being enhanced when APAP was added in the presence of 
MG132.  
In related experiments, over-expression of PTP1B in HEK 293T cells inhibited 
antioxidant response element (ARE)-mediated luciferase expression after 
treatment with APAP for 16 h (Figure 14E), reinforcing the involvement of this 
phosphatase in Nrf2-mediated antioxidant response to APAP. 
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Figure 14. PTP1B deficiency protects hepatocytes against GSH depletion and 
elevation of ROS; effect on nuclear Nrf2 accumulation. PTP1B+/+ and PTP1B-/- 
immortalized hepatocytes were treated with various doses of APAP for different 
time-periods. A. Analysis of GSH content (4 h), ROS levels (6 h) and GPx and GR 
activity (16 h) in three independent experiments. *P<0.05, **P<0.01 and ***P<0.005 
PTP1B-/- versus PTP1B+/+ B. (upper panel) Analysis of Nrf2 in nuclear cell lysates by 
Western blot in PTP1B+/+ and PTP1B-/- immortalized hepatocytes treated with 1 
mM APAP for several time-periods. Representative autoradiograms of 3-4 
independent experiments are shown. (lower panel) Representative images 
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corresponding to the intracellular localization of Nrf2 by immunofluorescence 
microscopy in PTP1B+/+ and PTP1B-/- immortalized hepatocytes treated with 1 mM 
APAP for several time-periods. Bar scale 50 µm. C. (upper panel) PTP1B+/+ and 
PTP1B-/- immortalized hepatocytes were treated with 1 mM APAP for several time-
periods. Nrf2 tyrosine phosphorylation was analyzed by inmunoprecipitation with 
the anti-Nrf2 antibody followed by Western blot with the anti-Tyr(P) antibody. Total 
Nrf2 and HO-1 was analyzed by Western blot. (lower panel) PTP1B+/+ and PTP1B-/- 
mouse primary hepatocytes were treated with 10 mM APAP for various time-
periods. Total Nrf2 and HO-1 was analyzed by Western blot.  D. PTP1B+/+ and 
PTP1B-/- immortalized hepatocytes were treated with MG132 (10 nM) for 30 min 
and then with 1 mM APAP for different time-periods. Whole cell lysates were 
analyzed by inmunoprecipitation with anti-Nrf2 antibody followed by Western blot 
with anti-ubiquitin antibody. E. Antioxidant response element (ARE)-mediated 
luciferase activity was measured in HEK 293T cells transfected with the expression 
vectors for pcDNA3.1mNrf2-V5/HisB and 3xARE-Luc combined with myc-PTP1B 
only in the indicated cases and treated with various doses of APAP for 16 h. tBHQ 
(15 mM) was used as a positive control (n=3 independent experiments performed in 
triplicate). ***P<0.005 PTP1B-transfected (Nrf2 ARE+PTP1B) versus empty vector-
transfected (Nrf2 ARE) cells. 
 
 
Figure 15. A. Serine phosphorilation of Nrf2 and dissociation with its 
inhibitor Keap1 at early time-periods upon APAP stimulation in wild-type 
and PTP1B-/- hepatocytes. PTP1B+/+ and PTP1B-/- hepatocytes were treated 
with 1 mM APAP  for different time periods. Analysis of total cell lysates by 
inmunoprecipitation and western blot (n=3 independent experiments).  
B. Nuclear/cytosolic ratio in wild-type and PTP1B
-/- 
hepatocytes stimulated 
with APAP. Cells were stimulated with 1 mM APAP for various time-periods. Nrf2 
was analyzed in cytosolic extracts by Western blot. The ratio between 
nuclear/cytosolic Nrf2 was calculated. 
*
P<0.05 PTP1B
-/-
 vs. PTP1B
+/+
. 
 
 
1.6 PTP1B modulates GSK3β/SKF-mediated Nrf2 nuclear accumulation in 
APAP-treated mouse hepatocytes.  
In response to oxidative stress, GSK3β is activated by phosphorylation at Tyr 
216 by an unknown tyrosine kinase. Then, activated GSK3β phosphorylates an 
activates Src kinase family (SKF) members in the cytosol allowing their nuclear 
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translocation and subsequent tyrosine phosphorylation of Nrf2 at Tyr 568, 
ultimately resulting in Nrf2 nuclear exclusion and degradation (Niture et al., 
2011; Jain et al., 2007). Thus, we first examined if this molecular mechanism 
was triggered in APAP-treated hepatocytes. The efficacy of G3K3β siRNA in 
immortalized hepatocytes is shown in (Figure 16, 18).  
 
 
 
 
 
 
 
 
 
Figure 16. Reduction of GSK3β expression by 
siRNA in  PTP1B+/+  mouse hepatocytes. 
PTP1B
+/+
 cells were transfected with various 
doses of GSK3β siRNA for 48 h following 
DharmaFECT General Transfection Protocol and 
total cell lysates were analyzed by western blot. 
 
 
Silencing GSK3β in wild-type and PTP1B-/- cells hepatocytes prolonged Nrf2 
nuclear accumulation up to 24 h upon APAP treatment similar to our 
observations in PTP1B-/- cells (Figures 14B, 17). 
 
Figure 17. Reduction of GSK3β expression by siRNA in 
PTP1B
-/-
 mouse hepatocytes. PTP1B-/- cells were transfected 
25nm of GSK3β siRNA for 48 h following DharmaFECT General 
Transfection Protocol and total cell lysates were analyzed by 
western blot. 
 
Moreover, nuclear translocation of Fyn and Src was also impaired in GSK3β 
silenced cells, although no effects of nuclear translocation of Yes were observed 
(results not shown). To obtain further support for the role of SKF in nuclear 
accumulation of Nrf2 in response to APAP, we treated wild-type hepatocytes 
with the SKF inhibitor PP2. As shown in Figure 18B, PP2 increased nuclear Nrf2 
levels at 2-8 h after APAP treatment. In addition, mouse embryonic fibroblasts 
(MEFs) deficient in Src, Fyn and Yes (SYF-/-) treated with 1 mM APAP showed 
nuclear Nrf2 accumulation up to 24 h. We next analyzed the effect of PTP1B 
deficiency on the GSK3β/SKF signaling pathway. In wild-type cells, APAP-
induced GSK3β tyrosine phosphorylation was detected at 1 h and peaked at 4 h. 
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This response was parallel to the re-entry of Fyn and Src into the nucleus 
(Figure 18C). In PTP1B-/- hepatocytes, maximal GSK3β phosphorylation 
occurred at 8-16 h after APAP treatment and also paralleled with a latter re-
entry of Src and Fyn into the nucleus as compared to wild-type. 
Figure 18. PTP1B modulates GSK3b/Src-Fyn-mediated Nrf2 nuclear 
accumulation in APAP-treated hepatocytes. A. PTP1B+/+ immortalized 
hepatocytes were transfected with control or GSK3b siRNAs (25 nM) for 48 h 
followed by stimulation with 1 mM APAP. Nuclear and cytosolic extracts were 
analyzed by Western blot with antibodies against Nrf2, Fyn and Src. B. (upper 
panel) PTP1B+/+ immortalized hepatocytes were treated with PP2 (5 mM) for 30 
min following 1 mM APAP for different periods. Nrf2 in nuclear extracts was 
analyzed by Western blot. (lower panel) SYF-/- MEFs were treated with 1 mM 
APAP for different periods and Nrf2 was analyzed in nuclear extracts by Western 
blot. C. PTP1B+/+ and PTP1B-/- immortalized hepatocytes were treated with 1 
mM APAP for different periods. Phosphorylated GSK3β (Tyr 516) was analyzed  
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in cytosolic extracts by Western blot. Fyn and Src were analyzed in nuclear 
extracts. Similar results were obtained in 3 independent experiments. 
 
 
1.7 PTP1B-deficient mice are protected against APAP-induced oxidative 
stress through the enhancement of Nrf2 nuclear accumulation and IGFIR-
mediated survival signalling. 
Next, we evaluated liver injury induced by APAP to wild-type and PTP1B-/- 
mice. Increased survival was observed in PTP1B-/- mice injected with an APAP 
overdose (300 mg/kg) (Figure 19A). Consistently, serum alanine transaminase 
(ALT) was seven-fold higher in wild-type mice than in PTP1B-/- mice at 6 h 
post-injection; these differences were maintained at 24 h (Figure 19B). At this 
time, necrotic lesions were observed exclusively in livers of wild-type mice 
(Figure 19C). 
PTP1B deficiency also protected against a higher dose of APAP (500 mg/kg) 
(Figure 20). Next, we analyzed the expression of pro-inflammatory cytokines in 
livers of both genotypes of mice. At 6 h post APAP injection, elevated IL6 and 
IL1β mRNA levels were found in livers of wild-type mice, but not in PTP1B-/- 
animals (Figure 19D). Of note, APAP decreased TNFα mRNA levels in wild-type, 
but not in PTP1B-deficient mice.  
Since hepatic PTP1B expression is modulated by inflammation (Zabolotny et al., 
2008), we performed immunohistochemistry analysis of wild-type and PTP1B-/- 
livers. As shown in (Figure 19E), increased PTP1B staining was found in 
necrotic lesions of APAP-treated wild-type mice after 6h, particularly in areas 
surrounding the central veins.  
By contrast, not histological signs of liver injury were observed in sections from 
PTP1B-/- mice. We next determined if reduced sensitivity of PTP1B-/- mice to 
APAP-induced liver injury was associated with alterations in GSH levels. In 
livers of both mouse strains, the basal expression of Cyp2e1, both the catalytic 
and the modifier subunits of γ-glutamyl cysteine ligase (GCL-C and GCL-M) and 
basal GSH level were comparable (Figure 21). 
APAP administration depleted GSH at 3 and 6 h and increased APAP-protein 
aducts, but these effects being significantly ameliorated in the PTP1B-/- group 
(Figure 19F). Moreover, protein carbonyl levels, an indicator of tissue oxidative 
stress, were less elevated in APAP-injected PTP1B-/- mice than in wild-type 
controls and paralleled with reduced GSH depletion. 
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As intracellular redox state is chiefly regulated by Nrf2, we examined possible 
differences in nuclear levels of Nrf2. Nuclear Nrf2 was detected in wild-type mice 
at 3 and 6 h after APAP treatment (Figure 22A). In PTP1B-/- animals, basal 
nuclear Nrf2 was detected before APAP administration and increased at 3 and 6 
h after injection, where the levels were higher than those of control mice. 
Similarly, HO-1 induction in response to APAP was higher in PTP1B-/- mice. 
Next, we analyzed Nrf2 target genes. As shown in Figure 22B, mRNA levels of 
GPx, HO-1 and GCL-M (γ-glutamyl cysteine ligase modulatory subtunit ) 
significantly increased at 3 h post-APAP injection in livers of PTP1B-/- mice as 
compared to the wild-type controls and GPx, GCL-C (γ-glutamyl cysteine ligase 
catalytic subtunit), GCL-M and NQO1 (NAD(P)H quinone oxidoreductase) 
increased at 6 h. 
 
1.8 Decreased activation of JNK and maintenance of IGFIR/Akt/BclxL 
survival signaling in APAP-treated PTP1B-deficient mice.  
Activation of JNK was detected in APAP-treated wild-type mice at 3 and 6 h 
post-injection. As expected, this effect decreased in PTP1B-/- mice (Figure 22A). 
Regarding survival signaling, in wild-type mice phosphorylation of Insulin-like 
growth factor I receptor (IGFIR) was severely reduced at 6 h post-APAP injection 
and IRS1 protein levels were down-regulated in parallel with decreased Akt 
phosphorylation (Figure 22C). Consistently, anti-apoptotic BclxL protein was 
barely detected at 6 h post-APAP injection. Conversely, APAP-treated PTP1B-/- 
mice maintained IGFIR and Akt phosphorylation, as well as IRS1 and BclxL 
protein content to similar levels than those of mice injected with saline. 
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Figure 19. PTP1B-deficient mice are protected against APAP-induced, 
inflammation oxidative stress and liver damage. PTP1B+/+ and PTP1B-/- mice were 
injected with 300 mg/kg APAP or saline for 6 or 24 h. A. Survival curves after 24 h of 
APAP injection. B. Serum transaminase (ALT) activity at 6 and 24 h. C. Representative 
images of whole livers from PTP1B+/+ and PTP1B-/- mice 24 h after APAP injection. D. 
IL6, I1b and TNFa mRNA levels were determined by real-time PCR in livers from 
PTP1B+/+ and PTP1B-/- mice at 6 h after APAP injection. E. Representative anti-PTP1B 
immunostaining (left panel) and Hematoxylin & Eosin staining (right panel) in livers 
from PTP1B+/+ and PTP1B-/- mice 6 h after APAP injection. Bar scale 100 µm. F. GSH 
(left panel), APAP-protein aducts (middle panel) and carbonylated protein levels (right 
panel) were analyzed in livers from PTP1B+/+ and PTP1B-/- mice at various time-periods 
after APAP injection. *P<0.05, **P<0.01 and ***P<0.005 PTP1B-/- versus PTP1B+/+ (n= 6-
8 mice of each condition).  
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Figure20. PTP1B-deficient mice are protected against liver damage 
induced by a higher dose of APAP. PTP1B
+/+
 and PTP1B
-/-
 mice were injected 
with 500 mg/kg APAP or saline for 6 h. A. Serum transaminase (ALT) activity. 
B. Representative Hematoxylin & Eosin staining in livers from PTP1B+/+ and 
PTP1B-/- mice 6 h after APAP injection. Bar scale 100 µm. 
**
P<0.01 PTP1B
-/- 
vs. 
PTP1B
+/+
 (n= 6-8 mice of each condition).  
 
 
 
 
 
 
 
 
 
 
Figure 21. Basal GSH levels and expression of Cyp2e1, GCL-C, GCL-M 
and BclxL in livers from wild-type and PTP1B
-/- 
mice. A. Basal GSH 
levels. B. Whole cell lysates from PTP1B
+/+
 and PTP1B
-/- 
mice were analyzed 
by Western  blot with the indicated antibodies. Representative 
autoradiograms are shown. 
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Figure 22. Beneficial effects of PTP1B deficiency on the induction of Nrf2-mediated anti-
oxidant response and survival signaling in the liver. PTP1B+/+ and PTP1B-/- mice were injected 
with 300 mg/kg APAP or saline for 3 or 6 h. A. Western blot analysis of Nrf2 in nuclear extracts 
and HO-1, phospho-JNK and JNK in total liver extracts. B. GPx, HO-1, GCL-M, GCL- C and NQO1 
mRNA levels determined by qRT-PCR at 3 and 6 h post-APAP injection. *P<0.05, **P<0.01 and 
***P<0.005 PTP1B-/- versus PTP1B+/+ (n=6-8 mice of each condition). C. Western blot analysis of 
phospho-IGFIR, IGFIR, IRS1, IRS2, phospho-Akt, Akt and BclxL levels in total liver extracts from 
PTP1B+/+ and PTP1B-/- mice 6 h after APAP injection.  D. Schematic diagram illustrating the 
proposed mechanism by which PTP1B modulates Nrf2 nuclear accumulation. PTP1B might 
activate the unknown kinase upstream GSK3β by dephosphorylation, thereby, triggering 
activation of the GSK3 β /Src-Fyn axis in the nucleus that ultimately leads to Nrf2 tyrosine 
phosphorylation, ubiquitination and degradation. 
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2. EFFECT OF APAP TREATMENT IN HEPATIC INSULIN SIGNALING: 
ROLE OF PTP1B. 
2.1 Effect of subtoxic and toxic doses of APAP in insulin-mediated 
signaling in human hepatocytes. 
Since APAP activates stress-mediated signaling pathways that elicit a negative 
cross-talk with critical nodes of the insulin cascade (Aguirre et al., 2000), our 
first goal was to examine the effect of APAP treatment on insulin signaling in 
hepatocytes. Primary human hepatocytes were treated with subtoxic (10 mM) 
and toxic (20 mM) doses of APAP for 24 h. These doses were chosen on basis of 
experiments performed in Figure1. Then, hepatocytes were further stimulated 
with insulin (10 nM) for 10 minutes and insulin signaling cascade was analyzed.  
As shown in (Figure 23), insulin-induced IR tyrosine phosphorylation was 
significantly decreased in primary human hepatocytes treated with a subtoxic 
dose of APAP (10 mM) and was totally abolished at a toxic dose (20 mM).  
Downstream from the IR, levels of IRS1 were also decreased in human 
hepatocytes treated with 10 or 20 mM APAP. By contrast, APAP treatment did 
not decrease IRS2 levels. In the light of these results, insulin-induced Akt 
phosphorylation at Ser 473 residue was impaired by APAP. As indicated in 
section 1.1, stress-mediated signaling monitored by phosphorylation of JNK and 
p38 MAPK was induced at both doses of APAP.  
Due to the limitation in obtaining human primary hepatocytes for further 
experiments, we conducted similar assays in the hepatoma Huh7 human cell 
line. In these cells, APAP induced phosphorylation of JNK at 5 and 10 mM 
dose (Figure 24A). Cellular damage, monitored by microscopy analysis, crystal 
violet staining and released LDH activity, was elicited at 10 mM concentration 
whereas no toxicity was detected at 5 mM dose (Figure 24B, 24C). Thus, Huh7 
hepatic cells were treated with 5 (subtoxic dose) and 10 (toxic dose) mM APAP 
for 24 h and then stimulated with 10 nM insulin for 10 minutes.  As shown in 
Figure 24A, APAP attenuated insulin signaling as shown by reduced IR and 
IRS1 tyrosine phosphorylation as well as phosphorylation of Akt (Ser 473) at a 
subtoxic dose of APAP and almost suppressed all these effects at the toxic 
dose.  
 
 
 
 
 
Results  
 
91 
 
 
 
 
 
Figure 23. Effect of subtoxic and toxic doses of APAP in insulin-mediated 
signaling in human hepatocytes. A. Human primary hepatocytes were treated with 
two doses of APAP (10 and 20 mM) for 24 h. Then, hepatocytes were further 
stimulated with insulin (10 nM) for 10 min and insulin signaling cascade was analyzed 
by Western blot with the antibodies against phospho-IR, IR, IRS1, IRS2, phospho-Akt 
(Ser 473) and Akt. B. Autoradiograms were quantitated by scanning densitometry. 
Results are means ± SEM. *P<0.05, **P<0.01 and ***P<0.001 APAP-treated versus 
non-treated cells. (n=3 independent experiments). 
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Figure 24.Effect of subtoxic and toxic doses of APAP in insulin-mediated signaling 
in hepatoma Huh7 human cell line. A. The hepatoma Huh7 human cell line was 
treated with two doses of APAP (5 and 10 mM) for 24 h. Then, cells were stimulated with 
insulin (10 nM) for 10 minutes and insulin signaling cascade was analyzed by Western 
blot with the antibodies against phospho-IR, IR, IRS1, IRS2, phospho-Akt (Ser 473), 
Akt, phospho-JNK1/2, and JNK1/2. n=3 independent experiments (left panel). 
Autoradiograms were quantitated by scanning densitometry. Results are means ± SEM. 
*P<0.05, **P<0.01 and ***P<0.001 APAP-treated versus non-treated cells. (n=3 
independent experiments) (right panel). B. Huh7 cells were treated with two doses of 
APAP (5 and 10 mM) for 24 h. Representative phase-contrast microscopy images after 
APAP treatment. Bar scale 100 µm. C. Huh7 cells were treated with two doses of APAP 
(5 and 10 mM) for 24 h. Cellular viability and released LDH activity after APAP 
treatment. Results are means ± SEM. *P<0.05, **P<0.01 and ***P<0.001 APAP-treated 
versus non-treated cells (n=3 independent experiments). 
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2.2 Rosiglitazone decreased PTP1B and improved insulin signaling cascade 
in APAP-treated human primary hepatocytes. 
Next, we investigated the effect of rosiglitazone, a well-known insulin sensitizer 
that binds to the peroxisome proliferator-activated (PPAR)-γ receptors, on APAP-
mediated insulin resistance in hepatic cells. Human primary hepatocytes were 
treated with APAP (20 mM) without and with rosiglitazone (5 and 10 µM) for 24 
h, after that the cells were stimulated with insulin (10 nM) for a further 10 min. 
As shown in (Figure 25), rosiglitazone decreased JNK and p38 MAPK 
phosphorylation triggered by APAP. Moreover, PTP1B levels were significantly 
decreased in human hepatocytes co-treated with APAP and 10 µM rosiglitazone. 
Interestingly, rosiglitazone increased Bcl-xL expression in APAP-treated 
hepatocytes. Regarding insulin signaling, rosiglitazone protected against APAP-
mediated decreases in IR and IRS1 tyrosine phosphorylation, degradation of 
IRS1 and also maintained insulin-induced Akt  Ser 473 phosphorylation.  
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Figure 25.Rosiglitazone decreased PTP1B and improved insulin sensitivity in APAP-
treated human primary hepatocytes. A.Human primary hepatocytes were treated with 
APAP (20 mM) without and with rosiglitazone (5 and 10 µM) for 24 h, after that the cells 
were stimulated with insulin (10 nM) for 10 minutes. Then, total cell lysates were analyzed 
by Western blot with the antibodies against phospho-JNK1/2, JNK1/2, phospho-p38 
MAPF, p38 MAPK, PTP1B, BclxL, and p85-PI3K as a loading control. Also, insulin signaling 
cascade was analyzed by Western blot with the antibodies against phospho-IR, IR, IRS1, 
IRS2, phospho-Akt (Ser 473) and Akt. B. Autoradiograms were quantitated by scanning 
densitometry. Results are means ± SEM. *P<0.05 and ***P<0.001 APAP-treated versus non-
treated cells (n=3 independent experiments). 
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2.3 Effect of reduction of PTP1B levels in insulin signaling in human 
hepatic cells. 
 
PTP1B dephosphorylates tyrosine residues at the catalytic domain of the IR in 
the liver and skeletal muscle and, therefore, its deficiency increases insulin 
sensitivity (Elchebly et al., 1999; Klaman et al., 2000). In order to investigate if 
PTP1B levels modulate the sensitivity to insulin-mediated signaling cascade in 
human liver cells, we established siRNA assays (Figure 26A). Huh7 cells were 
transfected with human PTP1B siRNA and control (scrambled) oligos for 48 h 
and then stimulated with 1-10 nM insulin for a further10 min. As expected, IR 
tyrosine phosphorylation and Akt phosphorylation were increased in Huh7 
cells with reduced PTP1B levels. To study the effect of PTP1B on the cross-talk 
between APAP and insulin signaling pathway, we generated stable Huh7 cell 
lines with reduced PTP1B levels by infection with lentivirus bearing PTP1B or 
scrambled short hairpin RNA (shRNA). As depicted in Figure 26B, PTP1B 
levels were reduced by 90% as compared with Huh7 cells infected with 
scrambled lentivirus. Next, cells were stimulated with insulin (1 and 10 nM) 
for 10 minutes and insulin signaling was analyzed. Tyrosine phosphorylation 
of IR as well as phosphorylation of Akt (Ser 473 and Thr 308) in response to 
insulin were enhanced in Huh7 hepatic cells transfected with siRNA PTP1B 
oligo, as well as in stable Huh7 cells with reduced PTP1B levels as compared 
to their corresponding controls expressing normal levels of PTP1B (Figure 26C 
and 26D).  
Figure 26. Effect of reduction of PTP1B levels in insulin signaling in 
hepatoma Huh7 human cell line. A. Hepatoma Huh7 human cell line was 
transfected with the human PTP1B siRNA(10 and 25 nM) or scrambled oligos 
(10nM) for 48 h or B. Hepatoma Huh7 human cell line was infected with 
lentivirus bearing scrambled or PTP1B short hairpin RNA (shRNA). Total cell 
lysates were analyzed by Western blot with the corresponding antibodies against 
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PTP1B and β actin as a loading control (n=3 independent experiments). C. Huh7 
cells treated with siRNA oligos as described in A,then were stimulated with 
insulin (1 and 10 nM) for 10 minutes and insulin signaling cascade was analyzed 
by Western blot with the antibodies against phospho-IR, IR, phospho-Akt (Ser 
473), phospho-Akt (Thr 308) and Akt. D. Huh7 cells infected with control and 
PTP1B shRNA lentiviral particles (B) were stimulated with insulin (1 and 10 nM) 
for 10 minutes and insulin signaling cascade was analysed as detailed in C. 
Representative autoradiograms are shown (n= 3 independent experiments). 
 
 
2.4 PTP1B-deficient mouse hepatocytes are protected against APAP-
mediated effects on insulin signaling.  
To get further insights on the role of PTP1B in insulin signaling in APAP-
treated hepatocytes, we used immortalized hepatocytes from wild-type 
(PTP1B+/+) and PTP1B-deficient (PTP1B-/-) mice. Cells from both genotypes 
were treated for 16 h with a low toxic APAP dose (0.5 mM) or a high toxic dose 
(1 mM) and then stimulated with 1-10 nM insulin for 10 minutes. As shown in 
(Figure 27), in wild-type immortalized hepatocytes stress-mediated signaling 
monitored by the phosphorylation of JNK and p38 MAPK and elevation of 
PTP1B levels, was observed at both APAP doses. In these cells insulin-
mediated IR tyrosine phosphorylation was reduced at both APAP doses (Figure 
27A). Likewise, IRS1 tyrosine phosphorylation was severely impaired in 
parallel with a marked reduction of total IRS1 levels. Regarding insulin-
induced IRS2 tyrosine phosphorylation, it was partly (around 50%) or totally 
reduced when immortalized hepatocytes were pretreated with 0.5 and 1 mM 
APAP, respectively. Of note, total IRS2 levels were partly reduced at both APAP 
doses. Downstream IRS proteins, phosphorylation of Akt at both Ser 473 and 
Thr 308 in response to insulin were reduced with a more prominent effects in 
immortalized hepatocytes pretreated with 1 mM APAP. Next, we performed 
similar analysis in PTP1B-/- immortalized mouse hepatocytes (Figure 27B). As 
stated in section 1.4, these cells showed a lower response to APAP in the 
activation of stress kinases (JNK and p38 MAPK). In the light of these data, 
PTP1B-/- immortalized hepatocytes pretreated with 0.5 mM APAP were 
resistant to the decrease in IR tyrosine phosphorylation, IRS1 and IRS2 
tyrosine phosphorylation and phosphorylation of Akt at both residues. When 
cells were pretreated with 1 mM APAP IRS2 tyrosine phosphorylation was 
further reduced.  In addition, total levels of IRS1 and IRS2 were unaffected by 
APAP. 
IRS1 phosphorylation at serine residues precedes its degradation via 
ubiquitination and proteosomal degradation (Terry et al., 2001). Among IRS1 
serine kinases, JNK has been extensively study in insulin resistant states. 
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Therefore, we treated wild-type and PTP1B-/- immortalized hepatocytes with 1 
mM APAP for short time-periods (1-4 hours) and phosphorylations of JNK, p38 
MAPK and IRS1 at serine 307 were analyzed.  As depicted in (Figure 28), both 
early JNK and p38 MAPK phosphorylation in response to APAP were delayed 
and reduced in PTP1B-/- immortalized hepatocytes as compared to the 
responses of the control cells. Similarly, phosphorylation of IRS1 at serine 307 
was attenuated in PTP1B-/- cells. 
 
 
Figure 27. Effect of reduction of PTP1B levels in the effects of APAP on insulin 
signaling in mouse immortalized hepatocytes. Wild-type (PTP1B+/+) immortalized mouse 
hepatocytes (A) or PTP1B-/-  immortalized mouse hepatocytes (B) were treated with two doses 
of APAP (0,5 and 1 mM) for 16 h. Then, hepatocytes were stimulated with insulin (1 and 10 
nM) for 10 minutes and insulin signaling cascade was analyzed by Western blot with the 
antibodies against phospho-IRS1, IRS1,  phospho-Akt (Ser 473), phospho-Akt (Thr 308) and 
Akt. Also, total cell lysates were analyzed by Western blot with the antibodies against PTP1B, 
phospho-JNK1/2, JNK1/2, phospho-p38 and p38. In the lower panels IR and IRS2 tyrosine 
phosphorylation was analyzed by immunoprecipitation with the corresponding antibody 
followed by Western blot with the anti-Tyr(P) antibody (4G10). IR and IRS2 were analyzed in 
whole cell lysates. Representative autoradiograms are shown (n= 3 independent 
experiments). 
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Figure 28. Effect of PTP1B deficiency in the early induction of 
the stress signaling by APAP in immortalized hepatocytes. Wild-
type (PTP1B+/+) and PTP1B-/- immortalized mouse hepatocytes were 
treated with APAP (1mM) for various time periods. IRS1 Ser 307 
phosphorylation was analyzed by immunoprecipitation with the 
corresponding anti-IRS1 antibody followed by Western blot with the 
anti-phospho IRS1 (Ser 307) antibody. Total cell lysates were 
analyzed by Western blot with the antibodies against IRS1, phospho-
JNK1/2, JNK1/2, phospho-p38 MAPK and p38 MAPK. 
Representative autoradiograms are shown (n= 3 independent 
experiments). 
 
2.5 Effect of chronic APAP treatment on glucose homeostasis in wild-type 
and PTP1B-deficient mice. 
As stated in the introduction, mice lacking the ptpn1 gene exhibit increased 
insulin sensitivity owing to enhanced phosphorylation of IR in liver and 
skeletal muscle, resistance to weight gain on a high-fat diet, and an increased 
basal metabolic rate (Klaman et al., 2000; Elchebly et al., 1999). Accordingly, 
our next step was to study firstly if chronic APAP treatment at sub-toxic doses 
has an impact in whole body glucose homeostasis and insulin sensitivity and, 
secondly, the potential beneficial effects of the lack of PTP1B. Wild-type and 
PTP1B-/- mice were treated with APAP in the drinking water during 6 months 
accordingly with the protocol described in Materials and Methods (section 
2.2.1.2).  At this time-period there were no evidences of liver damage by APAP 
as reflected by normal serum ALT levels in all experimental groups and normal 
liver histology (Figure 29A and 29B). 
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Figure 29. Chronic APAP treatment in mice did not induce liver liver damage.  
PTP1B+/+ and PTP1B-/- mice were treated with APAP in the drinking water during 6 
months (90-120 mg/kg/day).  A. Serum transaminase (ALT) activity. B. 
Representative Hematoxylin & Eosin staining in livers from PTP1B+/+ and PTP1B-/- 
mice after chronic APAP treatment. Bar scale 100 µm. **P<0.01 PTP1B-/- vs. 
PTP1B+/+ (n= 6-8 mice of each condition). 
 
Body weight was monitored through chronic APAP treatment. Wild-type mice 
increased body weight during the treatment, this effect was not observed in 
those mice receiving APAP (Figure 30A). However, body weight of PTP1B-/- mice 
was maintained during treatment, no differences being observed in mice 
receiving APAP.  
We assessed whole-body glucose homeostasis at the end of the APAP 
treatment by performing the glucose tolerance test (GTT). (Figure 30B) shows 
that APAP slightly decreased glucose tolerance in wild-type, but not in PTP1B-
/- mice. Of note, enhanced glucose tolerance was evident in PTP1B-/- as 
compared to the wild-type mice regardless of APAP treatment.   
To further investigate the effects of chronic APAP treatment in insulin 
sensitivity, we performed insulin tolerance tests (ITT). As shown in (Figure 
30C) PTP1B-/- mice displayed increased insulin sensitivity as compared to the 
wild-type control. However, chronic APAP treatment did not affect the ability of 
exogenously injected insulin to decrease glucose levels in both genotypes of 
mice.   
In addition to the reduction in whole-body glucose disposal (mainly accounted 
by skeletal muscle-mediated glucose uptake), increased hepatic glucose 
production (HGP) has also been reported to contribute to glucose intolerance.  
To assess whether increased HGP was involved in glucose intolerance of the 
APAP-treated wild-type animals, we performed pyruvate tolerance tests (PTT). 
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The PTT measures the extension of the whole-body conversion of pyruvate into 
glucose and allows the assessment of the rate of gluconeogenesis, which is an 
important component of hepatic insulin action. In wild-type mice, we found 
increased glucose levels after pyruvate injection (Figure 30D). This effect was 
slightly enhanced in mice that had received the chronic APAP treatment. In 
PTP1B-/- mice blood glucose levels were less elevated after pyruvate injection in 
both vehicle and APAP-treated groups. 
Figure 30. Effect of PTP1B deficiency in glucose homeostasis in mice treated 
chronically with APAP in the drinking water. PTP1B+/+ and PTP1B-/- mice were treated 
with APAP in the drinking water during 6 months (90 mg/kg/day). A. Body weight of mice 
during the treatment. B. Glucose tolerance test (GTT) tolerance tests were performed in 
animals that had been fasted for 24 h and were given an intraperitoneal injection of 
glucose (2 g/kg). The area under the curve (AUC) was calculated as AUCGround (AUC 
Gmmol/L *min) and represented in graph (left panel).  C. Insulin tolerance test (ITT) was 
performed in animals that had been fasted for 4 h and were given an intraperitoneal 
injection of (0.75 U/kg) of human regular insulin.  D. Pyruvate tolerance test (PTT) 
tolerance test was performed on animals that had been fasted for 24 h and were given an 
intraperitoneal injection of pyruvate (2 g/kg). The area under the curve (AUC) was 
calculated as AUCGround (AUC Gmmol/L * min) (left panel). (n= 6-8 animals/group). 
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*p<0.05 and **p<0.01 PTP1B+/+ APAP vs   PTP1B+/+ veh and PTP1B-/- APAP vs   PTP1B-- 
veh. 
 
 
Finally, we determined fasted insulin levels in serum in the four experimental 
groups. As depicted in Figure 31, insulin levels were significantly lower in 
PTP1B-/- mice as compared to the wild-type controls. This result is in 
agreement with the work of Bence and co-workers (Bence et al., 2000). 
Importantly, chronic APAP treatment decreased serum insulin in wild-type 
mice but not in mice lacking PTP1B. 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Effect of chronic APAP treatment on 
Insulin levels in PTP1B+/+ and PTP1B-/- mice. 
PTP1B+/+ and PTP1B-/- mice were treated with APAP in 
the drinking water during 6 months (90-120 
mg/kg/day). Blood was collected from mice that had 
been fasted for 24 h and the serum insulin was 
determined by RIA. (n= 6-8 animals/group). 
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1. ROLE OF PTP1B IN APAP-INDUCED ACUTE LIVER FAILURE:-  
There is evidence of increased PTP1B expression during the progression of 
non-alcoholic fatty liver disease that concurs with insulin resistance and liver 
damage (Sanderson et al., 2005; Garcia-Monzón et al., 2011). However, PTP1B 
functions in other in vivo physiological responses regulated by tyrosine kinase 
signaling, such as hepatic proliferation and, particularly, hepatocellular 
survival during drug injury are poorly understood. The current study has 
unraveled a central role of PTP1B in the molecular mechanism that mediates 
APAP-induced liver failure, thereby identifying PTP1B as a potential 
therapeutic target in the treatment of human APAP hepatotoxicity. In fact, this 
study emerged from the observation of elevated PTP1B expression in livers 
from individuals suffering of APAP intoxication. Moreover, in APAP-treated 
human and mouse hepatocytes up-regulation of PTP1B preceded cell death. 
     Our experiments in mouse hepatocytes demonstrated that PTP1B 
deficiency attenuates cellular damage in response to APAP treatment. The fact 
that released LDH activity was reduced in PTP1B-/- hepatocytes indicates that 
necrotic cell death was less severe than in wild-type controls. In wild-type 
hepatocytes APAP also increased percentage of sub G0/G1 cells, release of 
cytochrome C from mitochondria, activation of caspase-3 and decreased anti-
apoptotic proteins BclxL and Mcl1. These results strongly suggest that APAP 
triggered apoptosis in hepatocytes and, again, these effects were ameliorated 
by PTP1B deficiency. In light of these data, we and others have shown that 
PTP1B inhibition protects hepatocytes against activation of mitochondrial 
(intrinsic) and death receptor (extrinsic)-mediated apoptotic pathways ( 
Gonzalez-Rodriguez  et al., 2007; Sangwan et al., 2006), reinforcing the role of 
this phosphatase in programmed cell death. 
     It is known that APAP-induced cell death in hepatocytes is, in part, the 
result of a series of events that increase cellular oxidative stress; mainly 
depletion of the GSH pool by conjugation with NAPQI and subsequent 
generation of ROS (Reid et al., 2005). Since these processes are significantly 
ameliorated in PTP1B-/- hepatocytes, we investigated the modulation of 
oxidative stress by PTP1B. In this regard, an unknown tyrosine kinase has 
been proposed to be the upstream activator of GSK3βby phosphorylation at 
tyrosine 216 (Niture et al., 2011; Jain et al., 2007). This phenomenon leads to 
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SKF-mediated tyrosine phosphorylation, nuclear export, ubiquitination, and 
degradation of Nrf2 in response to oxidative stress inducers. Our data 
demonstrated firstly that this signaling pathway is activated by APAP in 
hepatocytes and, secondly, as discussed below, that PTP1B deficiency 
mimicked the inhibition of GSK3β or SKF on the downstream mediators of this 
pathway. Therefore, silencing of GSK3 β delayed Src and Fyn nuclear 
translocation, which correlated with delayed Nrf2 nuclear exclusion in 
response to APAP. Likewise, chemical inhibition of SKF by PP2 in hepatocytes 
or, deletion of these kinases in MEFs (SFY-/-), also augmented/prolonged Nrf2 
nuclear accumulation in response to APAP. Importantly, the effect of PTP1B 
deficiency on this pathway was manifested by delayed Src-Fyn nuclear 
translocation, Nrf2 tyrosine phosphorylation and its subsequent 
ubiquitination and degradation, leading to enhanced HO-1 induction. These 
results suggest that PTP1B might activate this unknown kinase upstream 
from GSK3β probably by dephosphorylation, thereby, triggering activation of 
the GSK3β/Src-Fyn axis that, as stated above, ultimately leads to Nrf2 
degradation. Consequently, as demonstrated in hepatocytes, PTP1B deficiency 
might delay and/or reduce activation of this complex axis resulting in 
prolonged nuclear accumulation of Nrf2 and enhanced anti-oxidant defense. 
Recent findings have reported a direct effect of GSK3β in APAP hepatotoxicity 
in mediating GCLC and Mcl1 protein degradation (Shinohara et al., 2010).  
Although our results point PTP1B as an upstream mediator of GSK3β 
activation (Figure 17D), additional direct effects of the PTP1B/GSK3β pathway 
independent of Nrf2-mediated transcription should not be excluded. 
   Besides the novel role of PTP1B in anti-oxidant defense reported in the 
present study, this phosphatase regulates duration and/or intensity of 
survival signals emerging from the tyrosine kinase receptor family ( Zabolotny 
et al., 2002; Haj et al., 2003; Sangwan et al., 2006)  . Since IGFIR triggers 
survival responses in hepatocytes (Tovar et al., 2010), the lack of PTP1B 
prevented the drop in the IGFIR/IRS1/2/Akt-mediated survival signaling in 
APAP-treated cells. In fact, this is the first report showing degradation of IRS 
proteins in hepatocytes by APAP, suggesting that high doses of this analgesic 
may also interfere with hepatic insulin signaling and increase the risk of 
metabolic diseases such as insulin resistance and type 2 diabetes mellitus.  
Thus, in wild-type hepatocytes, increased ROS-mediated JNK and p38 MAPK 
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phosphorylation by APAP are likely to be responsible for the feed-back 
mechanism on the IGFIR-mediated signaling leading to IRS1/2 serine 
phosphorylation that precedes degradation (Vinayagamoorthi et al., 2008) .  
Thus, in the absence of PTP1B the decrease in ROS-mediated activation of 
JNK and p38 MAPK and the increase in tyrosine phosphorylation of IGFIR 
might act in conjunction with the effects on the GSK3β/Src-Fyn axis thereby 
attenuating oxidative stress and increasing cell survival in response to APAP.  
   Several studies have shown the mechanistic importance of hepatic cytokine 
network in APAP-induced liver injury. In the liver, cytokines are mainly 
produced by non-parenchymal cells. Our in vivo data show significant lower 
expression levels of IL1β and IL6 mRNAs in livers of PTP1B-/- mice upon APAP 
injection as compared to the elevated levels of the wild-type controls, 
suggesting that PTP1B also modulate cytokine production by non-
parenchymal cells in response to liver damage. Cytokines play an essential 
role as inducers of PTP1B in metabolic diseases. Activation of JNK together 
with elevated expression of PTP1B in response to IL6 has been reported in 
skeletal muscle of insulin resistant mice (Nieto-Vazquez et al., 2008). Likewise, 
IL4 induces PTP1B and enhances its protein stability to suppress IL4-induced 
STAT6 signaling in B cells (Lu et al., 2008). Since PTP1B is increased in the 
livers of APAP-injected wild-type mice, this effect is likely to be due to elevation 
of IL6 and IL1β .Therefore, cytokine-mediated increases in PTP1B expression 
might lead to enhancement of the GSK3β/Src-Fyn axis resulting in increased 
Nrf2 tyrosine phosphorylation and a rapid nuclear exclusion. Moreover, in the 
liver of APAP-injected wild-type mice, the negative cross-talk elicited by JNK 
on IRS proteins and also by PTP1B by direct dephosphorylation of the IGFIR 
might synergize with the enhancement of the GSK3β/Src-Fyn axis to reduce 
survival of hepatic cells. This mechanism is supported by lower activation of 
JNK, higher IGFIR tyrosine phosphorylation and nuclear Nrf2 accumulation in 
livers of APAP-injected PTP1B-/- mice as compared to wild-type controls. As a 
result, PTP1B-deficient livers are protected against APAP-induced oxidative 
stress and injury as manifested by decreased GSH depletion that might favour 
NAPQI detoxification lowering the formation of APAP-protein aducts. However, 
the effects of APAP in vivo are not exclusively mediated by elevation of PTP1B 
expression by pro-inflammatory cytokines secreted by non-parenchymal (i.e 
kuppfer) cells; our in vitro data have also demonstrated direct effects of APAP 
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in hepatocytes. Nevertheless, PTP1B deficiency protects against damage in 
hepatocytes in culture and in whole liver reinforcing the modulatory role of 
this phosphatase in multiple molecular mechanisms triggered in response to 
APAP in distinct liver cells.   
    In conclusion, we have demonstrated the unique role of PTP1B in the liver 
as a critical crossroad in the signaling pathways triggered in response to APAP 
by a dual modulation of Nrf2-mediated anti-oxidant response through the 
GSK3β/Src-Fyn kinases axis and survival signaling through its effects on the 
IGFIR/IRSs/Akt pathway. Our data suggest that inhibition of this 
phosphatase would be a suitable therapeutic approach against APAP-induced 
hepatotoxicity.  
2. EFFECT OF APAP TREATMENT IN HEPATIC INSULIN SIGNALING: 
ROLE OF PTP1B. 
Many drugs are associated with the development of glucose intolerance or with 
deterioration in glycaemic control in patients with pre-existing diabetes. Some 
of them show dose-dependent effects. For example, anti-inflammatory doses of 
corticosteroids may necessitate use of insulin in patients that are controlled 
with oral anti-diabetic agents. Such therapy not infrequently precipitates 
diabetes in middle-aged or elderly individuals with no history of glucose 
intolerance. Other notable examples include oral contraceptives, estrogen 
replacement therapy, cyclophilin immunosuppressants, protease inhibitors 
etc… (Reviewed in Insulin Resistance. A clinical Handbook. AJ Krentz Ed. 
2002 Blackwell Science Ltd). 
 
In the initial experiments of APAP-mediated toxicity in hepatocytes we found 
that APAP also increased PTP1B levels at subtoxic doses. Interestingly, PTP1B 
expression is elevated in hepatocytes treated with the proinflammatory 
cytokine TNFα that modulates insulin signaling in insulin-sensitive cellular 
models (Zabolotny et al. 2008; Nieto-Vazquez et al., 2007; Fernández-Veledo et 
al. 2006). In addition to the elevation of PTP1B, subtoxic doses of APAP also 
activated JNK. In this regard, it has been shown that JNK interferes with 
insulin signaling through the serine phosphorylation of IRS1 at serine 307 and 
subsequent degradation (Vincent et al., 2000). These data prompted us to 
evaluate a possible cross-talk between subtoxic doses of APAP and insulin 
signaling in hepatocytes.  
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Our results in three different hepatic cellular models (human primary 
hepatocytes, Huh7 human hepatic cell line and immortalized mouse 
hepatocytes) revealed a decreased response to insulin in IR tyrosine 
phosphorylation in cells pretreated with subtoxics doses of APAP. This effect is 
particularly relevant since indicated a negative cross-talk between APAP and 
insulin signaling at the level of IR that conforms together with IRS proteins the 
critical node 1 of insulin signaling (Taniguchi et al., 2006). As expected, 
downstream IR signaling was also attenuated in APAP treated hepatic cells 
reflected by decreased IRS1 and IRS2 tyrosine phosphorylation and Akt 
phosphorylation (Ser 473 and Thr 308).  
 
IRS1 is particularly susceptible to proteasomal-mediated degradation by 
different triggers including oxidative stress. Acute oxidative stress leads to a 
short term activation of insulin signaling (Piwkowska et al., 2012), but if 
prolonged can have other effects including degradation of IRS1. In this regard, 
it has been shown that urea at concentrations that induce ROS production in 
cultured 3T3-L1 adipocytes increases modification of insulin signaling 
molecules by O-GlcNAc and reduces insulin-stimulated IRS1 and Akt 
phosphorylation and glucose transport (D’Apolito et al., 2010). Our data in the 
three hepatic cellular models clearly show that APAP triggers degradation of 
IRS1. In fact, we demonstrated in immortalized hepatocytes that APAP induces 
a rapid IRS1 serine phosphorylation at serine 307 in parallel to the 
phosphorylation of JNK. Therefore, in these cells the negative cross-talk 
elicited by JNK on IRS1 and by PTP1B on the IR might synergize to decrease 
Akt phosphorylation that is a critical node for insulin´s metabolic actions. 
Regarding IRS2, there are few data regarding the triggers and the molecular 
mechanisms responsible of its degradation (Copps and White 2012). However, 
it has been described decreased levels of IRS2 in response of oxidative stress 
induced by Bisphenol A in rat testis (D´Cruz et al., 2012). Another in vitro 
study demonstrated IRS2 degradation in muscle cells treated with H2O2 
(Archuleta et al., 2009). Our results in hepatic human and mouse cell lines 
show IRS2 degradation upon subtoxic APAP doses. On the contrary, in 
primary human hepatocytes IRS2 levels were not affected by APAP indicating 
that IRS2 might be more resistant to degradation compared to IRS1 and also, 
the susceptibility to its degradation by oxidative stressors might vary among 
different cell systems. It has been well established that low chronic 
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inflammation in white adipose tissue induced in obesity leads to insulin 
resistance in the liver (Johnson and Olefsky 2013). In a similar manner, APAP 
at subtoxic doses might induce a low chronic oxidative stress that leads to the 
activation of some of the stress kinases such as JNK, also involved in the 
inflammatory negative cross-talk that ends up with the blockade of insulin 
signaling.  
 
     Although the past decade has proven that the ligands for PPARγ TZDs are 
effective insulin-sensitizing agents. Several studies have demonstrated 
compounds containing scaffolds similar to TZD exhibit inhibitory effects 
against PTP1B (Bhattarai et al., 2009). Similarly, Combs et al. reported 
isothiazolidinone-containing compounds as potent inhibitors of PTP1B (Combs 
et al., 2005).  In an attempt to ameliorate the negative effects of APAP in 
insulin signaling, we treated human primary hepatic cells with the 
combination of APAP plus rosiglitazone. Under these experimental conditions 
the two APAP-mediated negative modulators of insulin signaling PTP1B and 
phospho-JNK were decreased, thereby recovering insulin sensitization. All 
together, these results in reinforce the importance of the modulation of PTP1B 
expression as a therapeutic strategy to ameliorate insulin resistance. Our 
previous work has evidence the beneficial effects of PTP1B inhibition to 
overcome hepatic insulin resistance due to IRS2 deficiency (González-
Rodriguez et al., 2010) or aging (González-Rodriguez et al., 2012). In the light 
of these data, the results presented herein in immortalized hepatocytes lacking 
PTP1B showing a protection against APAP-mediated negative effects in insulin 
signaling, reinforce the benefits of inhibiting PTP1B in the liver to treat insulin 
resistance. 
     Finally, we have extended our investigations in an in vivo model of chronic 
APAP treatment in wild-type and PTP1B-/- mice (described in detail in 
Materials and Methods). This treatment did not produce changes in liver 
histology in both genotypes of mice, although ALT was increased by around 
twofold; this effect was less evident in PTP1B-/- mice. Even though, ALT values 
we maintained within normal range according to data provided from 
Laboratory Animal Resources at State University of Iowa 
(http://www.lar.iastate.edu/). Control wild-type mice (not receiving APAP) 
gained weight thorough the 6 months of the study, this effect being not 
observed in control PTP1B-/- mice. These data are in agreement with our recent 
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study regarding protection of PTP1B deficiency against age-mediated weight 
gain and adiposity (González-Rodriguez et al., 2012). If fact, the increase in 
body weight in wild-type mice correlated to increased adiposity (data not 
shown). Unexpectedly, weight loss was observed in wild-type mice that 
received a non-toxic dose of APAP for 6 months whereas weight loss was not 
observed in APAP-treated PTP1B-/- mice. One possible explanation for such an 
effect could be decreased food intake and/or increased energy expenditure. 
Daily food intake was similar among groups (results not shown). At present, 
we are performing indirect calorimetry to evaluate energy expenditure in light 
and dark cycles. Regarding whole body glucose homeostasis, the GTT tests 
revealed a trend towards an increased area under the curve (AUC) in wild-type 
mice that received APAP. Differences in glucose tolerance were not observed in 
both groups of APAP-/- mice. Importantly, PTP1B-/- mice displayed the 
phenotype of improved glucose tolerance initially reported by Elchebly et al., 
(1999) and Bence et al., (2000). However, data from the ITT tests indicated no 
differences in peripheral insulin sensitivity among groups. As skeletal muscle 
accounts for 85% of whole body glucose disposal (reviewed by Pillon et al., 
2013), moderate alterations in hepatic insulin sensitivity are difficult to detect 
by the ITT. Therefore, we performed PTT and again, a trend towards an 
increase in the AUC was observed in wild-type mice treated with APAP, 
reflecting the possibility of decreased insulin suppression of hepatic glucose 
production (HGP). Again, the AUC was lower in PTP1B-/- mice due to the 
increased hepatic insulin sensitivity reported by several laboratories including 
ours, no tendency to increased AUC being observed in these mice by the 
chronic APAP treatment. At present, we are evaluating insulin signaling in 
both liver and skeletal muscle in the four experimental groups. Nevertheless, 
since APAP significantly decreased serum insulin in wild-type mice, it is 
possible that the chronic treatment induces alterations in beta cell mass 
and/or insulin secretion machinery. To unravel this critical issue, we are 
performing histological evaluation of beta cell mass, insulin and glucagon 
content, as well as markers of oxidative stress and apoptosis in pancreatic 
sections from the four experimental groups. Of note, the hypoinsulinemia 
characteristic of the insulin hypersensitivity phenotype of PTP1B-/- mice 
confirms again the maintenance of the phenotype of our colony. 
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CONCLUSIONS 
1-PTP1B expression was elevated during APAP-induced liver injury in 
humans. In APAP-treated human hepatocytes, elevation of PTP1B was 
detected before the induction of cell death. 
2-PTP1B-deficiency protected against APAP-induced cell death in mouse 
hepatocytes.  
3-PTP1B deficiency decreased the activation of stress-mediated signalling 
pathways and prolonged the survival-mediated signalling in hepatocytes. 
4-PTP1B deficiency protected mouse hepatocytes against GSH depletion and 
elevation of ROS induced by the APAP treatment. 
5-PTP1B deficiency modulated GSK3β/SKF-mediated Nrf2 nuclear 
accumulation in APAP-treated mouse hepatocytes, and delayed Nrf2 
nuclear exclusion and degradation. 
6-PTP1B-deficient mice were protected against APAP-induced oxidative stress 
through the decrease in the activation of JNK, enhancement of Nrf2 nuclear 
accumulation and maintenance of IGFIR/Akt/BclxL survival signalling. 
7-Insulin signalling was decreased in hepatocytes pretreated with subtoxic 
and toxic doses of APAP. 
8-Both rosiglitazone co-treatment and PTP1B inhibition protected against 
APAP-mediated effects on the insulin signalling cascade. 
 
9-Chronic APAP treatment in wild-type mice showed a decrease in whole-body 
glucose homeostasis. This effect was not observed in PTP1B-deficient mice. 
 
 
 
 
 
Conclusions 
 
112 
CONCLUSIONES 
1- La expresión de PTP1B se encontraba aumentada en el hígado de 
individuos que habrían sufrido intoxicación por sobredosis de paracetamol. 
En hepatocitos tratados con dosis tóxicas de paracetamol, el aumento en la 
expresión de PTP1B era previo a la muerte celular. 
2- La deficiencia en PTP1B confiere protección frente a la muerte celular 
inducida por paracetamol en hepatocitos de ratón.  
3- La deficiencia en PTP1B disminuyó la activación de la señalización celular 
mediada por la activación de las quinasas de estrés a la vez que prolongaba 
la señalización de supervivencia celular en los hepatocitos. 
4- La deficiencia en PTP1B protegía a los hepatocitos frente a la depleción de 
glutation reducido y la elevación de las especies reactivas de oxígeno tras el 
tratamiento con paracetamol.  
5- La PTP1B modula la ruta GSK3β/SKF que conduce a la acumulación de 
Nrf2 en el núcleo. Los hepatocitos deficientes en PTP1B presentaron un 
retraso en la exclusión nuclear de Nrf2, así como en la posterior 
ubiquitinación y degradación del mismo. 
6- En el hígado, los ratones deficientes en PTP1B presentaban protección 
frente al estrés oxidativo inducido por el paracetamol mediante la atenuación 
de la activación de JNK, el aumento en la acumulación de Nrf2 en el núcleo y 
el mantenimiento de la señalización de supervivencia  IGFIR/Akt/BclxL. 
7- La respuesta a la insulina en la activación de la cascada de señalización 
mediada por su receptor se encontraba disminuida  cuando los hepatocitos 
habían sido pretratados con dosis subtóxicas y tóxicas de paracetamol. 
8- El co-tratamiento con rosiglitazona ó la inhibición de PTP1B recuperaron la 
respuesta a la insulina en la activación de su ruta de señalización en 
hepatocitos tratados con paracetamol.  
9-El tratamiento crónico con paracetamol en ratones de genotipo salvaje 
disminuyó la homeostasis glucídica. Dicho efecto no se observó en los 
ratones deficientes en PTP1B. 
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OPEN
Protein tyrosine phosphatase 1B modulates
GSK3b/Nrf2 and IGFIR signaling pathways in
acetaminophen-induced hepatotoxicity
MA Mobasher1,2, A´ Gonza´lez-Rodriguez1,2, B Santamarı´a1,2, S Ramos3, MA´ Martı´n2,3, L Goya3, P Rada1,4, L Letzig5,
LP James5, A Cuadrado1,4, J Martı´n-Pe´rez1, KJ Simpson6, J Muntane´7,8 and AM Valverde*,1,2
Acute hepatic failure secondary to acetaminophen (APAP) poisoning is associated with high mortality. Protein tyrosine
phosphatase 1B (PTP1B) is a negative regulator of tyrosine kinase growth factor signaling. In the liver, this pathway confers
protection against injury. However, the involvement of PTP1B in the intracellular networks activated by APAP is unknown. We
have assessed PTP1B expression in APAP-induced liver failure in humans and its role in the molecular mechanisms that
regulate the balance between cell death and survival in human and mouse hepatocytes, as well as in a mouse model of APAP-
induced hepatotoxicity. PTP1B expression was increased in human liver tissue removed during liver transplant from patients for
APAP overdose. PTP1B was upregulated by APAP in primary human and mouse hepatocytes together with the activation of c-jun
(NH2) terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK), resulting in cell death. Conversely, Akt
phosphorylation and the antiapoptotic Bcl2 family members BclxL and Mcl1 were decreased. PTP1B deficiency in mouse
protects hepatocytes against APAP-induced cell death, preventing glutathione depletion, reactive oxygen species (ROS)
generation and activation of JNK and p38 MAPK. APAP-treated PTP1B / hepatocytes showed enhanced antioxidant defense
through the glycogen synthase kinase 3 (GSK3)b/Src kinase family (SKF) axis, delaying tyrosine phosphorylation of the
transcription factor nuclear factor-erythroid 2-related factor (Nrf2) and its nuclear exclusion, ubiquitination and degradation.
Insulin-like growth factor-I receptor-mediated signaling decreased in APAP-treated wild-type hepatocytes, but was maintained in
PTP1B / cells or in wild-type hepatocytes with reduced PTP1B levels by RNA interference. Likewise, both signaling cascades
were modulated in mice, resulting in less severe APAP hepatotoxicity in PTP1B / mice. Our results demonstrated that PTP1B
is a central player of the mechanisms triggered by APAP in hepatotoxicity, suggesting a novel therapeutic target against APAP-
induced liver failure.
Cell Death and Disease (2013) 4, e626; doi:10.1038/cddis.2013.150; published online 9 May 2013
Subject Category: Experimental Medicine
Acetaminophen (APAP) or paracetamol is a widely used
analgesic and antipyretic, which is drug safe at therapeutic
doses,1 but accidental or intentional overdose induces severe
hepatotoxicity in experimental animals and humans. APAP
overdose is the most frequent cause of drug-induced liver
failure in the United States2,3 and most of Europe.4,5 In these
countries, APAP is a leading cause of urgent liver transplanta-
tion, which accounts for considerable levels of morbidity and
mortality.2 Therefore, APAP-induced acute toxicity has
become an essential model for studying drug-induced
liver and kidney failure. In the liver, APAP overdose
produces centrilobular hepatic necrosis that can be fatal as
it progresses to fulminant liver failure.6 However, despite
substantial progress in understanding APAP-induced
hepatotoxicity,7–9 additional injurious mechanisms responsi-
ble for the cellular damage induced by APAP remain unknown.
At normal dosage, the major elimination pathways of APAP
involve glucuronide and sulfate conjugation. The initial step in
toxicity is bioactivation of APAP by cytochrome P450 2e1
(Cyp2e1) to an electrophilic metabolite, N-acetyl-p-amino-
benzoquinone imine (NAPQI).10 At therapeutic doses, NAPQI
is detoxified by glutathione (GSH) and eliminated in urine
or bile as APAP-cysteine, APAP-N-acetylcysteine and
APAP-APAP-GSH.11 After an overdose, glucuronidation and
sulfation routes become saturated and more extensive
bioactivation of APAP occurs, leading to rapid depletion of
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the hepatic GSH pool. Subsequently, NAPQI binds to cysteine
groups on cellular proteins forming APAP–protein adducts.
NAPQI also binds to mitochondrial proteins, which, in turn,
causes oxidative stress that may trigger signaling pathways
through mitochondrial toxicity, leading to lethal cell injury.
Moreover, generation of reactive oxygen (ROS) and nitrogen
species, lipid peroxidation, mitochondrial dysfunction, disrup-
tion of calcium homeostasis and induction of apoptosis and
necrosis are also involved in APAP-induced hepatotoxicity.12–
14 Therefore, tight control of ROS levels by antioxidant
molecules and detoxifying enzymes is important to restore
the balance between oxidants and antioxidants in cells
challenged with oxidative insults. In this regard, nuclear factor
erythroid-2-related factor 2 (Nrf2) activates detoxifying
enzymes by binding to antioxidant response elements
(AREs). Nrf2-deficient mice are highly susceptible to APAP-
induced liver injury.15 Thus, Nrf2 may serve as an endogen-
ous regulator by which cells combat oxidative stress.
Protein tyrosine phosphorylation is crucial in the mechan-
isms by which growth factors and hormones regulate cellular
metabolism, differentiation, growth and survival. Given the
importance in maintaining survival and death fates of cells, the
balance between tyrosine kinases and phosphatases is
carefully regulated. Protein tyrosine phosphatases (PTPs)
catalyze dephosphorylation of tyrosine-phosphorylated
proteins.16 Among them, protein tyrosine phosphatase 1B
(PTP1B) is a widely expressed non-receptor PTP, which is
associated with the endoplasmic reticulum by interaction
through the C-terminal domain.17 PTP1B has been proposed
as a therapeutic target against type 2 diabetes and obesity
via its capacity to dephosphorylate insulin and leptin
receptors.18,19 PTP1B also dephosphorylates and inactivates
receptors of the tyrosine kinase superfamily, such as
EGF receptor, PDGF receptor,20 hepatocyte growth factor
receptor/met 21 and insulin-like growth factor-I receptor
(IGFIR),22 which are involved in hepatocyte survival.23,24 On
this basis, the aim of this study was to investigate the role of
PTP1B in APAP-induced hepatotoxicity.
Results
PTP1B expression increased during APAP-induced
liver injury in human liver and APAP-treated human
hepatocytes. We investigated if PTP1B was modulated
during APAP-induced human liver injury. Figure 1a shows
elevated PTP1B in surviving hepatocytes, mainly in the areas
surrounding the central veins (middle panel), during APAP
intoxication as compared with a normal liver (left panel). In a
more severe intoxication (right panel), where it is difficult to
detect surviving hepatocytes, strong staining was observed in
precipitated proteins released from dead cells and not yet
cleared. PTP1B protein content was also upregulated in
human primary hepatocytes and in the human Chang liver cell
line (CHL) treated with APAP in a dose- and time-dependent
manner (Figures 1b and c and Supplementary Figure 1).
Elevation of PTP1B was detected at 8 h after APAP addition,
whereas cells with death morphology were visualized at 16 h.
Moreover, in APAP-treated human hepatocytes activation of
c-jun (NH2) terminal kinase (JNK) and p38 mitogen-activated
protein kinase (p38 MAPK) and inhibition of Akt phosphoryla-
tion correlated with decreased levels of the antiapoptotic Bcl2
family members BclxL and Mcl1 and with detection of the
active caspase-3 fragment (Figure 1d).
PTP1B-deficient mouse hepatocytes are protected
against APAP-induced necrotic and apoptotic cell death.
As observed in human hepatocytes (Figure 1c), PTP1B was
upregulated in primary hepatocytes from wild-type (PTP1Bþ /þ )
mice treated with APAP (10 mM) at 8 h, whereas maximal cell
death was observed at 16 h (Figure 2a). Next, we explored
APAP-induced hepatotoxicity in mouse primary hepatocytes
from wild-type and PTP1B / mice. Cells were treated with
5 and 10 mM APAP for 16 h and cell death was analyzed.
Phase-contrast microscopy revealed many APAP-treated
wild-type primary hepatocytes with cell death morphology.
Conversely, most of PTP1B / primary hepatocytes
remained attached to the plate and only few cells displayed
a death phenotype (Figure 2b). Quantification analysis of
crystal violet staining and released lactate dehydrogenase
(LDH) activity showed that primary PTP1B / hepatocytes
were more protected against APAP-induced necrotic cell
death. Moreover, APAP treatment also increased the
incidence of condensed and/or fragmented nuclei and the
percentage of hypodiploid (sub-G0/G1) population in wild-
type primary hepatocytes indicating apoptotic cell death
(Figure 2c). These effects were reduced in PTP1B / cells.
Apoptosis in APAP-treated wild-type primary hepatocytes
correlated with the release of cytochrome C from the
mitochondrial compartment and with the subsequent activa-
tion of caspase-3 (Figure 2d). These effects were signifi-
cantly ameliorated in PTP1B / primary hepatocytes.
Similar results were obtained using wild-type and PTP1B /
 immortalized hepatocytes that express comparable levels
of pro- and antiapoptotic proteins than primary hepatocytes
and are highly sensitive to APAP-induced cell death25
(Supplementary Figure 2).
Effect of PTP1B deficiency on the activation of stress-
and survival-mediated signaling pathways in mouse
hepatocytes. Next, we analyzed stress- and survival-
mediated signaling in primary hepatocytes from wild-type
and PTP1B / mice in response to APAP. JNK and p38
MAPK phosphorylation was detected at 8 h in primary
hepatocytes treated with 10 mM APAP, this effect being
ameliorated in PTP1B / cells (Figure 3a). Survival signal-
ing monitored by IGFIR phosphorylation, levels of insulin
receptor substrates 1 (IRS1) and 2 (IRS2) and Akt
phosphorylation, was reduced in APAP-treated wild-type
primary hepatocytes, but preserved in PTP1B / cells.
Consistently, the antiapoptotic markers BclxL and Mcl1 were
decreased in wild-type primary hepatocytes treated with
APAP but, again, this effect was reduced in PTP1B /
hepatocytes. Similar responses were found in immortalized
hepatocytes that activate stress kinases at lower APAP
doses (Figure 3b).
To exclude the possibility that the protection elicited by
PTP1B deficiency against APAP-induced cell death could be
secondary to compensatory adaptations in PTP1B /
hepatocytes, we established siRNA assays. Reduction of
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PTP1B in wild-type immortalized hepatocytes decreased
APAP-induced JNK phosphorylation and levels of the active
caspase-3 fragment, and also maintained IGFIR tyrosine
phosphorylation, IRS1 and IRS2 expression, Akt phosphory-
lation and abolished downregulation of BclxL upon APAP
treatment (Figure 3c).
PTP1B deficiency protects mouse hepatocytes against
GSH depletion and elevation of ROS by prolonging Nrf2
nuclear accumulation. In the liver, Cyp2e1 converts APAP
to NAPQI that depletes GSH and, therefore, the degree of
GSH consumption is a biomarker for APAP bioactivation.26 As
the expression of Cyp2e1 did not change in primary and
immortalized hepatocytes from both genotypes of mice
(Supplementary Figure 3), we used immortalized cells for
further experiments. APAP induced depletion of GSH in
wild-type immortalized hepatocytes after 4 h, and this effect
was absent in PTP1B / cells (Figure 4a). Likewise, a
significant elevation of ROS was detected in APAP-treated
wild-type hepatocytes for 6 h, but not in PTP1B / cells. Next,
we measured the enzymatic activity of the detoxifying enzymes
glutathione peroxidase (GPx) and glutathione reductase (GR).
GPx activity increased in APAP-treated wild-type hepatocytes
compared with untreated controls, as expected for an
antioxidant defense system. Conversely, GR was not
increased by APAP, suggesting impairment in pathways
replenishing GSH stores. PTP1B /hepatocytes did not
activate the GPx/GR system in response to APAP, probably
due to an insufficient threshold to trigger the activation of
detoxifying enzymes under these experimental conditions.
To investigate at the molecular level the mechanisms for
protection of PTP1B deficiency against APAP-induced
Figure 1 PTP1B expression is increased during APAP-induced liver injury and in human primary hepatocytes treated with APAP. (a) Representative anti-PTP1B
immunostaining of liver biopsy sections from patients with histologically normal liver (NL) or with an APAP overdose (APAP) (n¼ 7). Bar¼ 50mm. (b) Human primary
hepatocytes were treated with various doses of APAP (5–20 mM) for 24 h. Total cell lysates were analyzed by western blot with the antibodies against PTP1B and b-actin as a
loading control. Autoradiograms corresponding were quantitated by scanning densitometry. Results are means±S.E.M. *Po0.05 and ***Po0.005 APAP-treated versus
non-treated cells. Representative phase-contrast microscopy images after APAP treatment. Bar¼ 100mm. (c) Human primary hepatocytes were treated with 20 mM APAP for
various time-periods (4, 8 and 24 h). Total cell lysates were analyzed by western blot with the antibodies against PTP1B and b-actin as a loading control. Autoradiograms
corresponding were quantitated by scanning densitometry. Results are means±S.E.M. *Po0.05 APAP-treated versus non-treated cells. Representative phase-contrast
microscopy images after APAP treatment. Bar¼ 100mm. (d) Human primary hepatocytes were treated with various doses of APAP for 24 h and total cell lysates were
analyzed by western blot with the antibodies against phospho (p)-JNK1/2, JNK1/2, phospho-p38, p38, active caspase-3, phospho-Akt, Akt, BclxL, Mcl1 and p85-PI3K as a
loading control. *Po0.05 and ***Po0.005 APAP-treated versus non-treated cells (n¼ 3 independent experiments)
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oxidative stress, we analyzed the dynamics of Nrf2 nuclear
accumulation. As no differences in Nrf2 serine phosphoryla-
tion that dissociates Nrf2 to its inhibitor Keap1 at early time-
periods upon APAP treatment were found (Supplementary
Figure 4A), we analyzed the nuclear accumulation of Nrf2 at
later time-periods. Western blot and immunofluorescence
revealed that Nrf2 was maximally accumulated in the nucleus
at 8 h after APAP treatment in wild-type and PTP1B /
hepatocytes, but was retained for up to 16 h exclusively in
PTP1B / cells (Figure 4b). Nuclear Nrf2 accumulation was
accompanied by decreases in cytosolic expression
(Supplementary Figure 4B).
Tyrosine phosphorylation of Nrf2 results in its nuclear
export, ubiquitination and degradation in the cytosol.27
Figure 4c shows that in APAP-treated wild-type hepatocytes,
maximal Nrf2 tyrosine phosphorylation was observed at
8 h and total Nrf2 protein content decreased at 16 h. In
PTP1B / cells, maximal Nrf2 tyrosine phosphorylation
Figure 2 PTP1B-deficient primary hepatocytes are protected against APAP-induced cell death. (a, left panel) Wild-type (PTP1Bþ /þ ) mouse primary hepatocytes were
treated with 10 mM APAP for various time-periods. The expression of PTP1B was analyzed by western blot. *Po0.05 APAP-treated versus non-treated cells (n¼ 3
independent experiments). (Right panel) Representative phase-contrast microscopy images and analysis of the percentage of sub-G0/G1 cell population by flow cytometry.
(b) PTP1Bþ /þ and PTP1B / primary hepatocytes were treated with APAP (5 and 10 mM) for 16 h. (Left panel) Representative phase-contrast microscopy images.
Bar¼ 100mm. (Right panel) Cellular viability and released LDH activity. (c) PTP1Bþ /þ and PTP1B / primary hepatocytes were treated with APAP (5 and 10 mM) for 16 h.
(Left panel) Representative nuclear morphology images after DAPI staining and analysis by fluorescence microscopy. (Right panel) Quantification of apoptotic nuclei.
Percentage of sub-G0/G1 cell population analyzed by flow cytometry. (d, left panel) PTP1B
þ /þ and PTP1B / primary hepatocytes were treated with APAP (5 and 10 mM)
for 16 h. Western blot with anticytochrome C and anti-cytochrome C oxidase antibodies in mitochondrial extracts. (Right panel) PTP1Bþ /þ and PTP1B / primary
hepatocytes were treated with APAP (10 mM) for various time-periods. Analysis of caspase-3 enzymatic activity. *Po0.05, **Po0.01 and ***Po0.005 PTP1B / versus
PTP1Bþ /þ (n¼ 4 independent experiments)
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occurred at 16 h, a time-point at which total Nrf2 levels were
maintained as in non-treated cells. These data correlated with
greater increase in the expression of the Nrf2 target heme
oxygenase-1 (HO-1) in PTP1B / hepatocytes. As occurred
in immortalized hepatocytes, Nrf2 levels were maintained and
the induction of HO-1 was higher in APAP-treated mouse
primary PTP1B / hepatocytes for 16 h as compared with
the wild-type cells.
Next, ubiquitination analysis of Nrf2 was performed in
immortalized hepatocytes treated with APAP for 8–24 h either
in the absence or presence of the proteasome inhibitor MG132
(Figure 4d). In APAP-treated wild-type cells, ubiquitinated Nrf2
was detected at earlier time-points (8 h) compared with
PTP1B / cells, which displayed this response at 16 h; this
effect was enhanced when APAP was added with MG132. In
related experiments, overexpression of PTP1B in HEK 293T
cells inhibited ARE-mediated luciferase expression after treat-
ment with APAP for 16 h (Figure 4e), reinforcing the involvement
of PTP1B in Nrf2-mediated antioxidant response to APAP.
PTP1B modulates GSK3b/SKF-mediated Nrf2 nuclear
accumulation in APAP-treated mouse hepatocytes. In
response to oxidative stress, GSK3b is activated by
phosphorylation at Tyr216 by an unknown tyrosine kinase.
Activated GSK3b phosphorylates and activates Src kinase
family (SKF) members in the cytosol, allowing their nuclear
translocation and subsequent tyrosine phosphorylation of
Nrf2 at Tyr568, ultimately resulting in Nrf2 nuclear exclusion
and degradation.27,28 We examined if this molecular
mechanism was triggered in APAP-treated hepatocytes.
Silencing GSK3b in immortalized wild-type hepatocytes
(Supplementary Figure 5) prolonged Nrf2 nuclear accumula-
tion up to 24 h upon APAP treatment as observed in
PTP1B / cells (Figures 4b and 5a). Moreover, nuclear
translocation of Fyn and Src was also impaired in
GSK3b-silenced cells, although no effects of nuclear
translocation of Yes were observed (results not shown). To
reinforce the role of SKF in nuclear accumulation of Nrf2 in
response to APAP, we treated wild-type hepatocytes with the
Figure 3 Effect of PTP1B deficiency in stress and survival signaling in hepatocytes. (a, left panel) PTP1Bþ /þ and PTP1B / mouse primary hepatocytes were treated
with APAP (10 mM) for various time periods. Total cell lysates were analyzed by western blot with the antibodies against phospho (p)-JNK1/2, JNK1/2, phospho-p38 MAPK
and p38 MAPK. Representative autoradiograms corresponding to three independent experiments are shown. (Right panel) PTP1Bþ /þ and PTP1B / mouse primary
hepatocytes were treated with APAP (5 and 10 mM) for 16 h. Total cell lysates were analyzed by western blot with the antibodies against phospho (p)-IGFIR, IGFIR, IRS1,
IRS2, phospho-Akt, Akt, BclxL, Mcl1 and b-actin as a loading control. Representative autoradiograms corresponding to three independent experiments are shown.
(b) PTP1Bþ /þ and PTP1B / immortalized hepatocytes were treated with various doses of APAP for 16 h. Total cell lysates were analyzed by western blot with the
indicated antibodies. Representative autoradiograms corresponding to three independent experiments are shown. (c) Immortalized PTP1Bþ /þ hepatocytes transfected with
10 nM of control or PTP1B small interfering RNA (siRNA) for 48 h were further treated with various doses of APAP for 16 h. Total cell lysates were analyzed by western blot with
the indicated antibodies. Representative autoradiograms corresponding to three independent experiments are shown
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Figure 4 PTP1B deficiency protects hepatocytes against GSH depletion and elevation of ROS; effect on nuclear Nrf2 accumulation. PTP1Bþ /þ and PTP1B /
immortalized hepatocytes were treated with various doses of APAP for different time-periods. (a) Analysis of GSH content (4 h), ROS levels (6 h) and GPx and GR activity
(16 h) in three independent experiments. *Po0.05, **Po0.01 and ***Po0.005 PTP1B / versus PTP1Bþ /þ (b, upper panel) Analysis of Nrf2 in nuclear cell lysates by
western blot in PTP1Bþ /þ and PTP1B / immortalized hepatocytes treated with 1 mM APAP for several time-periods. Representative autoradiograms of three to four
independent experiments are shown. (Lower panel) Representative images corresponding to the intracellular localization of Nrf2 by immunofluorescence microscopy in
PTP1Bþ /þ and PTP1B / immortalized hepatocytes treated with 1 mM APAP for several time-periods. Bar¼ 50mm. (c) (Upper panel) PTP1Bþ /þ and PTP1B /
immortalized hepatocytes were treated with 1 mM APAP for several time-periods. Nrf2 tyrosine phosphorylation was analyzed by immunoprecipitation with the anti-Nrf2
antibody, followed by western blot with the anti-Tyr(P) antibody. Total Nrf2 and HO-1 was analyzed by western blot. (Lower panel) PTP1Bþ /þ and PTP1B / mouse
primary hepatocytes were treated with 10 mM APAP for various time-periods. Total Nrf2 and HO-1 was analyzed by western blot. (d) PTP1Bþ /þ and PTP1B /
immortalized hepatocytes were treated with MG132 (10 nM) for 30 min, and then with 1 mM APAP for different time-periods. Whole-cell lysates were analyzed by
immunoprecipitation with anti-Nrf2 antibody, followed by western blot with anti-ubiquitin antibody. (e) Antioxidant response element (ARE)-mediated luciferase activity was
measured in HEK 293T cells transfected with the expression vectors for pcDNA3.1mNrf2-V5/HisB and 3ARE-Luc combined with myc-PTP1B only in the indicated cases
and treated with various doses of APAP for 16 h. tBHQ (15 mM) was used as a positive control (n¼ 3 independent experiments performed in triplicate). ***Po0.005 PTP1B-
transfected (Nrf2 AREþPTP1B) versus empty vector-transfected (Nrf2 ARE) cells
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SKF inhibitor PP2. As shown in Figure 5b, PP2 increased
nuclear Nrf2 levels at 2–8 h after APAP treatment. In
addition, in mouse embryonic fibroblasts (MEFs) deficient
in SKF (SYF / ) treated with APAP Nrf2 was accumulated
in the nucleus up to 24 h.
We next analyzed the effect of PTP1B deficiency on the
GSK3b/SKF signaling pathway. In wild-type cells, APAP-
induced GSK3b tyrosine phosphorylation was detected at 1 h
and peaked at 4 h. This response paralleled the re-entry of
Fyn and Src into the nucleus (Figure 5c). In PTP1B /
hepatocytes, maximal GSK3b phosphorylation occurred
later at 8–16 h after APAP treatment and also paralleled
the re-entry of Src and Fyn into the nucleus as observed in
wild-type cells.
PTP1B-deficient mice are protected against APAP-
induced oxidative stress through the enhancement of
Nrf2 nuclear accumulation. Increased survival was
observed in PTP1B / mice injected with an APAP over-
dose (300 mg/kg) as compared with the wild-type control
(Figure 6a). Consistently, serum alanine transaminase (ALT)
was sevenfold higher in wild-type mice than in PTP1B /
mice at 6 and 24 h after injection (Figure 6b). Of note,
necrotic lesions were observed exclusively in livers of
wild-type mice (Figure 6c). Next, we analyzed the hepatic
expression of proinflammatory cytokines. At 6 h after
APAP injection, elevated IL6 and IL1b mRNA levels were
found in livers of wild-type mice, but not in PTP1B /
animals (Figure 6d). APAP decreased TNFa mRNA levels in
Figure 5 PTP1B modulates GSK3b/Src-Fyn-mediated Nrf2 nuclear accumulation in APAP-treated hepatocytes. (a) PTP1Bþ /þ immortalized hepatocytes were
transfected with control or GSK3b small interfering RNAs (siRNAs) (25 nM) for 48 h, followed by stimulation with 1 mM APAP. Nuclear and cytosolic extracts were analyzed by
western blot with antibodies against Nrf2, Fyn and Src. (b, upper panel) PTP1Bþ /þ immortalized hepatocytes were treated with PP2 (5 mM) for 30 min following 1 mM APAP
for different periods. Nrf2 in nuclear extracts was analyzed by western blot. (Lower panel) SYF / MEFs were treated with 1 mM APAP for different periods and Nrf2 was
analyzed in nuclear extracts by western blot. (c) PTP1Bþ /þ and PTP1B / immortalized hepatocytes were treated with 1 mM APAP for different periods. Phosphorylated
GSK3b (Tyr216) was analyzed in cytosolic extracts by western blot. Fyn and Src were analyzed in nuclear extracts. Similar results were obtained in three independent
experiments
Role of PTP1B in APAP-induced hepatotoxicity
MA Mobasher et al
7
Cell Death and Disease
wild-type, but not in PTP1B-deficient mice. As hepatic
PTP1B expression is modulated by inflammation,29 we
performed the immunohistochemistry analysis. Increased
PTP1B staining was found in necrotic lesions of APAP-
treated wild-type mice after 6 h, particularly in areas
surrounding the central veins, but no signs of liver injury
were observed in sections from PTP1B / mice (Figure 6e).
We next determined if reduced sensitivity of PTP1B / mice
to APAP-induced liver injury was associated with alterations
in GSH levels. APAP administration depleted GSH at 3 and
6 h and increased APAP–protein adducts, these effects
being significantly ameliorated in the PTP1B / group
(Figure 6f). Protein carbonyl levels, an indicator of tissue
oxidative stress, were less elevated in APAP-injected
PTP1B / mice than in wild-type mice and paralleled the
reduced GSH depletion.
Figure 6 PTP1B-deficient mice are protected against APAP-induced, inflammation oxidative stress and liver damage. PTP1Bþ /þ and PTP1B / mice were injected
with 300 mg/kg APAP or saline for 6 or 24 h. (a) Survival curves after 24 h of APAP injection. (b) ALT activity at 6 and 24 h. (c) Representative images of whole livers from
PTP1Bþ /þ and PTP1B / mice 24 h after APAP injection. (d) IL6, IL1b and TNFa mRNA levels were determined by real-time polymerase chain reaction in livers from
PTP1Bþ /þ and PTP1B / mice at 6 h after APAP injection. (e) Representative anti-PTP1B immunostaining (left panel) and hematoxylin and eosin staining (right panel) in
livers from PTP1Bþ /þ and PTP1B / mice 6 h after APAP injection. Bar¼ 100mm. (f) GSH (left panel), APAP–protein adducts (middle panel) and carbonylated protein
levels (right panel) were analyzed in livers from PTP1Bþ /þ and PTP1B / mice at various time-periods after APAP injection. *Po0.05, **Po0.01 and ***Po0.005
PTP1B / versus PTP1Bþ /þ (n¼ 6–8 mice of each condition). Cys, cysteine. Veh, vehicle
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As intracellular redox state is chiefly regulated by Nrf2, we
examined differences in nuclear levels of Nrf2 in vivo. Nuclear
Nrf2 was detected in livers of wild-type mice at 3 and 6 h
after APAP treatment (Figure 7a). In PTP1B / animals,
basal nuclear Nrf2 was detected before APAP administration
and increased at 3 and 6 h after injection, where the
levels were higher than those of control mice. Similarly,
APAP-induced HO-1 protein content was higher in
PTP1B / mice. Then, we analyzed additional Nrf2 target
genes. mRNA levels of GPx, HO-1 and g-glutamyl cysteine
ligase modulatory subunit (GCL-M) significantly increased
at 3-h after APAP injection in livers of PTP1B / mice
as compared with the wild-type and GPx, g-glutamyl
cysteine ligase catalytic subunit (GCL-C), GCL-M and
NAD(P)H quinone oxidoreductase 1 (NQO1) mRNA increased
at 6 h (Figure 7b).
Figure 7 Beneficial effects of PTP1B deficiency on the induction of Nrf2-mediated antioxidant response and survival signaling in the liver. PTP1Bþ /þ and PTP1B /
mice were injected with 300 mg/kg APAP or saline for 3 or 6 h. (a) Western blot analysis of Nrf2 in nuclear extracts and HO-1, phospho (p)-JNK and JNK in total liver extracts.
(b) GPx, HO-1, GCL-M, GCL-C and NQO1 mRNA levels determined by quantitative real-time polymerase chain reaction (qRT-PCR) at 3 and 6 h after APAP injection.
*Po0.05, **Po0.01 and ***Po0.005 PTP1B / versus PTP1Bþ /þ (n¼ 6–8 mice of each condition). (c) Western blot analysis of phospho (p)-IGFIR, IGFIR, IRS1, IRS2,
phospho-Akt, Akt and BclxL levels in total liver extracts from PTP1Bþ /þ and PTP1B / mice 6 h after APAP injection. (d) Schematic diagram illustrating the proposed
mechanism by which PTP1B modulates Nrf2 nuclear accumulation. PTP1B might activate the unknown kinase upstream GSK3b by dephosphorylation, thereby triggering
activation of the GSK3b/Src-Fyn axis in the nucleus that ultimately leads to Nrf2 tyrosine phosphorylation, ubiquitination and degradation. Veh, vehicle
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Decreased JNK activation and sustained IGFIR/Akt/
BclxL survival signaling in APAP-treated PTP1B-defi-
cient mice. Activation of JNK was detected in APAP-treated
wild-type mice at 3 and 6 h after injection. As expected, this
effect decreased in PTP1B / mice (Figure 7a). Regarding
survival signaling, in wild-type mice IGFIR phosphorylation
was severely reduced at 6 h after APAP injection and IRS1
protein levels were downregulated in parallel with decreased
Akt phosphorylation (Figure 7c). Consistently, antiapoptotic
BclxL protein was barely detected at 6 h after APAP injection.
Conversely, APAP-treated PTP1B / mice maintained IGFIR
and Akt phosphorylation, as well as IRS1 and BclxL protein
content to similar levels than those of mice injected with saline.
Discussion
There is evidence of increased PTP1B expression during the
progression of non-alcoholic fatty liver disease that concurs
with insulin resistance and liver damage.30,31 However,
PTP1B functions in physiological responses regulated by
tyrosine kinase signaling, such as hepatocellular survival
during drug injury, are poorly understood. Our results
have unraveled a central role of PTP1B in the molecular
mechanism that mediates APAP-induced liver failure, identi-
fying PTP1B as a potential therapeutic target in the treatment
of human APAP hepatotoxicity. This study emerged from the
observation of elevated PTP1B expression in livers from
individuals suffering from APAP intoxication. Importantly, in
APAP-treated human and mouse hepatocytes, upregulation
of PTP1B preceded cell death.
Results in mouse hepatocytes demonstrated that PTP1B
deficiency attenuates cellular damage in response to APAP.
The fact that released LDH activity was reduced in PTP1B /
hepatocytes indicates that necrotic cell death was less severe
than in wild-type cells. In wild-type hepatocytes, APAP also
increased the percentage of sub-G0/G1 cells and release of
cytochrome C from the mitochondria. APAP also induced
activation of caspase-3 and decreased expression of anti-
apoptotic proteins BclxL and Mcl1. These results strongly
suggest that APAP also triggered apoptosis in hepatocytes
and, again, these effects were ameliorated by PTP1B
deficiency. The role of apoptosis in APAP-induced hepatocyte
cell death is controversial. However, there are studies that
clearly demonstrate both types of cell death following APAP
overdose. Circulating apoptotic and necrotic cell death markers
have been detected in patients with APAP-induced acute liver
injury.32–34 Cell death via necrosis and apoptosis has been
reported in the livers removed during transplantation because
of APAP intoxication.35 These data have also been shown in
mice during APAP poisoning.36 In light of these results, we and
others have shown that PTP1B inhibition protects hepatocytes
against activation of mitochondrial (intrinsic) and death
receptor (extrinsic)-mediated apoptotic pathways,21,25 reinfor-
cing the role of this phosphatase in programmed cell death.
As cellular oxidative stress processes (GSH depletion and
ROS generation)13 are ameliorated in PTP1B / hepato-
cytes, we investigated the modulation of oxidative stress by
PTP1B. An unknown tyrosine kinase has been proposed to be
the upstream activator of GSK3b by phosphorylation at
Tyr216.27,28 This phenomenon leads to SKF-mediated
tyrosine phosphorylation, nuclear export, ubiquitination and
degradation of Nrf2 in response to oxidative stress inducers.
Our data demonstrated firstly that this signaling pathway is
activated by APAP in hepatocytes and secondly that PTP1B
deficiency mimics the inhibition of GSK3b or SKF on the
downstream mediators of this pathway. Inhibition of GSK3b or
SKF augmented and prolonged Nrf2 nuclear accumulation,
delaying its nuclear exclusion in response to APAP.
Importantly, the effect of PTP1B deficiency on this pathway
was manifested by delayed Src-Fyn nuclear translocation,
Nrf2 tyrosine phosphorylation and its subsequent ubiquitina-
tion and degradation, leading to enhanced HO-1 induction.
These results suggest that PTP1B might activate this
unknown kinase upstream from GSK3b, probably by
dephosphorylation, and thereby triggering the activation of
the GSK3b/Src-Fyn axis that ultimately leads to Nrf2
degradation. Consequently, as demonstrated in hepatocytes,
PTP1B deficiency might delay and/or reduce activation of this
complex axis, resulting in prolonged nuclear accumulation of
Nrf2 and enhanced antioxidant defense.
Besides the novel role of PTP1B in antioxidant defense
reported herein, this phosphatase regulates duration and/or
intensity of survival signals emerging from the tyrosine kinase
receptor family.19–21 As IGFIR triggers survival responses in
hepatocytes,37 the lack of PTP1B prevented the reduction in
IGFIR/IRS1/2/Akt-mediated survival signaling in APAP-
treated cells. In fact, this is the first report showing degrada-
tion of IRS proteins in hepatocytes by APAP, suggesting that
high doses of this analgesic may also interfere with hepatic
insulin signaling and increase the risk of metabolic diseases
such as type 2 diabetes mellitus. Thus, in wild-type hepatocytes,
increased ROS-mediated JNK and p38 MAPK phosphorylation
by APAP are likely to be responsible for the feedback
mechanism on IGFIR-mediated signaling, leading to IRS1/2
serine phosphorylation that precedes degradation.38 In the
absence of PTP1B, the decrease in ROS-mediated activation of
JNK and p38 MAPK and the increase in IGFIR tyrosine
phosphorylation might act in conjunction with the effects on
the GSK3b/Src-Fyn axis, resulting in attenuated oxidative stress
and increased cell survival in response to APAP.
Several studies have shown the mechanistic importance of
hepatic cytokines in APAP-induced liver injury. In the liver,
cytokines are mainly produced by non-parenchymal cells. Our
in vivo data show significant lower expression levels of IL1b
and IL6 mRNAs in the livers of PTP1B / mice upon APAP
injection as compared with the elevated levels of the wild-type
controls, suggesting that PTP1B also modulates cytokine
production by non-parenchymal (i.e. Kupffer) cells in
response to liver damage. Cytokines have an essential role
as inducers of PTP1B in metabolic diseases. Activation of
JNK together with elevated expression of PTP1B in response
to IL6 has been reported in skeletal muscle of insulin-resistant
mice.39 Likewise, IL4 induces PTP1B to suppress IL4-induced
STAT6 signaling in B cells.40 As PTP1B is increased in the
livers of APAP-injected wild-type mice, this effect is likely to be
due to elevation of IL6 and IL1b. Therefore, cytokine-
mediated increases in PTP1B expression might enhance
the GSK3b/Src-Fyn axis, resulting in increased Nrf2 tyrosine
phosphorylation and a rapid nuclear exclusion. Moreover, in
the liver of APAP-injected wild-type mice, the negative
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cross-talk elicited by JNK on IRS proteins and also by PTP1B
by direct dephosphorylation of the IGFIR might synergize with
the enhancement of the GSK3b/Src-Fyn axis to reduce
survival of hepatocytes in vivo. This mechanism is supported
by lower activation of JNK, higher IGFIR tyrosine phosphory-
lation and nuclear Nrf2 accumulation in livers of APAP-
injected PTP1B / mice as compared with the wild-type
controls. As a result, PTP1B-deficient livers are protected
against APAP-induced oxidative stress and injury as mani-
fested by decreased GSH depletion favoring NAPQI
detoxification and subsequently limiting the formation of
APAP–protein adducts. However, the effects of APAP
in vivo are not exclusively mediated by elevation of PTP1B
expression induced by proinflammatory cytokines secreted by
non-parenchymal cells; our in vitro data have also demon-
strated direct effects of APAP in hepatocytes. Nevertheless,
PTP1B deficiency protects against damage in hepatocytes in
culture and in whole liver, reinforcing the regulatory role of this
phosphatase in multiple molecular mechanisms triggered in
response to APAP in distinct liver cells.
As summarized in Figure 7d, we have demonstrated the
unique role of PTP1B in the liver as a critical crossroad in the
signaling pathways triggered in response to APAP by dual
modulation of the Nrf2-mediated antioxidant response
through the GSK3b/Src-Fyn kinases axis and the survival
signaling through its effects on the IGFIR/IRSs/Akt signaling
pathway. Collectively, our data suggest that inhibition of
PTP1B would be a suitable therapeutic approach against
APAP-induced hepatotoxicity.
Materials and Methods
Reagents and antibodies. Fetal bovine serum and culture media were
obtained from Invitrogen (Carlsbad, CA, USA). Protein A agarose was purchased
from Roche Diagnostics. APAP and MG132 were from Sigma-Aldrich (St. Louis,
MO, USA). PP2 was purchased from Tocris Bioscience (Ellsville, MO, USA). The
antibodies used in this study were: anti-cleaved (Asp175) caspase-3 (no. 9661),
anti-phospho-JNK (Thr183/Tyr185) (no. 4668), anti-phospho-p38 MAPK (Thr180/
Tyr182) (no. 9211), anti-p38 MAPK (no. 9212), anti-Akt (no. 9272), and anti-
ubiquitin (no. 3936) antibodies were from Cell Signaling Technology (Danvers,
MA, USA). Anti-Bclx (no. 610211), anti-phospho-GSK3b (no. 612312), anti-
GSK3b (no. 6102019) and anti-cytochrome C (no. 556433) antibodies were from
BD Biosciences (San Diego, CA, USA). Anti-phospho-IGF-IR (Tyr1165/1166)
(sc-101704), anti-JNK (sc-571), anti-phospho-Akt1/2/3 (Ser473) (sc-7985-R), anti-
Nrf2 (C-20, sc-722), anti-Mcl1 (sc-819), anti-Fyn (sc-16), anti-Keap1 (sc-33569),
anti-Lamin B (sc-20682 in Figure 4b) and anti-human PTP1B (sc-14021) were
from Santa Cruz Biotechnology (Palo Alto, CA, USA). The anti-IRS1 (06-248),
anti-IRS2 (06-506), anti-p85a (06-195), anti-mouse PTP1B (07-088), anti-HO1
(AB1284), anti-phospho-Ser (clone 4A4, 05-1000X) and anti-phospho-Tyr (clone
4G10, 05-321) antibodies were purchased from Merck Millipore (Merck KGaA,
Darmstadt, Germany). Anti-IGF-IR antibody was a gift from S Pons (CSIC, Madrid,
Spain). Anti-b-actin (A-5441) antibody was from Sigma Chemical Co. (St. Louis,
MO, USA). Anti-Lamin B (aB16048) and anti-Cyp2e1 antibody (aB19140) were from
Abcam (Cambridge, UK). Mouse monoclonal antibody (mAb) 327 against c-Src was
from Calbiochem (Merck KGaA, Darmstadt, Germany). Anti-cytochrome C oxidase
subunit I antibody (A-6403) was from Molecular Probes (Eugene, OR, USA).
Human liver biopsies. Human liver samples were obtained from the
Department of Pathology, University of Edinburgh (Edinburgh, UK). Written
informed consent was obtained from each patient. Characteristics of five patients
transplanted following APAP overdose are shown in Table 1.
Animal models. Three-month-old male PTP1Bþ /þ (wild-type) and
PTP1B / mice on the C57Bl/6J 129Sv/J genetic background and maintained
as described previously41 were used throughout this study. Animal experimenta-
tion was approved by the ethic committee at CSIC and was conducted according
to the accepted guidelines for animal care of the Comunidad de Madrid (Spain).
Overnight fasted mice were intraperitoneally (i.p.) injected with 300 mg/kg APAP
dissolved in physiological saline. Mice were killed at 1, 3, 6 and 24 h and livers and
blood were collected.
Cell culture. Human hepatocytes were prepared from liver biopsies obtained
from 12 patients (eight male, four female aged 58±4.0 years) submitted to a
surgical resection for liver tumors after obtaining patients’ written consent.
Hepatocytes’ isolation was based on the two-step collagenase procedure.42
Mouse hepatocytes were isolated from male mice (8–12 weeks old) by perfusion
with collagenase and cultured as described.41 CHLs, purchased from the ATCC,
(Manassas, VA, USA) were a gift from P Martin-Sanz (CSIC). The generation and
characterization of immortalized hepatocyte cell lines from wild-type and PTP1B /
 mice has been described previously.43 Cells were grown in DMEM plus 10%
heat-inactivated fetal calf serum and stimulated with various doses of APAP.
Liver histology. Histological grading of hepatic necrosis was performed by
two blinded observers using hematoxylin and eosin (H&E)-stained sections as
follows: 30% of the total area necrotic (one point); 30–60% of the total area
necrotic (two points); and 60% of the total area necrotic (three points). PTP1B
immunohistochemistry was performed as described previously.44
Analysis of ALT activity. Blood was collected in tubes containing heparin
and diluted 1/30 with saline (0.9% NaCl). ALT activity was determined by direct
measurement with the Reflotron test (Ref. 10745120; Roche Diagnostics,
Indianapolis, IN, USA).
Transient transfection with siRNA. siRNA oligonucleotides were
synthesized by Dharmacon RNAi Technologies (Fisher Scientific-USA, Pittsburgh,
PA, USA) for gene silencing of mouse PTP1B and GSK3b. Wild-type immortalized
hepatocytes were seeded in 6-cm dishes and incubated overnight at 37 1C with
5% CO2. When 40–50% confluence was reached, cells were transfected with
10 nM of PTP1B or 25 nM GSK3b siRNAs or with a scrambled control siRNA
following DharmaFECT General Transfection Protocol. After 48 h, cells were used
for experiments.
Immunofluorescence. Cells were grown in glass coverslips until 80%
confluence was reached. Then, cells were washed two times with PBS, fixed in
methanol ( 20 1C) for 2 min and processed to immunofluorescence. Primary
anti-Nrf2 antibody was applied for 1 h at 37 1C in PBS–1% bovine serum albumin
(BSA), followed by 4 5 min washes in PBS, a 45-min incubation with
fluorescence-conjugated secondary antibody (Alexa 488 goat anti-rabbit) and
Table 1 Demographic and biochemical characteristics of patients with APAP hepatotoxicity
Patient
number
Age
(years)
Sex Acetaminophen
dose
Staggered
overdose
Admission alanine
aminotransferase (IU/l)
Admission
creatinine (lmol/l)
Prothrombin
time (s)
Overdose to
transplant (h)
1 42 Female 32 g No 12755 218 77 212
2 43 Female NA NA 7106 192 182 NA
3 48 Male 16 g Yes 20800 124 96 NA
4 45 Female 10 g No 1097 142 69 176
5 36 Male 50 g No 9847 152 87 70
NA, not available
Normal range alanine aminotransferase 10–50 IU/l, creatinine 60—120 mmol/l and prothrombin time 10.2–12.7 s
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four final washes of 5 min each in PBS. Immunofluorescence was examined in a
Nikon Eclipse 90i microscope (Nikon Instruments, Inc., Melville, NY, USA).
Immunofluorescence mounting medium was from Vector Laboratories Inc.
(Burlingame, CA, USA). For 4,6-diamidino-2-phenylindole (DAPI) staining, cells
were washed with PBS, fixed in methanol ( 20 1C) for 2 min and stained with
1mM DAPI for 5 min in the dark. After washing with PBS, nuclear morphology was
analyzed by fluorescence microscopy.
Evaluation of cell viability by LDH leakage assay. Cellular damage
was evaluated by LDH leakage assay as described.45
Analysis of cellular viability by crystal violet. After cell incubation
with APAP, the medium was discarded, and the remaining viable adherent cells
were stained with crystal violet (0.2% (w/v) in 2% ethanol) for 20 min. After this
time, plates were rinsed with tap water and allowed to dry, and 1% SDS was
added to solubilize them. The absorbance of each plate was read spectro-
photometrically at 560 nm. Dishes without cells were processed in parallel to
correct the nonspecific adhesion of crystal violet to the plastic. The remaining
viable cells were calculated as the percentage of absorbance with respect to
control cells (incubated in the absence of APAP).
Quantification of apoptotic cells by flow cytometry. After induction
of apoptosis, adherent and non-adherent cells were collected by centrifugation,
washed with PBS and fixed with cold ethanol. The cells were then washed,
resuspended in PBS and incubated with RNAse A (25mg/106 cells) for 30 min at
37 1C. After addition of 0.05% propidium iodide, cells were analyzed by flow cytometry.
Analysis of caspase-3 activity. Cells were scraped off, collected by
centrifugation at 2500 g for 5 min and lysed at 4 1C in 5 mM Tris/HCl (pH 8),
20 mM EDTA and 0.5% Triton X-100. Caspase-3 activity was determined as
described previously.25 Protein concentration of cell lysates was determined, and
the results are presented as caspase-3 activity per micrograms of total protein.
Luciferase assays. HEK 293T cells were seeded on 24-well plates (100 000
cells per well), cultured for 16 h and transfected using calcium phosphate.
Transient transfections of HEK 293T cells were performed with the expression
vectors for pcDNA3.1mNrf2-V5/HisB (a gift from Dr. JD Hayes, Biomedical
Research Institute, Ninewells Hospital and Medical School, University of Dundee,
Dundee, UK), Renilla (Promega, Madison, WI, USA) and 3ARE-Luc (a gift from
Dr. J Alam, Department of Molecular Genetics, Ochsner Clinic Foundation, Baton
Rouge, LA, USA) combined with myc-PTP1B (a gift from Dr. M Tremblay,
Department of Biochemistry, McGill University, Montreal, QC, Canada) only in the
indicated cases. After transfection, cells were treated with vehicle (PBS), APAP
(10 and 20 mM) or tert-butyl hydroquinone (tBHQ) (15 mM) for 16 h. Cells were
lysed and assayed for luciferase activity with the dual luciferase assay system
(Promega), according to the manufacturer’s instructions. Relative light units were
measured in a GloMax 96 microplate luminometer with dual injectors (Promega,
Madison, WI, USA).
Homogenization and preparation of tissue extracts. Frozen livers
were homogenized in 16 volumes (w/v) of ice-cold lysis buffer containing 50 mM
Tris-HCl, 1% Triton X-100, 2 mM EGTA, 10 mM EDTA acid, 100 mM NaF, 1 mM
Na4P2O7, 2 mM Na3VO4, 100mg/ml phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml
aprotinin, 1mg/ml pepstatin A and 1mg/ml leupeptin. Livers were homogenized in
the same lysis buffer using the Brinkman PT 10/35 Polytron (American Laboratory
Trading, Inc. East Lyme, CT, USA). Extracts were kept ice-cold at all times. Liver
extracts were cleared by microcentrifugation at 40 000 g for 20 min at 4 1C. The
supernatant was aliquoted and stored at  70 1C.
Protein determination. Protein determination was performed by the
Bradford dye method, using the Bio-Rad reagent and BSA as the standard.
Immunoprecipitations and western blot. To obtain total cell lysates,
cells from supernatants were collected by centrifugation at 2000 g for 5 min at
4 1C. Attached cells were scraped off in ice-cold PBS, pelleted by centrifugation at
4000 g for 10 min at 4 1C and resuspended in lysis buffer (25 mM HEPES,
2.5 nM EDTA, 0.1% Triton X-100, 1 mM PMSF and 5 mg/ml leupeptin). Cellular
lysates were clarified by centrifugation at 12 000 g for 10 min. After protein
content determination, equal amounts of protein (600mg–1 mg) were
immunoprecipitated at 4 1C with the corresponding antibodies. The immune
complexes were collected on agarose beads and submitted to western blot
analysis. After SDS-PAGE, gels were transferred to Immobilon membranes and
were blocked using 5% non-fat dried milk or 3% BSA in 10 mM Tris-HCl, 150 mM
NaCl (pH 7.5) and incubated overnight with antibodies as indicated in 0.05%
Tween-20, 10 mM Tris-HCl and 150 mM NaCl (pH 7.5). Immunoreactive bands
were visualized using the ECL Western blotting protocol (Millipore).
Extraction of nuclear and cytosolic proteins. Cells and liver were
resuspended at 4 1C in 10 mM HEPES-KOH (pH 7.9), 1.5 mM MgCl2, 10 mM KCl,
0.5 mM DTT, 0.2 mM PMSF, 0.75mg/ml leupeptin, 0.75mg/ml aprotinin (Buffer A),
allowed to swell on ice for 10 min, and then vortexed for 10 s. Samples were
centrifuged and the supernatant containing the cytosolic fraction was stored at
 70 1C. The pellet was resuspended in cold buffer C (20 mM HEPES-KOH
(pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT,
0.2 mM PMSF, 0.75mg/ml leupeptin, 0.75mg/ml aprotinin) and incubated on ice
for 20 min for high salt extraction. Cellular debris was removed by centrifugation
for 2 min at 4 1C, and the supernatant fraction was stored at  70 1C.
Isolation of mitochondrial and cytosolic extracts. At the end of the
culture time, cells were recovered by scrapping and collected by centrifugation at
2500 g for 5 min at 4 1C. Mitochondrial and cytosolic extracts were obtained as
described previously.25
Determination of GSH. The content of GSH was quantified by the
fluorometric assay of Hissin and Hilf.46
Determination of GPx and GR enzymatic activities. Cells were
collected in PBS and centrifuged at low speed (300 g) for 5 min to pellet cells.
Cell pellets were resuspended in 20 mM Tris containing 5 mM EDTA and 0.5 mM
mercaptoethanol, submitted to ultrasound and centrifuged at 3000 g for 15 min.
Enzyme activities were measured in the supernatants as described.47
Measurement of intracellular ROS. For visualization and analysis of
intracellular ROS by flow cytometry, the oxidation-sensitive DCFH-DA probe was
used. Cells were detached by trypsinization and the cellular fluorescence intensity
was measured after 30-min incubation with 5mM DCFH-DA by using a FACScan
flow cytometer (BD Biosciences, San Jose´, CA, USA). For each analysis, 10 000
events were recorded.
Determination of protein carbonyl content. Protein oxidation of liver
homogenates was measured as carbonyl groups’ content according to the method
of Richert et al.48
Determination of APA–protein adducts. Analysis of APAP covalently
bound to proteins in liver was measured by initial protease treatment of liver
homogenates, followed by high-performance liquid chromatography-electrochemical
analysis for APAP-cysteine as described previously.49
Quantitative real-time PCR analysis and primer sequence. Total
RNA was extracted with Trizol (Invitrogen) and reverse transcribed using a
SuperScriptTM III First-Strand Synthesis System for qPCR following the manufac-
turer’s indications (Invitrogen). qPCR was performed with an ABI 7900 sequence
detector (Invitrogen) using the SyBr Green method and d(N)6 random hexamer with
the primers indicated in Supplementary Table 1. Primer-probe sets for mouse PTP1B,
TNFa, IL6 and IL1b were purchased as predesigned TaqMan gene expression
assays (Applied Biosystems, Life Technologies, Carlsbad, CA, USA).
Data analysis. Data are expressed as mean±S.E.M. Comparisons between
groups were made using one-way ANOVA. For qRT-PCR, a two-way ANOVA test
followed by a Bonferroni’s post-test was used. Differences were considered to be
statistically significant at Po0.05. The data were analyzed with the SPSS
(windows statistical package, version 9.0.1, SPSS Inc., Chicago, IL, USA).
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